Compounds for treatment of complement mediated disorders

ABSTRACT

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D&#39;s ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.14/631,828, filed Feb. 25, 2015, which claims the benefit of provisionalU.S. Application No. 61/944,189 filed Feb. 25, 2014, provisional U.S.Application No. 62/022,916 filed Jul. 10, 2014, and provisional U.S.Application 62/046,783 filed Sep. 5, 2014. The entirety of each of theseapplications is hereby incorporated by reference for all purposes.

BACKGROUND

The complement system is a part of the innate immune system which doesnot adapt to changes over the course of the host's life, but isrecruited and used by the adaptive immune system. For example, itassists, or complements, the ability of antibodies and phagocytic cellsto clear pathogens. This sophisticated regulatory pathway allows rapidreaction to pathogenic organisms while protecting host cells fromdestruction. Over thirty proteins and protein fragments make up thecomplement system. These proteins act through opsonization (enhancingphaogytosis of antigens), chemotaxis (attracting macrophages andneutrophils), cell lysis (rupturing membranes of foreign cells) andagglutination (clustering and binding of pathogens together).

The complement system has three pathways: classical, alternative andlectin. Complement factor D plays an early and central role inactivation of the alternative pathway of the complement cascade.Activation of the alternative complement pathway is initiated byspontaneous hydrolysis of a thioester bond within C3 to produce C3(H₂O),which associates with factor B to form the C3(H₂O)B complex. Complementfactor D acts to cleave factor B within the C3(H₂O)B complex to form Baand Bb. The Bb fragment remains associated with C3(H₂O) to form thealternative pathway C3 convertase C3(H₂O)Bb. Additionally, C3b generatedby any of the C3 convertases also associates with factor B to form C3bB,which factor D cleaves to generate the later stage alternative pathwayC3 convertase C3bBb. This latter form of the alternative pathway C3convertase may provide important downstream amplification within allthree of the defined complement pathways, leading ultimately to therecruitment and assembly of additional factors in the complement cascadepathway, including the cleavage of C5 to C5a and C5b. C5b acts in theassembly of factors C6, C7, C8, and C9 into the membrane attack complex,which can destroy pathogenic cells by lysing the cell.

The dysfunction of or excessive activation of complement has been linkedto certain autoimmune, inflammatory, and neurodegenerative diseases, aswell as ischemia-reperfusion injury and cancer. For example, activationof the alternative pathway of the complement cascade contributes to theproduction of C3a and C5a, both potent anaphylatoxins, which also haveroles in a number of inflammatory disorders. Therefore, in someinstances, it is desirable to decrease the response of the complementpathway, including the alternative complement pathway. Some examples ofdisorders mediated by the complement pathway include age-related maculardegeneration (AMD), paroxysmal nocturnal hemoglobinuria (PNH), multiplesclerosis, and rheumatoid arthritis.

Age-related macular degeneration (AMD) is a leading cause of vision lossin industrialized countries. Based on a number of genetic studies, thereis evidence of the link between the complement cascade and maculardegeneration. Individuals with mutations in the gene encoding complementfactor H have a fivefold increased risk of macular degeneration andindividuals with mutations in other complement factor genes also have anincreased risk of AMD. Individuals with mutant factor H also haveincreased levels of C-reactive protein, a marker of inflammation.Without adequate functioning factor H, the alternative pathway of thecomplement cascade is overly activated leading to cellular damage.Inhibition of the alternative pathway is thus desired.

Paroxysmal nocturnal hemoglobinuria (PNH) is a non-malignant,hematological disorder characterized by the expansion of hematopoieticstem cells and progeny mature blood cells which are deficient in somesurface proteins. PNH erythrocytes are not capable of modulating theirsurface complement activation, which leads to the typical hallmark ofPNH—the chronic activation of complement mediated intravascular anemia.Currently, only one product, the anti-C5 monoclonal antibody eculizumab,has been approved in the U.S. for treatment of PNH. However, many of thepatients treated with eculizumab remain anemic, and many patientscontinue to require blood transfusions. In addition, treatment witheculizumab requires life-long intravenous injections. Thus, there is anunmet need to develop novel inhibitors of the complement pathway.

Factor D is an attractive target for inhibition or regulation of thecomplement cascade due to its early and essential role in thealternative complement pathway, and its potential role in signalamplification within the classical and lectin complement pathways.Inhibition of factor D effectively interrupts the pathway and attenuatesthe formation of the membrane attack complex.

While initial attempts have been made to develop inhibitors of factor D,there are currently no small molecule factor D inhibitors in clinicaltrials. Examples of factor D inhibitors or prolyl compounds aredescribed in the following disclosures.

Biocryst Pharmaceuticals U.S. Pat. No. 6,653,340 titled “Compoundsuseful in the complement, coagulat and kallikrein pathways and methodfor their preparation” describes fused bicyclic ring compounds that arepotent inhibitors of factor D. Development of the factor D inhibitorBCX1470 was discontinued due to lack of specificity and short half-lifeof the compound.

Novartis PCT patent publication WO2012/093101 titled “Indole compoundsor analogues thereof useful for the treatment of age-related maculardegeneration” describes certain factor D inhibitors.

Novartis PCT patent publications WO2014/002057 titled “Pyrrolidinederivatives and their use as complement pathway modulators” andWO2014/009833 titled “Complement pathway modulators and uses thereof”describe additional factor D inhibitors with heterocyclic substituents.Additional factor D inhibitors are described in Novartis PCT patentpublications WO2014/002051, WO2014/002052, WO2014/002053, WO2014/002054,WO2014/002058, WO2014/002059, and WO2014/005150.

Bristol-Myers Squibb PCT patent publication WO2004/045518 titled “Openchain prolyl urea-related modulators of androgen receptor function”describes open chain prolyl urea and thiourea related compounds for thetreatment of androgen receptor-associated conditions, such asage-related diseases, for example, sarcopenia.

Japan Tobacco Inc. PCT patent publication WO1999/048492 titled “Amidederivatives and nociceptin antagonists” describes compounds with aproline-like core and aromatic substituents connected to the prolinecore through amide linkages useful for the treatment of pain.

Ferring B. V. and Yamanouchi Pharmaceutical Co. lTD. PCT patentpublication WO1993/020099 titled “CCK and/or gastrin receptor ligands”describes compounds with a proline-like core and heterocyclicsubstituents connected to the proline core through amide linkages forthe treatment of, for example, gastric disorders or pain.

Alexion Pharmaceuticals PCT patent publication WO1995/029697 titled“Methods and compositions for the treatment of glomerulonephritis andother inflammatory diseases” discloses antibodies directed to C5 of thecomplement pathway for the treatment of glomerulonephritis andinflammatory conditions involving pathologic activation of thecomplement system. Alexion Pharmaceutical's anti-C5 antibody eculizumab(Soliris®) is currently the only complement-specific antibody on themarket, and is the first and only approved treatment for paroxysmalnocturnal hemoglobinuria (PNH).

Compounds which mediate the complement pathway, and for example, act asfactor D inhibitors are needed for treatment of disorders in a host,including a human, associated with misregulation of the complementcascade.

SUMMARY

According to the present invention, a compound of Formula I is provided:

as well as the pharmaceutically acceptable salts and compositionsthereof. Formula I can be considered to have a central core, an L-Bsubstituent, and a (C═O)A substituent. It has been discovered that acompound of Formula I, or a pharmaceutically acceptable salt orcomposition thereof, is a superior inhibitor of complement factor D, andtherefore can be used as an effective amount to treat a host in need ofcomplement factor D modulation. As described below, the inventionprovides compounds of Formula I, wherein either X² is nitrogen or atleast one of (d), (e), (g), (i), (l), (n), (p), (s), (v), (x), and (y)is present, as defined below. Pharmaceutical compositions comprising acompound or salt of Formula I together with a pharmaceuticallyacceptable carrier are also disclosed.

In one embodiment, a method for the treatment of a disorder associatedwith a dysfunction, including increased activity, of the complementpathway is provided that includes the administration of an effectiveamount of a compound of Formula I, or a pharmaceutically acceptable saltthereof, optionally in a pharmaceutically acceptable carrier, asdescribed in more detail below.

In one embodiment, the disorder is associated with the alternativecomplement cascade pathway. In yet another embodiment, the disorder isassociated with the complement classical pathway. In a furtherembodiment, the disorder is associated with the complement lectinpathway. The factor D inhibitors provided herein can thus dampen orinhibit detrimental complement activity in a host, by administration ofan effective amount in a suitable manner to a host in need thereof.

Specific embodiments of this invention are directed to certain diseaseindications. In one embodiment, a method for the treatment of paroxysmalnocturnal hemoglobinuria (PNH) is provided that includes theadministration of an effective amount of a compound of Formula I, or apharmaceutically acceptable salt thereof, optionally in apharmaceutically acceptable carrier. In another embodiment, a method forthe treatment of age-related macular degeneration (AMD) is provided thatincludes the administration of an effective amount of a compound ofFormula I, or a pharmaceutically acceptable salt thereof, optionally ina pharmaceutically acceptable carrier. In another embodiment, a methodfor the treatment of rheumatoid arthritis is provided that includes theadministration of an effective amount of a compound of Formula I, or apharmaceutically acceptable salt thereof, optionally in apharmaceutically acceptable carrier. In another embodiment, a method forthe treatment of multiple sclerosis is provided that includes theadministration of an effective amount of a compound of Formula I, or apharmaceutically acceptable salt thereof, optionally in apharmaceutically acceptable carrier.

In other embodiments of the invention, an active compound providedherein can be used to treat or prevent a disorder in a host mediated bycomplement factor D, or by an excessive or detrimental amount of the C3amplification loop of the complement pathway. As examples, the inventionincludes methods to treat or prevent complement associated disordersthat are induced by antibody-antigen interactions, a component of animmune or autoimmune disorder or by ischemic injury. The invention alsoprovides methods to decrease inflammation or an immune response,including an autoimmune response, where mediated or affected by factorD.

Formula I carries variables, e.g., A, B, L, X¹, X², Q¹, Q², and Q³, withthe following definitions.

Q¹ is N(R¹) or C(R¹R^(1′)).

Q² is C(R²R^(2′)), C(R²R^(2′))—C(R²R^(2′)), S, O, N(R²) or C(R²R^(2′))O.

Q³ is N(R³), S, or C(R³R^(3′)).

(a) X¹ and X² are independently N, CH, or CZ, or (b) X¹ and X² togetherare C═C.

Q¹, Q², Q³, X¹, and X² are selected such that a stable compound results.

Non-limiting examples of the

ring are illustrated below (any of which can be otherwise substitutedwith R¹, R^(1′), R², R^(2′), R³ and R^(3′)) as described in more detailbelow.

wherein q is 0, 1, 2 or 3 and r is 1, 2 or 3.

R and R′ are independently chosen from H, alkyl, cycloalkyl,alkylcycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl,aralkyl, heteroaryl, heteroarylalkyl wherein each group can beoptionally substituted or any other substituent group herein thatprovides the desired properties. In some embodiments, the ring includesone or more chiral carbon atoms. The invention includes embodiments inwhich the chiral carbon can be provided as an enantiomer, or mixtures ofenantiomers, including a racemic mixture. Where the ring includes morethan one stereocenter, all of the enantiomers and diastereomers areincluded in the invention as individual species.

Z is F, Cl, NH₂, CH₃, CH₂D, CHD₂, or CD₃.

R¹, R^(1′), R², R^(2′), R³, and R^(3′) are independently chosen at eachoccurrence from (c) and (d):

(c) hydrogen, halogen, hydroxyl, nitro, cyano, amino, C₁-C₆alkyl,C₂-C₆alkenyl, C₁-C₆alkoxy, C₂-C₆alkynyl, C₂-C₆alkanoyl, C₁-C₆thioalkyl,hydroxyC₁-C₆alkyl, aminoC₁-C₆alkyl, —C₀-C₄alkylNR⁹R¹⁰, —C(O)OR⁹,—OC(O)R⁹, —NR⁹C(O)R¹⁰, —C(O)NR⁹R¹⁰, —OC(O)NR⁹R¹⁰, —O(heteroaryl),—NR⁹C(O)OR¹⁰, C₁-C₂haloalkyl, and C₁-C₂haloalkoxy, where R⁹ and R¹⁰ areindependently chosen at each occurrence from hydrogen, C₁-C₆alkyl, and(C₃-C₇cycloalkyl)C₀-C₄alkyl;

(d) —C₀-C₄alkyl(C₃-C₇cycloalkyl) and —O—C₀-C₄alkyl(C₃-C₇cycloalkyl).

In alternative embodiments, any one of the following rings (e), (f),(g), (h), (i), or (j) may be present:

(e) R¹ and R^(1′) or R³ and R^(3′) may be taken together to form a 3- to6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclicspiro ring containing 1 or 2 heteroatoms independently chosen from N, O,or S;

(f) R² and R^(2′) may be taken together to form a 3- to 6-memberedcarbocyclic spiro ring,

(g) R² and R^(2′) may be taken together to form a 3- to 6-memberedheterocyclic spiro ring,

each of which spiro rings (e), (f), and (g) is unsubstituted orsubstituted with 1 or more substituents independently chosen fromhalogen (and in particular F), hydroxyl, cyano, —COOH, C₁-C₄alkyl(including in particular methyl), C₂-C₄alkenyl, C₂-C₄alkynyl,C₁-C₄alkoxy, C₂-C₄alkanoyl, hydroxyC₁-C₄alkyl, (mono- anddi-C₁-C₄alkylamino)C₀-C₄alkyl, —C₀-C₄alkyl(C₃-C₇cycloalkyl),—O—C₀-C₄alkyl(C₃-C₇cycloalkyl), C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.

(h) R¹ and R² may be taken together to form a 3-membered carbocyclicring;

(i) R¹ and R² may be taken together to form a 4- to 6-memberedcarbocyclic ring or a 4- to 6-membered heterocyclic ring containing 1 or2 heteroatoms independently chosen from N, O, and S.

(j) R² and R³, if bound to adjacent carbon atoms, may be taken togetherto form a 3- to 6-membered carbocyclic ring or a 3- to 6-memberedheterocyclic ring; each of which ring (h), (i), and (j) may beunsubstituted or substituted with 1 or more substituents independentlychosen from halogen (and in particular F), hydroxyl, cyano, —COOH,C₁-C₄alkyl (including in particular methyl), C₂-C₄alkenyl, C₂-C₄alkynyl,C₁-C₄alkoxy, C₂-C₄alkanoyl, hydroxyC₁-C₄alkyl, (mono- anddi-C₁-C₄alkylamino)C₀-C₄alkyl, —C₀-C₄alkyl(C₃-C₇cycloalkyl),—O—C₀-C₄alkyl(C₃-C₇cycloalkyl), C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.

In alternative embodiments, R¹ and R^(1′), R² and R^(2′), or R³ andR^(3′) can be taken together to form a carbonyl group. In alternativeembodiments, R¹ and R² or R² and R³ can be taken together to form acarbon-carbon double bond.

A is a group chosen from (k) and (l) where (k) is

X⁴ is B(OH) and Y is CHR⁹; or X⁴ is CHR⁹ and Y is B(OH).

R¹⁰¹ is hydrogen, alkyl, carboxy.

R⁴ is (m) or (n):

(m) —CHO, —CONH₂, or C₂-C₆alkanoyl, including C(O)C₃-C₇cycloalkyl;

(n) hydrogen, —SO₂NH₂, —C(CH₂)₂F, —CH(CF₃)NH₂, C₁-C₆alkyl,—C₀-C₄alkyl(C₃-C₇cycloalkyl), —C(O)C₀-C₂alkyl(C₃-C₇cycloalkyl),

each of which R⁴ other than hydrogen, —CHO, and —CONH₂, is unsubstitutedor substituted with one or more of amino, imino, halogen, hydroxyl,cyano, cyanoimino, C₁-C₂alkyl, C₁-C₂alkoxy, —C₀-C₂alkyl(mono- anddi-C₁-C₄alkylamino), C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.

R⁵ and R⁶ are independently chosen from (o) and (p):

(o) —CHO, —C(O)NH₂, —C(O)NH(CH₃), or C₂-C₆alkanoyl;

(p) hydrogen, hydroxyl, halogen, cyano, nitro, —COOH, —SO₂NH₂,—C(NH₂)C₁-C₃alkyl, —C(NH₂)C₁-C₃haloalkyl, —CF(C═CH₂),—C(═NCN)C₁-C₆alkyl, C₁-C₆alkyl, C₂-C₆alkenyl, C₁-C₆alkoxy,—C₀-C₄alkyl(C₃-C₇cycloalkyl), —C(O)C₀-C₄alkyl(C₃-C₇cycloalkyl),—P(O)(OR⁹)₂, —OC(O)R⁹, —C(O)OR⁹, —C(O)N(CH₂CH₂R⁹)(R¹⁰), —NR⁹C(O)R¹⁰,phenyl, or 5- to 6-membered heteroaryl.

Each R⁵ and R⁶ other than hydrogen, hydroxyl, cyano, and —COOH isunsubstituted or optionally substituted. For example, R⁵ and R⁶ otherthan hydrogen, hydroxyl, cyano, and —COOH may be substituted with one ormore substituents independently chosen from halogen, hydroxyl, amino,imino, cyano, cyanoimino, C₁-C₂alkyl, C₁-C₄alkoxy, —C₀-C₂alkyl(mono- anddi-C₁-C₄alkylamino), C₁-C₂haloalkyl, C₁-C₂haloalkoxy, C(O)alkyl,C(O)cycloalkyl, C(O)aryl, C(O)heterocycle, and C(O)heteroaryl.

R^(6′) is hydrogen, halogen, hydroxyl, C₁-C₄alkyl, or C₁-C₄alkoxy; or R⁶and R^(6′) may be taken together to form an oxo, vinyl, or imino group.

R⁷ is hydrogen, C₁-C₆alkyl, or —C₀-C₄alkyl(C₃-C₇cycloalkyl).

In an alternate embodiment, two A groups can be bonded together to forma dimer through a suitable linking group that achieves the desiredpurpose. Examples of linking groups include but are not limited to,urea, amide, —C(O)—C(O)—, carbamate and ketone. In one embodiment, twoheteroaryl rings, for example, two indole rings, are linked through aurea to form the dimer.

R⁸ and R^(8′) are independently chosen from hydrogen, halogen, hydroxyl,C₁-C₆alkyl, C₁-C₆alkoxy, and (C₁-C₄alkylamino)C₀-C₂alkyl, or R⁸ andR^(8′) are taken together to form an oxo group, or can be taken togetherwith the carbon that they are bonded to form a 3-membered carbocyclicring.

R¹⁶ is 0 or 1 or more substituents independently chosen from halogen,hydroxyl, nitro, cyano, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkanoyl,C₁-C₆alkoxy, —C₀-C₄alkyl(mono- and di-C₁-C₆alkylamino),—C₀-C₄alkyl(C₃-C₇cycloalkyl), C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.

R¹⁹ is hydrogen, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkanoyl,—SO₂C₁-C₆alkyl, (mono- and di-C₁-C₆alkylamino)C₁-C₄alkyl,—C₀-C₄alkyl(C₃-C₇cycloalkyl), —C₀-C₄alkyl(C₃-C₇heterocycloalkyl),—C₀-C₄alkyl(aryl), C₀-C₄alkyl(heteroaryl), and —C(O)(CH₂)₁₋₂C(O)OR⁹ eachof which R¹⁹ other than hydrogen is substituted with 0 or 1 or moresubstituents independently chosen from halogen, hydroxyl, amino, —COOH,and —C(O)OC₁-C₄alkyl.

X¹¹ is N or CR¹¹.

X¹² is N or CR¹².

X¹³ is N or CR¹³.

X¹⁴ is N or CR¹⁴.

No more than two of X¹¹, X¹², X¹³, and X¹⁴ are N.

R¹¹, R¹⁴, and R¹⁵ are independently chosen at each occurrence fromhydrogen, halogen, hydroxyl, nitro, cyano, —NR⁹C(O)R¹⁰, C(O)NR⁹R¹⁰,—O(PO)(OR⁹)₂, —(PO)(OR⁹)₂, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkenyl(aryl),C₂-C₆alkenyl(cycloalkyl), C₂-C₆alkenyl(heterocycle),C₂-C₆alkenyl(heteroaryl), C₂-C₆alkynyl, C₂-C₆alkynyl(aryl),C₂-C₆alkynyl(cycloalkyl), C₂-C₆alkynyl(heterocycle),C₂-C₆alkynyl(heteroaryl), C₂-C₆alkanoyl, C₁-C₆alkoxy, C₁-C₆thioalkyl,—C₀-C₄alkyl(mono- and di-C₁-C₆alkylamino), —C₀-C₄alkyl(C₃-C₇cycloalkyl),(phenyl)C₀-C₄alkyl, (4- to 7-membered heterocycloalkyl)C₀-C₄alkyl having1, 2, or 3 heteroatoms independently chosen from N, O, and S, and (5- or6-membered unsaturated heterocycle or heteroaryl)C₀-C₄alkyl having 1, 2,or 3 heteroatoms independently chosen from N, O, and S),—C₀-C₄alkoxy(C₃-C₇cycloalkyl), C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.

Alternatively, R¹³ and R¹⁴ can together form a bridge that can be anoptionally substituted cycloalkyl, heterocycle or heteroaryl ring.

R¹² and R¹³ are independently chosen at each occurrence from (q), (r)and (s).

(q) hydrogen, halogen, hydroxyl, nitro, cyano, amino, —COOH,C₁-C₂haloalkyl, C₁-C₂haloalkoxy;

(r) C₁-C₆alkyl, —C₀-C₄alkyl(C₃-C₇cycloalkyl), C₂-C₆alkenyl,C₂-C₆alkanoyl, C₁-C₆alkoxy, C₂-C₆alkenyloxy, —C(O)OR⁹, C₁-C₆thioalkyl,—C₀-C₄alkylNR⁹R¹⁰, —C(O)NR⁹R¹⁰, —SO₂R⁹, —SO₂NR⁹R¹⁰, —OC(O)R⁹, and—C(NR⁹)NR⁹R¹⁰, each of which (r) is unsubstituted or substituted withone or more substituents independently selected from halogen, hydroxyl,nitro, cyano, amino, —COOH, —CONH₂, C₁-C₂haloalkyl, and C₁-C₂haloalkoxy,and each of which (r) is also optionally substituted with onesubstituent chosen from phenyl and 4- to 7-membered heterocyclecontaining 1, 2, or 3 heteroatoms independently chosen from N, O, and S;which phenyl or 4- to 7-membered heterocycle is unsubstituted orsubstituted with one or more substituents independently chosen fromhalogen, hydroxyl, nitro, cyano, C₁-C₆alkyl, C₂-C₆alkenyl,C₂-C₆alkanoyl, C₁-C₆alkoxy, (mono- and di-C₁-C₆alkylamino)C₀-C₄alkyl,C₁-C₆alkylester, —(C₀-C₄alkyl)(C₃-C₇cycloalkyl), C₁-C₂haloalkyl, andC₁-C₂haloalkoxy;

(s) —C(CH₂)₂R³⁰.

R³⁰ is —NR⁹C(O)R³¹ or R³².

R³¹ and R³² are each independently selected from C₁-C₆alkyl,C₁-C₆haloalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, (C₃-C₇cycloalkyl)C₀-C₄alkyl,(aryl)C₀-C₄alkyl, (heterocycle)C₀-C₄alkyl and (heteroaryl)C₀-C₄alkylwherein each group can be optionally substituted; or each of which (s)may be unsubstituted or substituted with one or more substituentsindependently chosen from, but not limited to, halogen, hydroxyl, nitro,cyano, amino, oxo, —B(OH)₂, —Si(CH₃)₃, —COOH, —CONH₂, —P(O)(OH)₂,C₁-C₆alkyl, C₁-C₆alkoxy, —C₀-C₂alkyl(mono- and di-C₁-C₄alkylamino),C₁-C₆alkylester, C₁-C₄alkylamino, C₁-C₄hydroxylalkyl, C₁-C₂haloalkyl,and C₁-C₂haloalkoxy.

L is either (t), (u), or (v):

(t) is a group of the formula

where R¹⁷ is hydrogen or C₁-C₆alkyl and R¹⁸ and R^(18′) areindependently chosen from hydrogen, halogen, hydroxymethyl, and methyl;and m is 0, 1, 2, or 3;

(u) is a bond,

(v) or a directly linked optionally substituted alkyl,alkyl(heteroaryl), heterocyclic aryl, heteroaryl, moiety including butnot limited to:

B is a monocyclic, bicyclic carbocyclic or carbocyclic-oxy group or amonocyclic, bicyclic, or tricyclic heterocyclic group having 1, 2, 3, or4 heteroatoms independently selected from N, O, and S and from 4 to 7ring atoms per ring, or B is a C₂-C₆alkenyl or C₂-C₆alkynyl group, or Bis —(C₀-C₄alkyl)(aryl), —(C₀-C₄alkyl)(heteroaryl), or—(C₀-C₄alkyl)(biphenyl).

Each of which B is unsubstituted or substituted with one or moresubstituents independently chosen from (w) and (x) and 0 or 1substituents chosen from (y) and (z):

(w) halogen, hydroxyl, —COOH, cyano, C₁-C₆alkyl, C₂-C₆alkanoyl,C₁-C₆alkoxy, —C₀-C₄alkylNR⁹R¹⁰, —SO₂R⁹, C₁-C₂haloalkyl, andC₁-C₂haloalkoxy;

(x) nitro, C₂-C₆alkenyl, C₂-C₆alkynyl, C₁-C₆thioalkyl,-JC₃-C₇cycloalkyl, —B(OH)₂, -JC(O)NR⁹R²³, -JOSO₂OR²¹,—C(O)(CH₂)₁₋₄S(O)R²¹, SR⁹, —O(CH₂)₁₋₄S(O)NR²¹R²², -JOP(O)(OR²¹)(OR²²),-JP(O)(OR²¹)(OR²²), -JOP(O)(OR²¹)R²², -JP(O)(OR²¹)R²², -JOP(O)R²¹R²²,-JP(O)R²¹R²², -JSP(O)(OR²¹)(OR²²), -JSP(O)(OR²¹)(R²²),-JSP(O)(R²¹)(R²²), -JNR⁹P(O)(NHR²¹)(NHR²²), -JNR⁹P(O)(OR²¹)(NHR²²),-JNR⁹P(O)(OR²¹)(OR²²), -JC(S)R²¹, -JNR²¹SO₂R²², -JNR⁹S(O)NR¹⁰R²²,-JNR⁹SO₂NR¹⁰R²², -JSO₂NR⁹COR²², -JSO₂NR⁹CONR²¹R²², -JNR²¹SO₂R²²,-JC(O)NR²¹SO₂R²², -JC(NH₂)NR²², -JC(NH₂)NR⁹S(O)₂R²², -JOC(O)NR²¹R²²,-JNR²¹C(O)OR²², -JNR²¹OC(O)R²², —(CH₂)₁₋₄C(O)NR²¹R²², -JC(O)R²⁴R²⁵,-JNR⁹C(O)R²¹, -JC(O)R²¹, -JNR⁹C(O)NR¹⁰R²², —CCR²¹, —(CH₂)₁₋₄OC(O)R²¹,and -JC(O)OR²³; each of which (x) may be unsubstituted or substitutedwith one or more substituents independently chosen from halogen,hydroxyl, nitro, cyano, amino, oxo, —B(OH)₂, —Si(CH₃)₃, —COOH, —CONH₂,—P(O)(OH)₂, C₁-C₆alkyl, C₁-C₆alkoxy, —C₀-C₂alkyl(mono- anddi-C₁-C₄alkylamino), C₁-C₆alkylester, C₁-C₄alkylamino,C₁-C₄hydroxylalkyl, C₁-C₂haloalkyl, and C₁-C₂haloalkoxy;

(y) naphthyl, naphthyloxy, indanyl, (4- to 7-memberedheterocycloalkyl)C₀-C₄alkyl containing 1 or 2 heteroatoms chosen from N,O, and S, and bicyclic heterocycle containing 1, 2, or 3 heteroatomsindependently chosen from N, O, and S, and containing 4- to 7-ring atomsin each ring; each of which (y) is unsubstituted or substituted with oneor more substituents independently chosen from halogen, hydroxyl, nitro,cyano, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkanoyl, C₁-C₆alkoxy, (mono- anddi-C₁-C₆alkylamino)C₀-C₄alkyl, C₁-C₆alkylester,—C₀-C₄alkyl(C₃-C₇cycloalkyl), —SO₂R⁹, C₁-C₂haloalkyl, andC₁-C₂haloalkoxy; and

(z) tetrazolyl, (phenyl)C₀-C₂alkyl, (phenyl)C₁-C₂alkoxy, phenoxy, and 5-or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independentlychosen from N, O, B, and S, each of which (z) is unsubstituted orsubstituted with one or more substituents independently chosen fromhalogen, hydroxyl, nitro, cyano, C₁-C₆alkyl, C₂-C₆alkenyl,C₂-C₆alkanoyl, C₁-C₆alkoxy, (mono- and di-C₁-C₆alkylamino)C₀-C₄alkyl,C₁-C₆alkylester, —C₀-C₄alkyl(C₃-C₇cycloalkyl), —SO₂R⁹,—OSi(CH₃)₂C(CH₃)₃, —Si(CH₃)₂C(CH₃)₃, C₁-C₂haloalkyl, andC₁-C₂haloalkoxy.

J is independently chosen at each occurrence from a covalent bond,C₁-C₄alkylene, —OC₁-C₄alkylene, C₂-C₄alkenylene, and C₂-C₄alkynylene.

R²¹ and R²² are independently chosen at each occurrence from hydrogen,hydroxyl, cyano, amino, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy,(C₃-C₇cycloalkyl)C₀-C₄alkyl, (phenyl)C₀-C₄alkyl,—C₁-C₄alkylOC(O)OC₁-C₆alkyl, —C₁-C₄alkylOC(O)C₁-C₆alkyl,—C₁-C₄alkylC(O)OC₁-C₆alkyl, (4- to 7-memberedheterocycloalkyl)C₀-C₄alkyl having 1, 2, or 3 heteroatoms independentlychosen from N, O, and S, and (5- or 6-membered unsaturated or aromaticheterocycle)C₀-C₄alkyl having 1, 2, or 3 heteroatoms independentlychosen from N, O, and S.

R²³ is independently chosen at each occurrence from(C₃-C₇cycloalkyl)C₀-C₄alkyl, (phenyl)C₀-C₄alkyl, (4- to 7-memberedheterocycloalkyl)C₀-C₄alkyl having 1, 2, or 3 heteroatoms independentlychosen from N, O, and S, and (5- or 6-membered unsaturated or aromaticheterocycle)C₀-C₄alkyl having 1, 2, or 3 heteroatoms independentlychosen from N, O, and S.

R²⁴ and R²⁵ are taken together with the nitrogen to which they areattached to form a 4- to 7-membered monocyclic heterocycloalkyl group,or a 6- to 10-membered bicyclic heterocyclic group having fused, spiro,or bridged rings.

Either X² is nitrogen or at least one of (d), (e), (g), (i), (l), (n),(p), (s), (v), (x), and (y) is present. Pharmaceutical compositionscomprising a compound or salt of Formula I together with apharmaceutically acceptable carrier are also disclosed.

Methods of treating or preventing disorders mediated by complementcascade factor D, including but not limited to age-related maculardegeneration (AMD), retinal degeneration, other ophthalmic diseases(e.g., geographic atrophy), paroxysymal nocturnal hemoglobinuria (PNH),multiple sclerosis (MS), arthritis including rheumatoid arthritis (RA),a respiratory disease or a cardiovascular disease, are provided,comprising administering a therapeutically effective amount of acompound or salt of Formula I to a host, including a human, in need ofsuch treatment are also disclosed.

In another embodiment, an effective amount of an active factor Dinhibiting compound is provided to treat an inflammatory or immunedisorder, including an autoimmune disorder, that is meadited or affectedby factor D. In an alternative embodiment, the compound of Formula I canbe used to treat a disorder mediated by the complement pathway,regardless whether it is acting through Factor D.

The present invention includes at least the following features:

(a) a compound of Formula I as described herein, and pharmaceuticallyacceptable salts and prodrugs thereof (each of which and all subgenusesand species thereof considered individually and specifically described);

(b) Formula I as described herein, and pharmaceutically acceptable saltsand prodrugs thereof, for use in treating or preventing disordersmediated by the complement pathway, and for example, cascade factor D,including age-related macular degeneration (AMD), retinal degeneration,paroxysymal nocturnal hemoglobinuria (PNH), multiple sclerosis (MS), andrheumatoid arthritis (RA) and other disorders described further herein;

(c) use of Formula I, and pharmaceutically acceptable salts and prodrugsthereof in the manufacture of a medicament for use in treating orpreventing disorders mediated by complement cascade factor D, includingage-related macular degeneration (AMD), retinal degeneration,paroxysymal nocturnal hemoglobinuria (PNH), multiple sclerosis (MS), andrheumatoid arthritis (RA) and other disorders described further herein;

(d) a process for manufacturing a medicament intended for thetherapeutic use for treating or preventing treating or preventingdisorders mediated by complement cascade factor D, including age-relatedmacular degeneration (AMD), retinal degeneration, paroxysymal nocturnalhemoglobinuria (PNH), multiple sclerosis (MS), and rheumatoid arthritis(RA) and other disorders described further herein characterized in thatFormula I as described herein is used in the manufacture;

(e) a pharmaceutical formulation comprising an effective host-treatingamount of the Formula I or a pharmaceutically acceptable salt or prodrugthereof together with a pharmaceutically acceptable carrier or diluent;

(f) Formula I as described herein in substantially pure form, includingsubstantially isolated from other chemical entities (e.g., at least 90or 95%);

(g) processes for the manufacture of the compounds of Formula I andsalts, compositions, dosage forms thereof; and

(h) processes for the preparation of therapeutic products that containan effective amount of Formula I, as described herein.

DETAILED DESCRIPTION I. Terminology

Compounds are described using standard nomenclature. Unless definedotherwise, all technical and scientific terms used herein have the samemeaning as is commonly understood by one of skill in the art to whichthis invention belongs.

The compounds in any of the Formulas described herein includeenantiomers, mixtures of enantiomers, diastereomers, tautomers,racemates and other isomers, such as rotamers, as if each isspecifically described. “Formula I” includes all subgeneric groups ofFormula I, such as Formula IA and Formula IB and also includespharmaceutically acceptable salts of a compound of Formula I, unlessclearly contraindicated by the context in which this phrase is used.“Formula I” also includes all subgeneric groups of Formula I, such asFormulas IC-ID, and Formulas II-XXX, and also includes pharmaceuticallyacceptable salts of all subgeneric groups of Formula I, such as FormulasIA-ID, and Formulas II-XXX, unless contraindicated by the context inwhich this phrase is used.

The terms “a” and “an” do not denote a limitation of quantity, butrather denote the presence of at least one of the referenced item. Theterm “or” means “and/or”. Recitation of ranges of values are merelyintended to serve as a shorthand method of referring individually toeach separate value falling within the range, unless otherwise indicatedherein, and each separate value is incorporated into the specificationas if it were individually recited herein. The endpoints of all rangesare included within the range and independently combinable. All methodsdescribed herein can be performed in a suitable order unless otherwiseindicated herein or otherwise clearly contradicted by context. The useof examples, or exemplary language (e.g., “such as”), is intended merelyto better illustrate the invention and does not pose a limitation on thescope of the invention unless otherwise claimed. Unless definedotherwise, technical and scientific terms used herein have the samemeaning as is commonly understood by one of skill in the art to whichthis invention belongs.

The present invention includes compounds of Formula I and the use ofcompounds with at least one desired isotopic substitution of an atom, atan amount above the natural abundance of the isotope, i.e., enriched.Isotopes are atoms having the same atomic number but different massnumbers, i.e., the same number of protons but a different number ofneutrons.

Examples of isotopes that can be incorporated into compounds of theinvention include isotopes of hydrogen, carbon, nitrogen, oxygen,phosphorous, fluorine, and chlorine, such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹⁵N,¹⁸F, ³¹P, ³²P, ³⁵S, ³⁶CI, ¹²⁵I respectively. The invention includesvarious isotopically labeled compounds as defined herein, for examplethose into which radioactive isotopes, such as ³H, ¹³C, and ¹⁴C, arepresent. Such isotopically labelled compounds are useful in metabolicstudies (with ¹⁴C), reaction kinetic studies (with, for example ²H or³H), detection or imaging techniques, such as positron emissiontomography (PET) or single-photon emission computed tomography (SPECT)including drug or substrate tissue distribution assays, or inradioactive treatment of patients. In particular, an ¹⁸F labeledcompound may be particularly desirable for PET or SPECT studies.Isotopically labeled compounds of this invention and prodrugs thereofcan generally be prepared by carrying out the procedures disclosed inthe schemes or in the examples and preparations described below bysubstituting a readily available isotopically labeled reagent for anon-isotopically labeled reagent.

By way of general example and without limitation, isotopes of hydrogen,for example, deuterium (²H) and tritium (³H) may be used anywhere indescribed structures. Alternatively or in addition, isotopes of carbon,e.g., ¹³C and ¹⁴C, may be used. A typical isotopic substitution isdeuterium for hydrogen at one or more locations on the molecule toimprove the performance of the drug, for example, the pharmacodynamics,pharmacokinetics, biodistribution, half-life, stability, AUC, Tmax,Cmax, etc. For example, the deuterium can be bound to carbon in alocation of bond breakage during metabolism (an α-deuterium kineticisotope effect) or next to or near the site of bond breakage (aβ-deuterium kinetic isotope effect).

Isotopic substitutions, for example deuterium substitutions, can bepartial or complete. Partial deuterium substitution means that at leastone hydrogen is substituted with deuterium. In certain embodiments, theisotope is 90, 95 or 99% or more enriched in an isotope at any locationof interest. In one embodiments deuterium is 90, 95 or 99% enriched at adesired location. Unless otherwise stated, the enrichment at any pointis above natural abundance and enough to alter a detectable property ofthe drug in a human.

In one embodiment, the substitution of a hydrogen atom for a deuteriumatom occurs within an R group substituent on the L-B moiety region. Inone embodiment, the substitution of a hydrogen atom for a deuterium atomoccurs within an R group selected from any of R¹⁸, R^(18′), R³³, R³⁴,R³⁵, and/or R³⁶. In one embodiment, the substitution of a hydrogen atomfor a deuterium atom occurs within an R group substituent within theA-carbonyl moiety region. In one embodiment, the substitution of ahydrogen atom for a deuterium atom occurs at R⁴, R⁵, R⁶, R^(6′), R⁷, R⁸,R^(8′), R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁹, R²¹, R²², R²³, and R³⁰. Inother embodiments, certain substituents on the proline ring areselectively deuterated. For example, in one embodiment, the substitutionof a hydrogen atom for a deuterium atom occurs at R, R′, R¹, R^(1′), R²,R^(2′), R³, and/or R^(3′). In one embodiment, for example, when any ofthe R substituents of the proline ring are methyl or methoxy, the alkylresidue is optionally deuterated, e.g., CD₃ or OCD₃. In certain otherembodiments, when two substituents of the proline ring are combined toform a cyclopropyl ring, the unsubstituted methylene carbon isdeuterated.

In one embodiment, the substitution of a hydrogen atom for a deuteriumatom occurs within an R group when at least one of the variables withinthe R group is hydrogen (e.g., ²H or D) or alkyl (e.g., CD₃). Forexample, when any of R groups are, or contain for example throughsubstitution, methyl or ethyl, the alkyl residue is typicallydeuterated, e.g., CD₃, CH₂CD₃ or CD₂CD₃. In certain other embodiments,when any of the above mentioned R groups are hydrogen, the hydrogen maybe isotopically enriched as deuterium (i.e., ²H).

The compounds of the present invention may form solvates with solvents(including water). The term “solvate” refers to a molecular complex of acompound of the present invention (including salts thereof) with one ormore solvent molecules. Solvents include water, ethanol, dimethylsulfoxide, acetone and other common organic solvents. The term “hydrate”refers to a molecular complex comprising a compound of the invention andwater. Pharmaceutically acceptable solvates in accordance with theinvention include those wherein the solvent of crystallization may beisotopically substituted, e.g. D₂O, d₆-acetone, d₆-DMSO. A solvate canbe in a liquid or solid form.

A dash (“-”) that is not between two letters or symbols is used toindicate a point of attachment for a substituent. For example, —(C═O)NH₂is attached through carbon of the keto (C═O) group.

The term “substituted”, as used herein, means that any one or morehydrogens on the designated atom or group is replaced with a moietyselected from the indicated group, provided that the designated atom'snormal valence is not exceeded. For example, when the substituent is oxo(i.e., ═O) then two hydrogens on the atom are replaced. When an oxogroup replaces two hydrogens in an aromatic moiety, the correspondingpartially unsaturated ring replaces the aromatic ring. For example apyridyl group substituted by oxo is a pyridone. Combinations ofsubstituents and/or variables are permissible only if such combinationsresult in stable compounds or useful synthetic intermediates.

A stable compound or stable structure refers to a compound leading to acompound that can be isolated and can be formulated into a dosage formwith a shelf life of at least one month.

Any suitable group may be present on a “substituted” or “optionallysubstituted” position that forms a stable molecule and advances thedesired purpose of the invention and includes, but is not limited to,e.g., halogen (which can independently be F, Cl, Br or I); cyano;hydroxyl; nitro; azido; alkanoyl (such as a C₂-C₆ alkanoyl group);carboxamide; alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy suchas phenoxy; alkylthio including those having one or more thioetherlinkages; alkylsulfinyl; alkylsulfonyl groups including those having oneor more sulfonyl linkages; aminoalkyl groups including groups having oneor more N atoms; aryl (e.g., phenyl, biphenyl, naphthyl, or the like,each ring either substituted or unsubstituted aromatic); arylalkylhaving for example, 1 to 3 separate or fused rings and from 6 to about14 or 18 ring carbon atoms, with benzyl being an exemplary arylalkylgroup; arylalkoxy, for example, having 1 to 3 separate or fused ringswith benzyloxy being an exemplary arylalkoxy group; or a saturated,unsaturated, or aromatic heterocyclic group having 1 to 3 separate orfused rings with one or more N, O or S atoms, e.g. coumarinyl,quinolinyl, isoquinolinyl, quinazolinyl, pyridyl, pyrazinyl,pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, triazinyl, oxazolyl,isoxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyl,tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholinyl,piperazinyl, and pyrrolidinyl. Such heterocyclic groups may be furthersubstituted, e.g. with hydroxy, alkyl, alkoxy, halogen and amino. Incertain embodiments “optionally substituted” includes one or moresubstituents independently chosen from halogen, hydroxyl, amino, cyano,—CHO, —COOH, —CONH₂, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl,—C₁-C₆alkoxy, C₂-C₆alkanoyl, C₁-C₆alkylester, (mono- anddi-C₁-C₆alkylamino)C₀-C₂alkyl, C₁-C₂haloalkyl, hydoxyC₁-C₆alkyl, ester,carbamate, urea, sulfonamide, —C₁-C₆alkyl(heterocyclo),C₁-C₆alkyl(heteroaryl), —C₁-C₆alkyl(C₃-C₇cycloalkyl),O—C₁-C₆alkyl(C₃-C₇cycloalkyl), B(OH)₂, phosphate, phosphonate andC₁-C₂haloalkoxy.

“Alkyl” is a branched or straight chain saturated aliphatic hydrocarbongroup. In one embodiment, the alkyl contains from 1 to about 12 carbonatoms, more generally from 1 to about 6 carbon atoms or from 1 to about4 carbon atoms. In one embodiment, the alkyl contains from 1 to about 8carbon atoms. In certain embodiments, the alkyl is C₁-C₂, C₁-C₃, orC₁-C₆. The specified ranges as used herein indicate an alkyl grouphaving each member of the range described as an independent species. Forexample, the term C₁-C₆ alkyl as used herein indicates a straight orbranched alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and isintended to mean that each of these is described as an independentspecies. For example, the term C₁-C₄alkyl as used herein indicates astraight or branched alkyl group having from 1, 2, 3, or 4 carbon atomsand is intended to mean that each of these is described as anindependent species. When C₀-C_(n) alkyl is used herein in conjunctionwith another group, for example, (C₃-C₇cycloalkyl)C₀-C₄ alkyl, or—C₀-C₄alkyl(C₃-C₇cycloalkyl), the indicated group, in this casecycloalkyl, is either directly bound by a single covalent bond(C₀alkyl), or attached by an alkyl chain in this case 1, 2, 3, or 4carbon atoms. Alkyls can also be attached via other groups such asheteroatoms as in —O—C₀-C₄alkyl(C₃-C₇cycloalkyl). Examples of alkylinclude, but are not limited to, methyl, ethyl, n-propyl, isopropyl,n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, tert-pentyl,neopentyl, n-hexyl, 2-methylpentane, 3-methylpentane, 2,2-dimethylbutaneand 2,3-dimethylbutane. In one embodiment, the alkyl group is optionallysubstituted as described above.

“Alkenyl” is a branched or straight chain aliphatic hydrocarbon grouphaving one or more carbon-carbon double bonds that may occur at a stablepoint along the chain. Nonlimiting examples are C₂-C₈alkenyl,C₂-C₆alkenyl and C₂-C₄alkenyl. The specified ranges as used hereinindicate an alkenyl group having each member of the range described asan independent species, as described above for the alkyl moiety.Examples of alkenyl include, but are not limited to, ethenyl andpropenyl. In one embodiment, the alkenyl group is optionally substitutedas described above.

“Alkynyl” is a branched or straight chain aliphatic hydrocarbon grouphaving one or more carbon-carbon triple bonds that may occur at anystable point along the chain, for example, C₂-C₈alkynyl or C₂-C₆alkynyl.The specified ranges as used herein indicate an alkynyl group havingeach member of the range described as an independent species, asdescribed above for the alkyl moiety. Examples of alkynyl include, butare not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, 3-butynyl,1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl,3-hexynyl, 4-hexynyl and 5-hexynyl. In one embodiment, the alkynyl groupis optionally substituted as described above.

“Alkylene” is a bivalent saturated hydrocarbon. Alkylenes, for example,can be a 1 to 8 carbon moiety, 1 to 6 carbon moiety, or an indicatednumber of carbon atoms, for example C₁-C₄alkylene, C₁-C₃alkylene, orC₁-C₂alkylene.

“Alkenylene” is a bivalent hydrocarbon having at least one carbon-carbondouble bond. Alkenylenes, for example, can be a 2 to 8 carbon moiety, 2to 6 carbon moiety, or an indicated number of carbon atoms, for exampleC₂-C₄alkenylene.

“Alkynylene” is a bivalent hydrocarbon having at least one carbon-carbontriple bond. Alkynylenes, for example, can be a 2 to 8 carbon moiety, 2to 6 carbon moiety, or an indicated number of carbon atoms, for exampleC₂-C₄alkynylene.

“Alkoxy” is an alkyl group as defined above covalently bound through anoxygen bridge (—O—). Examples of alkoxy include, but are not limited to,methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2-butoxy, t-butoxy,n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexoxy,2-hexoxy, 3-hexoxy, and 3-methylpentoxy. Similarly an “alkylthio” or a“thioalkyl” group is an alkyl group as defined above with the indicatednumber of carbon atoms covalently bound through a sulfur bridge (—S—).In one embodiment, the alkoxy group is optionally substituted asdescribed above.

“Alkenyloxy” is an alkenyl group as defined covalently bound to thegroup it substitutes by an oxygen bridge (—O—).

“Alkanoyl” is an alkyl group as defined above covalently bound through acarbonyl (C═O) bridge. The carbonyl carbon is included in the number ofcarbons, that is C₂alkanoyl is a CH₃(C═O)— group. In one embodiment, thealkanoyl group is optionally substituted as described above.

“Alkylester” is an alkyl group as defined herein covalently boundthrough an ester linkage. The ester linkage may be in eitherorientation, e.g., a group of the formula —O(C═O)alkyl or a group of theformula —(C═O)Oalkyl.

“Amide” or “carboxamide” is —C(O)NR^(a)R^(b) wherein R^(a) and R^(b) areeach independently selected from hydrogen, alkyl, for example,C₁-C₆alkyl, alkenyl, for example, C₂-C₆alkenyl, alkynyl, for example,C₂-C₆alkynyl, —C₀-C₄alkyl(C₃-C₇cycloalkyl),—C₀-C₄alkyl(C₃-C₇heterocycloalkyl), —C₀-C₄alkyl(aryl), and—C₀-C₄alkyl(heteroaryl); or together with the nitrogen to which they arebonded, R^(a) and R^(b) can form a C₃-C₇heterocyclic ring. In oneembodiment, the R^(a) and R^(b) groups are each independently optionallysubstituted as described above.

“Carbocyclic group”, “carbocyclic ring”, or “cycloalkyl” is a saturatedor partially unsaturated (i.e., not aromatic) group containing allcarbon ring atoms. A carbocyclic group typically contains 1 ring of 3 to7 carbon atoms or 2 fused rings each containing 3 to 7 carbon atoms. Inone embodiment, a carbocyclic ring can be fused to an aryl ring.Cycloalkyl substituents may be pendant from a substituted nitrogen orcarbon atom, or a substituted carbon atom that may have two substituentscan have a cycloalkyl group, which is attached as a spiro group.Examples of carbocyclic rings include cyclohexenyl, cyclohexyl,cyclopentenyl, cyclopentyl, cyclobutenyl, cyclobutyl and cyclopropylrings. In one embodiment, the carbocyclic ring is optionally substitutedas described above. In one embodiment, the cycloalkyl is a partiallyunsaturated (i.e., not aromatic) group containing all carbon ring atoms.In another embodiment, the cycloalkyl is a saturated group containingall carbon ring atoms.

“Carbocyclic-oxy group” is a monocyclic carbocyclic ring or a mono- orbi-cyclic carbocyclic group as defined above attached to the group itsubstitutes via an oxygen, —O—, linker.

“Haloalkyl” indicates both branched and straight-chain alkyl groupssubstituted with 1 or more halogen atoms, up to the maximum allowablenumber of halogen atoms. Examples of haloalkyl include, but are notlimited to, trifluoromethyl, monofluoromethyl, difluoromethyl,2-fluoroethyl, and penta-fluoroethyl.

“Haloalkoxy” indicates a haloalkyl group as defined herein attachedthrough an oxygen bridge (oxygen of an alcohol radical).

“Hydroxyalkyl” is an alkyl group as previously described, substitutedwith at least one hydroxyl substituent.

“Aminoalkyl” is an alkyl group as previously described, substituted withat least one amino substituent.

“Halo” or “halogen” indicates independently any of fluoro, chloro,bromo, and iodo.

“Aryl” indicates aromatic groups containing only carbon in the aromaticring or rings. In one embodiment, the aryl groups contain 1 to 3separate or fused rings and is 6 to about 14 or 18 ring atoms, withoutheteroatoms as ring members. When indicated, such aryl groups may befurther substituted with carbon or non-carbon atoms or groups. Suchsubstitution may include fusion to a 5 to 7-membered saturated cyclicgroup that optionally contains 1 or 2 heteroatoms independently chosenfrom N, O, and S, to form, for example, a 3,4-methylenedioxyphenylgroup. Aryl groups include, for example, phenyl and naphthyl, including1-naphthyl and 2-naphthyl. In one embodiment, aryl groups are pendant.An example of a pendant ring is a phenyl group substituted with a phenylgroup. In one embodiment, the aryl group is optionally substituted asdescribed above.

The term “heterocycle,” or “heterocyclic ring” as used herein refers toa saturated or a partially unsaturated (i.e., having one or more doubleand/or triple bonds within the ring without aromaticity) carbocyclicradical of 3 to about 12, and more typically 3, 5, 6, 7 to 10 ring atomsin which at least one ring atom is a heteroatom selected from nitrogen,oxygen, phosphorus and sulfur, the remaining ring atoms being C, whereone or more ring atoms is optionally substituted independently with oneor more substituents described above. A heterocycle may be a monocyclehaving 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatomsselected from N, O, P, and S) or a bicycle having 6 to 10 ring members(4 to 9 carbon atoms and 1 to 6 heteroatoms selected from N, O, P, andS), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system. In oneembodiment, the only heteroatom is nitrogen. In one embodiment, the onlyheteroatom is oxygen. In one embodiment, the only heteroatom is sulfur.Heterocycles are described in Paquette, Leo A.; “Principles of ModernHeterocyclic Chemistry” (W. A. Benjamin, New York, 1968), particularlyChapters 1, 3, 4, 6, 7, and 9; “The Chemistry of Heterocyclic Compounds,A series of Monographs” (John Wiley & Sons, New York, 1950 to present),in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc.(1960) 82:5566. Examples of heterocyclic rings include, but are notlimited to, pyrrolidinyl, dihydrofuranyl, tetrahydrothienyl,tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino,piperidonyl, morpholino, thiomorpholino, thioxanyl, piperazinyl,homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl,oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl,3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl,1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl,dihydrothienyl, dihydrofuranyl, dihydroisoquinolinyl,tetrahydroisoquinolinyl, pyrazolidinylimidazolinyl, imidazolidinyl,2-oxa-5-azabicyclo[2.2.2]octane, 3-oxa-8-azabicyclo[3.2.1]octane,8-oxa-3-azabicyclo[3.2.1]octane, 6-oxa-3-azabicyclo[3.1.1]heptane,2-oxa-5-azabicyclo[2.2.1]heptane, 3-azabicyco[3.1.0]hexanyl,3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 3H-indolyl,quinolizinyl, N-pyridyl ureas, and pyrrolopyrimidine. Spiro moieties arealso included within the scope of this definition. Examples of aheterocyclic group wherein 1 or 2 ring carbon atoms are substituted withoxo (═O) moieties are pyrimidinonyl and 1,1-dioxo-thiomorpholinyl. Theheterocycle groups herein are optionally substituted independently withone or more substituents described herein.

“Heterocyclicoxy group” is a monocyclic heterocyclic ring or a bicyclicheterocyclic group as described previously linked to the group itsubstitutes via an oxygen, —O—, linker.

“Heteroaryl” indicates a stable monocyclic aromatic ring which containsfrom 1 to 3, or in some embodiments from 1 to 2, heteroatoms chosen fromN, O, and S, with remaining ring atoms being carbon, or a stablebicyclic or tricyclic system containing at least one 5- to 7-memberedaromatic ring which contains from 1 to 3, or in some embodiments from 1to 2, heteroatoms chosen from N, O, and S, with remaining ring atomsbeing carbon. In one embodiment, the only heteroatom is nitrogen. In oneembodiment, the only heteroatom is oxygen. In one embodiment, the onlyheteroatom is sulfur. Monocyclic heteroaryl groups typically have from 5to 7 ring atoms. In some embodiments bicyclic heteroaryl groups are 9-to 10-membered heteroaryl groups, that is, groups containing 9 or 10ring atoms in which one 5- to 7-member aromatic ring is fused to asecond aromatic or non-aromatic ring. When the total number of S and Oatoms in the heteroaryl group exceeds 1, these heteroatoms are notadjacent to one another. In one embodiment, the total number of S and Oatoms in the heteroaryl group is not more than 2. In another embodiment,the total number of S and O atoms in the aromatic heterocycle is notmore than 1. Examples of heteroaryl groups include, but are not limitedto, pyridinyl (including, for example, 2-hydroxypyridinyl), imidazolyl,imidazopyridinyl, pyrimidinyl (including, for example,4-hydroxypyrimidinyl), pyrazolyl, triazolyl, pyrazinyl, tetrazolyl,furyl, thienyl, isoxazolyl, thiazolyl, oxadiazolyl, oxazolyl,isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl,tetrahydroisoquinolinyl, indolyl, benzimidazolyl, benzofuranyl,cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl,triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl,thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl,benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl,naphthyridinyl, tetrahydrofuranyl, and furopyridinyl. Heteroaryl groupsare optionally substituted independently with one or more substituentsdescribed herein. “Heteroaryloxy” is a heteroaryl group as describedbound to the group it substituted via an oxygen, —O—, linker.

“Heterocycloalkyl” is a saturated ring group. It may have, for example,1, 2, 3, or 4 heteroatoms independently chosen from N, S, and O, withremaining ring atoms being carbon. In a typical embodiment, nitrogen isthe heteroatom. Monocyclic heterocycloalkyl groups typically have from 3to about 8 ring atoms or from 4 to 6 ring atoms. Examples ofheterocycloalkyl groups include morpholinyl, piperazinyl, piperidinyl,and pyrrolinyl.

The term “mono- and/or di-alkylamino” indicates secondary or tertiaryalkylamino groups, wherein the alkyl groups are independently chosenalkyl groups, as defined herein. The point of attachment of thealkylamino group is on the nitrogen. Examples of mono- and di-alkylaminogroups include ethylamino, dimethylamino, and methyl-propyl-amino.

A “dosage form” means a unit of administration of an active agent.Examples of dosage forms include tablets, capsules, injections,suspensions, liquids, emulsions, implants, particles, spheres, creams,ointments, suppositories, inhalable forms, transdermal forms, buccal,sublingual, topical, gel, mucosal, and the like. A “dosage form” canalso include an implant, for example an optical implant.

“Pharmaceutical compositions” are compositions comprising at least oneactive agent, such as a compound or salt of Formula I, and at least oneother substance, such as a carrier. “Pharmaceutical combinations” arecombinations of at least two active agents which may be combined in asingle dosage form or provided together in separate dosage forms withinstructions that the active agents are to be used together to treat anydisorder described herein.

“Pharmaceutically acceptable salts” includes derivatives of thedisclosed compounds in which the parent compound is modified by makinginorganic and organic, non-toxic, acid or base addition salts thereof.The salts of the present compounds can be synthesized from a parentcompound that contains a basic or acidic moiety by conventional chemicalmethods. Generally, such salts can be prepared by reacting free acidforms of these compounds with a stoichiometric amount of the appropriatebase (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or thelike), or by reacting free base forms of these compounds with astoichiometric amount of the appropriate acid. Such reactions aretypically carried out in water or in an organic solvent, or in a mixtureof the two. Generally, non-aqueous media like ether, ethyl acetate,ethanol, isopropanol, or acetonitrile are typical, where practicable.Salts of the present compounds further include solvates of the compoundsand of the compound salts.

Examples of pharmaceutically acceptable salts include, but are notlimited to, mineral or organic acid salts of basic residues such asamines; alkali or organic salts of acidic residues such as carboxylicacids; and the like. The pharmaceutically acceptable salts include theconventional non-toxic salts and the quaternary ammonium salts of theparent compound formed, for example, from non-toxic inorganic or organicacids. For example, conventional non-toxic acid salts include thosederived from inorganic acids such as hydrochloric, hydrobromic,sulfuric, sulfamic, phosphoric, nitric and the like; and the saltsprepared from organic acids such as acetic, propionic, succinic,glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic,maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic,mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric,toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic,HOOC—(CH₂)_(n)—COOH where n is 0-4, and the like. Lists of additionalsuitable salts may be found, e.g., in Remington's PharmaceuticalSciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418(1985).

The term “carrier” applied to pharmaceutical compositions/combinationsof the invention refers to a diluent, excipient, or vehicle with whichan active compound is provided.

A “pharmaceutically acceptable excipient” means an excipient that isuseful in preparing a pharmaceutical composition/combination that isgenerally safe, non-toxic and neither biologically nor otherwiseinappropriate for administration to a host, and includes, in oneembodiment, an excipient that is acceptable for veterinary use as wellas human pharmaceutical use. A “pharmaceutically acceptable excipient”as used in the present application includes both one and more than onesuch excipient.

A “patient” or “host” or “subject” is a human or non-human animal inneed of modulation of the complement factor D pathway. Typically thehost is a human. A “patient” or “host” or “subject” also refers to forexample, mammals, primates (e.g., humans), cows, sheep, goats, horses,dogs, cats, rabbits, rats, mice, fish, birds and the like.

A “prodrug” as used herein, means a compound which when administered toa host in vivo is converted into a parent drug. As used herein, the term“parent drug” means any of the presently described chemical compoundsthat are useful to treat any of the disorders described herein, or tocontrol or improve the underlying cause or symptoms associated with anyphysiological or pathological disorder described herein in a host,typically a human. Prodrugs can be used to achieve any desired effect,including to enhance properties of the parent drug or to improve thepharmaceutic or pharmacokinetic properties of the parent. Prodrugstrategies exist which provide choices in modulating the conditions forin vivo generation of the parent drug, all of which are deemed includedherein. Nonlimiting examples of prodrug strategies include covalentattachment of removable groups, or removable portions of groups, forexample, but not limited to acylation, phosphorylation, phosphonylation,phosphoramidate derivatives, amidation, reduction, oxidation,esterification, alkylation, other carboxy derivatives, sulfoxy orsulfone derivatives, carbonylation or anhydride, among others.

“Providing a compound of Formula I with at least one additional activeagent” means the compound of Formula I and the additional activeagent(s) are provided simultaneously in a single dosage form, providedconcomitantly in separate dosage forms, or provided in separate dosageforms for administration separated by some amount of time that is withinthe time in which both the compound of Formula I and the at least oneadditional active agent are within the blood stream of a patient. Incertain embodiments the compound of Formula I and the additional activeagent need not be prescribed for a patient by the same medical careworker. In certain embodiments the additional active agent or agentsneed not require a prescription. Administration of the compound ofFormula I or the at least one additional active agent can occur via anyappropriate route, for example, oral tablets, oral capsules, oralliquids, inhalation, injection, suppositories or topical contact.

A “therapeutically effective amount” of a pharmaceuticalcomposition/combination of this invention means an amount effective,when administered to a patient, to provide a therapeutic benefit such asan amelioration of symptoms, e.g., an amount effective to decrease thesymptoms of a macular degeneration. In one embodiment, a therapeuticallyeffective amount is an amount sufficient to prevent a significantincrease or will significantly reduce the detectable level of complementfactor D in the patient's blood, serum, or tissues.

II. Detailed Description of the Active Compounds

According to the present invention, a compound of Formula I is provided:

as well as the pharmaceutically acceptable salts and compositionsthereof. Formula I can be considered to have a central core, an L-Bsubstituent, and a (C═O)A substituent. It has been discovered that acompound of Formula I, or a pharmaceutically acceptable salt orcomposition thereof, is a superior inhibitor of complement factor D, andtherefore can be used as an effective amount to treat a host in need ofcomplement factor D modulation.

Non-limiting examples of compounds falling within Formula I withvariations in the variables e.g., A, B, and L, are illustrated below.The disclosure includes all combinations of these definitions so long asa stable compound results.

Formulas II-XXX

In one aspect, the disclosure includes compounds and salts of FormulaII, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII,XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIXand XXX which are within the scope of Formula I. The variables shown inFormula II-XXX carry the definitions set forth in the SUMMARY sectionfor Formula I or any of the definitions set forth in this disclosure.

Additionally, the disclosure includes compounds and salts of Formula Iand pharmaceutically acceptable compositions thereof, and any of itssubformulae (II-XXX) in which at least one of the following conditionsis met in the embodiments described below.

The R¹² and R¹³ Substituents

It has been discovered that a compound of Formula I, a pharmaceuticallyacceptable salt or composition thereof, is a superior inhibitor ofcomplement factor D.

In one embodiment, R¹² and R¹³ are independently chosen at eachoccurrence from (q), (r) and (s):

(q) hydrogen, halogen, hydroxyl, nitro, cyano, amino, —COOH,C₁-C₂haloalkyl, C₁-C₂haloalkoxy;

(r) C₁-C₆alkyl, —C₀-C₄alkyl(C₃-C₇cycloalkyl), C₂-C₆alkenyl,C₂-C₆alkanoyl, C₁-C₆alkoxy, C₂-C₆alkenyloxy, —C(O)OR⁹, C₁-C₆thioalkyl,—C₀-C₄alkylNR⁹R¹⁰, —C(O)NR⁹R¹⁰, —SO₂R⁹, —SO₂NR⁹R¹⁰, —OC(O)R⁹, and—C(NR⁹)NR⁹R¹⁰, each of which (r) is unsubstituted or substituted withone or more substituents independently selected from halogen, hydroxyl,nitro, cyano, amino, —COOH, —CONH₂, C₁-C₂haloalkyl, and C₁-C₂haloalkoxy,and each of which (r) is also optionally substituted with onesubstituent chosen from phenyl and 4- to 7-membered heterocyclecontaining 1, 2, or 3 heteroatoms independently chosen from N, O, and S;which phenyl or 4- to 7-membered heterocycle is unsubstituted orsubstituted with one or more substituents independently chosen fromhalogen, hydroxyl, nitro, cyano, C₁-C₆alkyl, C₂-C₆alkenyl,C₂-C₆alkanoyl, C₁-C₆alkoxy, (mono- and di-C₁-C₆alkylamino)C₀-C₄alkyl,C₁-C₆alkylester, —(C₀-C₄alkyl)(C₃-C₇cycloalkyl), C₁-C₂haloalkyl, andC₁-C₂haloalkoxy;

(s) —C(CH₂)₂₋₄R³⁰.

R³⁰ is —NR⁹C(O)R³¹ or R³².

R³¹ and R³² are C₁-C₆alkyl, C₁-C₆haloalkyl, (C₃-C₇cycloalkyl)C₀-C₄alkyl,(phenyl)C₀-C₄alkyl, (4- to 7-membered heterocycloalkyl)C₀-C₄alkyl having1, 2, or 3 heteroatoms independently chosen from N, O, and S, and (5- or6-membered unsaturated or aromatic heterocycle)C₀-C₄alkyl having 1, 2,or 3 heteroatoms independently chosen from N, O, and S.

Each of which (s) may be unsubstituted or substituted with one or moresubstituents independently chosen from halogen, hydroxyl, nitro, cyano,amino, oxo, —B(OH)₂, —Si(CH₃)₃,

—COOH, —CONH₂, —P(O)(OH)₂, C₁-C₆alkyl, C₁-C₆alkoxy, —C₀-C₂alkyl(mono-and di-C₁-C₄alkylamino), C₁-C₆alkylester, C₁-C₄alkylamino,C₁-C₄hydroxylalkyl, C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.

In certain embodiments, R¹² or R¹³ are independently selected from:

Non-Limiting R¹²/R¹³ Embodiments

In one embodiment, the disclosure provides compounds of Formula I,wherein; one of R¹² and R¹³ is H and the other of R¹² and R¹³ is chosenfrom (s):

(s) —C(CH₂)₂R³⁰;

wherein R³⁰ is as defined in the summary section above.

In another embodiment, the disclosure provides compounds of Formula I,wherein;

R¹, R^(1′), R², and R^(3′) are all hydrogen;

R² is fluoro and R³ is hydrogen, —C₀-C₄alkyl(C₃-C₇cycloalkyl), or—O—C₀-C₄alkyl(C₃-C₇cycloalkyl);

R⁵ is hydrogen, halogen, or C₁-C₂alkyl;

R¹¹, R¹³, R¹⁴, and R¹⁵, if present, are independently chosen at eachoccurrence from hydrogen, halogen, hydroxyl, amino, C₁-C₄alkyl,C₁-C₄alkoxy, —C₀-C₂alkyl(mono- and di-C₁-C₂alkylamino), trifluoromethyl,and trifluoromethoxy;

X¹² is CR¹²; and

R¹² is chosen from (s):

(s) —C(CH₂)₂R³⁰;

wherein R³⁰ is as defined in the summary section above.

In one embodiment, the disclosure provides compounds of Formula I,wherein;

m is 0 or 1;

R² is halogen, R^(2′) is hydrogen or halogen, and R³ is hydrogen,halogen, —C₀-C₄alkyl(C₃-C₇cycloalkyl), or—O—C₀-C₄alkyl(C₃-C₇cycloalkyl);

R⁶ is —C(O)C₁-C₄alkyl, —C(O)NH₂, —C(O)CF₃, —C(O)(C₃-C₇cycloalkyl), or-ethyl(cyanoimino);

one of R¹² and R¹³ is selected from hydrogen, halogen, C₁-C₄alkyl,C₁-C₄alkoxy, trifluoromethyl, and trifluoromethoxy; the other of R¹² andR¹³ is chosen from (s):

(s) —C(CH₂)₂R³⁰;

wherein R³⁰ is as defined in the summary section above.

In one embodiment, the disclosure provides compounds of Formula I,wherein;

one of R¹² and R¹³ is hydrogen, hydroxyl, halogen, methyl, or methoxy;and the other of R¹² and R¹³ is chosen from (s):

(s) —C(CH₂)₂R³⁰;

wherein R³⁰ is as defined in the summary section above.

Central Core Moiety

The central core moiety in Formula I is illustrated below:

wherein:

Q¹ is N(R¹) or C(R¹R^(1′)).

Q² is C(R²R^(2′)), C(R²R^(2′))—C(R²R^(2′)), S, O, N(R²) or C(R²R^(2′))O.

Q³ is N(R³), S, or C(R³R^(3′)).

(a) X¹ and X² are independently N, CH, or CZ, or (b) X¹ and X² togetherare C═C.

Q¹, Q², Q³, X¹, and X² are selected such that a stable compound results.

Non-limiting examples of the

ring are illustrated below (any of which can be otherwise substitutedwith R¹, R^(1′), R², R^(2′), R³ and R^(3′)) as described in more detailbelow.

wherein q is 0, 1, 2 or 3 and r is 1, 2 or 3.

R and R′ are independently chosen from H, alkyl, cycloalkyl,alkylcycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl,aralkyl, heteroaryl, heteroarylalkyl wherein each group can beoptionally substituted or any other substituent group herein thatprovides the desired properties. In some embodiments, the ring includesone or more chiral carbon atoms. The invention includes embodiments inwhich the chiral carbon can be provided as an enantiomer, or mixtures ofenantiomers, including a racemic mixture. Where the ring includes morethan one stereocenter, all of the enantiomers and diastereomers areincluded in the invention as individual species.

Z is F, Cl, NH₂, CH₃, CH₂D, CHD₂, or CD₃.

R¹, R^(1′), R², R^(2′), R³, and R^(3′) are independently chosen at eachoccurrence from (c) and (d):

(c) hydrogen, halogen, hydroxyl, nitro, cyano, amino, C₁-C₆alkyl,C₂-C₆alkenyl, C₁-C₆alkoxy, C₂-C₆alkynyl, C₂-C₆alkanoyl, C₁-C₆thioalkyl,hydroxyC₁-C₆alkyl, aminoC₁-C₆alkyl, —C₀-C₄alkylNR⁹R¹⁰, —C(O)OR⁹,—OC(O)R⁹, —NR⁹C(O)R¹⁰, —C(O)NR⁹R¹⁰, —OC(O)NR⁹R¹⁰, —O(heteroaryl),—NR⁹C(O)OR¹⁰, C₁-C₂haloalkyl, and C₁-C₂haloalkoxy, where R⁹ and R¹⁰ areindependently chosen at each occurrence from hydrogen, C₁-C₆alkyl, and(C₃-C₇cycloalkyl)C₀-C₄alkyl;

(d) —C₀-C₄alkyl(C₃-C₇cycloalkyl) and —O—C₀-C₄alkyl(C₃-C₇cycloalkyl).

Non-Limiting Central Core Embodiments

In alternative embodiments, any one of the following rings (e), (f),(g), (h), (i), or (j) may be present:

(e) R¹ and R^(1′) or R³ and R^(3′) may be taken together to form a 3- to6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclicspiro ring containing 1 or 2 heteroatoms independently chosen from N, O,or S;

(f) R² and R^(2′) may be taken together to form a 3- to 6-memberedcarbocyclic spiro ring,

(g) R² and R^(2′) may be taken together to form a 3- to 6-memberedheterocyclic spiro ring,

each of which spiro rings (e), (f), and (g) is unsubstituted orsubstituted with 1 or more substituents independently chosen fromhalogen (and in particular F), hydroxyl, cyano, —COOH, C₁-C₄alkyl(including in particular methyl), C₂-C₄alkenyl, C₂-C₄alkynyl,C₁-C₄alkoxy, C₂-C₄alkanoyl, hydroxyC₁-C₄alkyl, (mono- anddi-C₁-C₄alkylamino)C₀-C₄alkyl, —C₀-C₄alkyl(C₃-C₇cycloalkyl),—O—C₀-C₄alkyl(C₃-C₇cycloalkyl), C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.

(h) R¹ and R² may be taken together to form a 3-membered carbocyclicring;

(i) R¹ and R² may be taken together to form a 4- to 6-memberedcarbocyclic ring or a 4- to 6-membered heterocyclic ring containing 1 or2 heteroatoms independently chosen from N, O, and S.

(j) R² and R³, if bound to adjacent carbon atoms, may be taken togetherto form a 3- to 6-membered carbocyclic ring or a 3- to 6-memberedheterocyclic ring; each of which ring (h), (i), and (j) may beunsubstituted or substituted with 1 or more substituents independentlychosen from halogen (and in particular F), hydroxyl, cyano, —COOH,C₁-C₄alkyl (including in particular methyl), C₂-C₄alkenyl, C₂-C₄alkynyl,C₁-C₄alkoxy, C₂-C₄alkanoyl, hydroxyC₁-C₄alkyl, (mono- anddi-C₁-C₄alkylamino)C₀-C₄alkyl, —C₀-C₄alkyl(C₃-C₇cycloalkyl),—O—C₀-C₄alkyl(C₃-C₇cycloalkyl), C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.

In one embodiment, the central core moiety is proline.

In one embodiment, the central core moiety is 4-fluoroproline.

In one embodiment, R¹, R^(1′), R^(2′), R³, and R^(3′), if present, areall hydrogen; and R² is fluoro.

In one embodiment, R¹, R^(1′), R^(2′), and R^(3′), if present, are allhydrogen; and R² is fluoro and R³ is —C₀-C₄alkyl(C₃-C₇cycloalkyl) or—O—C₀-C₄alkyl(C₃-C₇cycloalkyl).

In one embodiment, R¹ and R² are taken together to form a 3- to6-membered cycloalkyl group, and R^(1′), R^(2′), R³, and R^(3′), wherepresent, are all hydrogen.

In one embodiment, R¹, R^(1′), R³, and R^(3′), if present, are allhydrogen, and R² and R^(2′) are taken together to form a 5- or6-membered heterocycloalkyl group having 1 or 2 oxygen atoms.

In one embodiment, R¹ is hydrogen and R² is fluoro.

In one embodiment, R¹ and R² are joined to form a 3 membered ring.

The disclosure includes compounds of Formula I in which the centralpyrrolidine is vinyl substituted, for example:

In one embodiment, the compound of Formula I has the structure:

In one embodiment, the central pyrrolidine is modified by addition of asecond heteroatom to a pyrrolidine ring, such as N, O, S, or Si, forexample:

Another modification within the scope of the disclosure is joining asubstituent on the central pyrrolidine ring to R⁷ or R⁸ to form a 5- to6-membered heterocyclic ring, for example:

Example compounds having the modifications disclosed above include:

Central Core L-B Substituents

The central core L-B substituents in Formula I are illustrated below:

L is either (t), (u), or (v):

(t) is a group of the formula

where R¹⁷ is hydrogen or C₁-C₆alkyl and R¹⁸ and R^(18′) areindependently chosen from hydrogen, halogen, hydroxymethyl, and methyl;and m is 0, 1, 2, or 3;

(u) is a bond,

(v) or a directly linked optionally substituted alkyl,alkyl(heteroaryl), heterocyclic aryl, heteroaryl, moiety including butnot limited to:

B is a monocyclic, bicyclic carbocyclic or carbocyclic-oxy group or amonocyclic, bicyclic, or tricyclic heterocyclic group having 1, 2, 3, or4 heteroatoms independently selected from N, O, and S and from 4 to 7ring atoms per ring, or B is a C₂-C₆alkenyl or C₂-C₆alkynyl group, or Bis —(C₀-C₄alkyl)(aryl), —(C₀-C₄alkyl)(heteroaryl), or—(C₀-C₄alkyl)(biphenyl).

Each of which B is unsubstituted or substituted with one or moresubstituents independently chosen from (w) and (x) and 0 or 1substituents chosen from (y) and (z):

(w) halogen, hydroxyl, —COOH, cyano, C₁-C₆alkyl, C₂-C₆alkanoyl,C₁-C₆alkoxy, —C₀-C₄alkylNR⁹R¹⁰, —SO₂R⁹, C₁-C₂haloalkyl, andC₁-C₂haloalkoxy;

(x) nitro, C₂-C₆alkenyl, C₂-C₆alkynyl, C₁-C₆thioalkyl,-JC₃-C₇cycloalkyl, —B(OH)₂, -JC(O)NR⁹R²³, -JOSO₂R²¹,—C(O)(CH₂)₁₋₄S(O)R²¹, SR⁹, —O(CH₂)₁₋₄S(O)NR²¹R²², -JOP(O)(OR²¹)(OR²²),-JP(O)(OR²¹)(OR²²), -JOP(O)(OR²¹)R²², -JP(O)(OR²¹)R²², -JOP(O)R²¹R²²,-JP(O)R²¹R²², -JSP(O)(OR²¹)(OR²²), -JSP(O)(OR²¹)(R²²),-JSP(O)(R²¹)(R²²), -JNR⁹P(O)(OR²¹)(NHR²²), -JNR⁹P(O)(OR²¹)(OR²²),-JNR⁹P(O)(OR²¹)(OR²²), -JC(S)R²¹, -JNR²¹SO₂R²², -JNR⁹S(O)NR¹⁰R²²,-JNR⁹SO₂NR¹⁰R²², -JSO₂NR⁹COR²², -JSO₂NR⁹CONR²¹R²², -JNR²¹SO₂R²²,-JC(O)NR²¹SO₂R²², -JC(NH₂)NR²², -JC(NH₂)NR⁹S(O)₂R²², -JOC(O)NR²¹R²²,-JNR²¹C(O)OR²², -JNR²¹OC(O)R²², —(CH₂)₁₋₄C(O)NR²¹R²², -JC(O)R²⁴R²⁵,-JNR⁹C(O)R²¹, -JC(O)R²¹, -JNR⁹C(O)NR¹⁰R²², —CCR²¹, —(CH₂)₁₋₄OC(O)R²¹,and -JC(O)OR²³; each of which (x) may be unsubstituted or substitutedwith one or more substituents independently chosen from halogen,hydroxyl, nitro, cyano, amino, oxo, —B(OH)₂, —Si(CH₃)₃, —COOH, —CONH₂,—P(O)(OH)₂, C₁-C₆alkyl, C₁-C₆alkoxy, —C₀-C₂alkyl(mono- anddi-C₁-C₄alkylamino), C₁-C₆alkylester, C₁-C₄alkylamino,C₁-C₄hydroxylalkyl, C₁-C₂haloalkyl, and C₁-C₂haloalkoxy;

(y) naphthyl, naphthyloxy, indanyl, (4- to 7-memberedheterocycloalkyl)C₀-C₄alkyl containing 1 or 2 heteroatoms chosen from N,O, and S, and bicyclic heterocycle containing 1, 2, or 3 heteroatomsindependently chosen from N, O, and S, and containing 4- to 7-ring atomsin each ring; each of which (y) is unsubstituted or substituted with oneor more substituents independently chosen from halogen, hydroxyl, nitro,cyano, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkanoyl, C₁-C₆alkoxy, (mono- anddi-C₁-C₆alkylamino)C₀-C₄alkyl, C₁-C₆alkylester,—C₀-C₄alkyl(C₃-C₇cycloalkyl), —SO₂R⁹, C₁-C₂haloalkyl, andC₁-C₂haloalkoxy; and

(z) tetrazolyl, (phenyl)C₀-C₂alkyl, (phenyl)C₁-C₂alkoxy, phenoxy, and 5-or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independentlychosen from N, O, B, and S, each of which (z) is unsubstituted orsubstituted with one or more substituents independently chosen fromhalogen, hydroxyl, nitro, cyano, C₁-C₆alkyl, C₂-C₆alkenyl,C₂-C₆alkanoyl, C₁-C₆alkoxy, (mono- and di-C₁-C₆alkylamino)C₀-C₄alkyl,C₁-C₆alkylester, —C₀-C₄alkyl(C₃-C₇cycloalkyl), —SO₂R⁹,—OSi(CH₃)₂C(CH₃)₃, —Si(CH₃)₂C(CH₃)₃, C₁-C₂haloalkyl, andC₁-C₂haloalkoxy.

In one embodiment, -L-B— is

where

R²⁶ and R²⁷ are independently chosen from hydrogen, halogen, hydroxyl,nitro, cyano, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkanoyl, C₁-C₆alkoxy,C₁-C₆thioalkyl, —C₀-C₄alkyl(mono- and di-C₁-C₆alkylamino),—C₀-C₄alkyl(C₃-C₇cycloalkyl), —C₀-C₄alkoxy(C₃-C₇cycloalkyl),C₁-C₂haloalkyl, C₁-C₂haloalkoxy, and C₁-C₂haloalkylthio.

Non-Limiting L-B Embodiments

In another embodiment, -L-B— is

wherein

R¹⁸ and R^(18′) are independently chosen from hydrogen, halogen,hydroxymethyl, and methyl; and m is 0 or 1; and

R²⁶, R²⁷, and R²⁸ are independently chosen from hydrogen, halogen,hydroxyl, nitro, cyano, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkanoyl,C₁-C₆alkoxy, C₁-C₆thioalkyl, (mono- and di-C₁-C₆alkylamino)C₀-C₄alkyl,(C₃-C₇cycloalkyl)C₀-C₄alkyl, (aryl)C₀-C₄alkyl-, (heteroaryl)C₀-C₄alkyl-,and —C₀-C₄alkoxy(C₃-C₇cycloalkyl); each of which R²⁶, R²⁷, and R²⁸ otherthan hydrogen, halogen, hydroxyl, nitro, cyano, is unsubstituted orsubstituted with one or more substituents independently chosen fromhalogen, hydroxyl, amino, C₁-C₂alkoxy, C₁-C₂haloalkyl,(C₃-C₇cycloalkyl)C₀-C₄alkyl-, and C₁-C₂haloalkoxy; and

R²⁹ is hydrogen, C₁-C₂alkyl, C₁C₂haloalkyl or —Si(CH₃)₂C(CH₃)₃.

In one embodiment, m is 0.

In one embodiment, the disclosure further includes compounds and saltsof Formula I in which B is 2-fluoro-3-chlorophenyl. In anotherembodiment, another carbocyclic, aryl, heterocyclic, or heteroaryl groupsuch as 2-bromo-pyridin-6-yl, 1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl,2,2-dichlorocyclopropylmethyl, or 2-fluoro-3-trimethyl silylphenyl isused.

In another embodiment, B is phenyl, pyridyl, or indanyl each of which isunsubstituted or substituted with one or more substituents independentlychosen from hydrogen, halogen, hydroxyl, nitro, cyano, C₁-C₆alkyl,C₂-C₆alkenyl, C₂-C₆alkanoyl, C₁-C₆alkoxy, C₁-C₆thioalkyl, (mono- anddi-C₁-C₆alkylamino)C₀-C₄alkyl, (C₃-C₇cycloalkyl)C₀-C₄alkyl,—C₀-C₄alkoxy(C₃-C₇cycloalkyl), (phenyl)C₀-C₂alkyl, (pyridyl)C₀-C₂alkyl;each of which substituents other than hydrogen, halogen, hydroxyl,nitro, cyano, is unsubstituted or substituted with one or moresubstituents independently chosen from halogen, hydroxyl, amino,C₁-C₂alkyl, C₁-C₂alkoxy, —OSi(CH₃)₂C(CH₃)₃, —Si(CH₃)₂C(CH₃)₃,C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.

In another embodiment, B is phenyl or pyridyl substituted with 1, 2, or3 substituents chosen from chloro, bromo, hydroxyl, —SCF₃, C₁-C₂alkyl,C₁-C₂alkoxy, trifluoromethyl, phenyl and trifluoromethoxy each of whichsubstituents other than chloro, bromo, hydroxyl, —SCF₃, can beoptionally substituted.

In certain embodiments, B is a 2-fluoro-3-chlorophenyl or a2-fluoro-3-trifluoromethoxyphenyl group.

In one embodiment, B is pyridyl, optionally substituted with halogen,C₁-C₂alkoxy, and trifluoromethyl.

In one embodiment, B is phenyl, substituted with 1, 2, or 3 substituentsindependently selected from halogen, C₁-C₂alkyl, C₁-C₂alkoxy,trifluoromethyl, and optionally substituted phenyl.

In one embodiment, R²³ is independently chosen at each occurrence from(C₃-C₇cycloalkyl)C₀-C₄alkyl, (phenyl)C₀-C₄alkyl, (4- to 7-memberedheterocycloalkyl)C₀-C₄alkyl having 1, 2, or 3 heteroatoms independentlychosen from N, O, and S, and (5- or 6-membered unsaturated or aromaticheterocycle)C₀-C₄alkyl having 1, 2, or 3 heteroatoms independentlychosen from N, O, and S.

In one embodiment, B is selected from

where R²⁷ is hydrogen, methyl, or trifluoromethyl; R²⁸ is hydrogen orhalogen; and R²⁹ is hydrogen, methyl, trifluoromethyl, or—Si(CH₃)₂C(CH₃)₃.Central Core (C═O)A Substituent

The central core (C═O)A substituent in Formula I is illustrated below:

A is a group chosen from (k) and (l) where (k) is

X⁴ is B(OH) and Y is CHR⁹; or X⁴ is CHR⁹ and Y is B(OH).

R¹⁰¹ is hydrogen, alkyl, carboxy.

R⁴ is (m) or (n):

(m) —CHO, —CONH₂, or C₂-C₆alkanoyl, including C(O)C₃-C₇cycloalkyl;

(n) hydrogen, —SO₂NH₂, —C(CH₂)₂F, —CH(CF₃)NH₂, C₁-C₆alkyl,—C₀-C₄alkyl(C₃-C₇cycloalkyl), —C(O)C₀-C₂alkyl(C₃-C₇cycloalkyl),

each of which R⁴ other than hydrogen, —CHO, and —CONH₂, is unsubstitutedor substituted with one or more of amino, imino, halogen, hydroxyl,cyano, cyanoimino, C₁-C₂alkyl, C₁-C₂alkoxy, —C₀-C₂alkyl(mono- anddi-C₁-C₄alkylamino), C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.

R⁵ and R⁶ are independently chosen from (o) and (p):

(o) —CHO, —C(O)NH₂, —C(O)NH(CH₃), or C₂-C₆alkanoyl;

(p) hydrogen, hydroxyl, halogen, cyano, nitro, —COOH, —SO₂NH₂,—C(NH₂)C₁-C₃alkyl, —C(NH₂)C₁-C₃haloalkyl, —CF(C═CH₂),—C(═NCN)C₁-C₆alkyl, C₁-C₆alkyl, C₂-C₆alkenyl, C₁-C₆alkoxy,—C₀-C₄alkyl(C₃-C₇cycloalkyl), —C(O)C₀-C₄alkyl(C₃-C₇cycloalkyl),—P(O)(OR⁹)₂, —OC(O)R⁹, —C(O)OR⁹, —C(O)N(CH₂CH₂R⁹)(R¹⁰), —NR⁹C(O)R¹⁰,phenyl, or 5- to 6-membered heteroaryl.

Each R⁵ and R⁶ other than hydrogen, hydroxyl, cyano, and —COOH isunsubstituted or optionally substituted. For example, R⁵ and R⁶ otherthan hydrogen, hydroxyl, cyano, and —COOH may be substituted with one ormore substituents independently chosen from halogen, hydroxyl, amino,imino, cyano, cyanoimino, C₁-C₂alkyl, C₁-C₄alkoxy, —C₀-C₂alkyl(mono- anddi-C₁-C₄alkylamino), C₁-C₂haloalkyl, C₁-C₂haloalkoxy, C(O)alkyl,C(O)cycloalkyl, C(O)aryl, C(O)heterocycle, and C(O)heteroaryl.

R^(6′) is hydrogen, halogen, hydroxyl, C₁-C₄alkyl, or C₁-C₄alkoxy; or R⁶and R^(6′) may be taken together to form an oxo, vinyl, or imino group.

R⁷ is hydrogen, C₁-C₆alkyl, or —C₀-C₄alkyl(C₃-C₇cycloalkyl).

R⁸ and R^(8′) are independently chosen from hydrogen, halogen, hydroxyl,C₁-C₆alkyl, C₁-C₆alkoxy, and (C₁-C₄alkylamino)C₀-C₂alkyl, or R⁸ andR^(8′) are taken together to form an oxo group, or can be taken togetherwith the carbon that they are bonded to form a 3-membered carbocyclicring.

R¹⁶ is 0 or 1 or more substituents independently chosen from halogen,hydroxyl, nitro, cyano, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkanoyl,C₁-C₆alkoxy, —C₀-C₄alkyl(mono- and di-C₁-C₆alkylamino),—C₀-C₄alkyl(C₃-C₇cycloalkyl), C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.

R¹⁹ is hydrogen, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkanoyl,—SO₂C₁-C₆alkyl, (mono- and di-C₁-C₆alkylamino)C₁-C₄alkyl,—C₀-C₄alkyl(C₃-C₇cycloalkyl), —C₀-C₄alkyl(C₃-C₇heterocycloalkyl),—C₀-C₄alkyl(aryl), C₀-C₄alkyl(heteroaryl), each of which R¹⁹ other thanhydrogen is substituted with 0 or 1 or more substituents independentlychosen from halogen, hydroxyl, amino, —COOH, and —C(O)OC₁-C₄alkyl.

X¹¹ is N or CR¹¹.

X¹² is N or CR¹².

X¹³ is N or CR¹³.

X¹⁴ is N or CR¹⁴.

No more than 2 of X¹¹, X¹², X¹³, and X¹⁴ are N.

R¹¹, R¹⁴, and R¹⁵ are independently chosen at each occurrence fromhydrogen, halogen, hydroxyl, nitro, cyano, —NR⁹C(O)R¹⁰, C(O)NR⁹R¹⁰,—O(PO)(OR⁹)₂, —(PO)(OR⁹)₂, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkenyl(aryl),C₂-C₆alkenyl(cycloalkyl), C₂-C₆alkenyl(heterocycle),C₂-C₆alkenyl(heteroaryl), C₂-C₆alkynyl, C₂-C₆alkynyl(aryl),C₂-C₆alkynyl(cycloalkyl), C₂-C₆alkynyl(heterocycle),C₂-C₆alkynyl(heteroaryl), C₂-C₆alkanoyl, C₁-C₆alkoxy, C₁-C₆thioalkyl,—C₀-C₄alkyl(mono- and di-C₁-C₆alkylamino), —C₀-C₄alkyl(C₃-C₇cycloalkyl),(phenyl)C₀-C₄alkyl, (4- to 7-membered heterocycloalkyl)C₀-C₄alkyl having1, 2, or 3 heteroatoms independently chosen from N, O, and S, and (5- or6-membered unsaturated or aromatic heterocycle)C₀-C₄alkyl having 1, 2,or 3 heteroatoms independently chosen from N, O, and S),—C₀-C₄alkoxy(C₃-C₇cycloalkyl), C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.Alternatively, R¹³ and R¹⁴ can together form a bridge that can be anoptionally substituted cycloalkyl, heterocycle or heteroaryl ring.

In one embodiment, R⁵ and R⁶ are independently chosen from —CHO,—C(O)NH₂, —C(O)NH(CH₃), C₂-C₆alkanoyl, and hydrogen.

In one embodiment, each R⁵ and R⁶ other than hydrogen, hydroxyl, cyano,and —COOH is unsubstituted or substituted with one or more substituentsindependently chosen from halogen, hydroxyl, amino, imino, cyano,cyanoimino, C₁-C₂alkyl, C₁-C₄alkoxy, —C₀-C₂alkyl(mono- anddi-C₁-C₄alkylamino), C₁-C₂haloalkyl, C₁-C₂haloalkoxy, C(O)alkyl,C(O)cycloalkyl, C(O)aryl, C(O)heterocycle, and C(O)heteroaryl.

In one embodiment, R⁸ and R^(8′) are independently hydrogen or methyl.

In one embodiment, R⁸ and R^(8′) are hydrogen.

In one embodiment, R⁷ is hydrogen or methyl.

In one embodiment, R⁷ is hydrogen.

In an alternate embodiment, two A groups can be bonded together to forma dimer through a suitable linking group that achieves the desiredpurpose. Examples of linking groups include but are not limited to,urea, amide, —C(O)—C(O)—, carbamate and ketone. In one embodiment, twoheteroaryl rings, for example, two indole rings, are linked through aurea to form indole-NHC(O)NH-indole.

Embodiments of Formulas IA, IB, IC, and ID

To further illustrate the invention, various embodiments of Formula IA,IB, IC and ID are provided. These are presented by way of example toshow some of the variations among presented compounds within theinvention and can be applied to any of the Formulas I-XXX.

In one aspect, this disclosure includes compounds and salts of FormulaIA:

where R⁶, R¹³, and B may carry any of the definitions set forth hereinfor this variable.

In another aspect, this disclosure includes compounds and salts ofFormula IB, IC, and ID.

In Formulas IA, IB, IC, and ID, the variables may include any of thedefinitions set forth herein that results in a stable compound.

Embodiments of Formula VII

To further illustrate the invention, various embodiments of Formula VII.In one aspect, the disclosure includes compounds and salts of FormulaVII:

wherein:

R¹, R², R^(2′), and R³ are independently chosen from hydrogen, halogen,C₁-C₄alkyl, C₁-C₄alkoxy, —C₀-C₂alkylNR⁹R¹⁰,—C₀-C₄alkyl(C₃-C₇cycloalkyl), —O—C₀-C₄alkyl(C₃-C₇cycloalkyl),C₁-C₂haloalkyl, and C₁-C₂haloalkoxy;

R⁸ and R^(8′) are independently chosen from hydrogen, halogen, andmethyl;

R⁵ is hydrogen, hydroxyl, cyano, —COOH, C₁-C₆alkyl, C₁-C₆alkoxy,C₂-C₆alkanoyl —C₀-C₄alkyl(C₃-C₇cycloalkyl),—C(O)C₀-C₄alkyl(C₃-C₇cycloalkyl, C₁-C₂haloalkyl, or C₁-C₂haloalkoxy;

R⁶ is —C(O)CH₃, —C(O)NH₂, —C(O)CF₃, —C(O)(cyclopropyl), or-ethyl(cyanoimino); and

R¹¹ and R¹⁴ are independently chosen from hydrogen, halogen, hydroxyl,amino, nitro, cyano, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkanoyl,C₁-C₆alkoxy, C₁-C₆thioalkyl, —C₀-C₄alkyl(mono- and di-C₁-C₆alkylamino),—C₀-C₄alkyl(C₃-C₇cycloalkyl), —OC₀-C₄alkyl(C₃-C₇cycloalkyl),C₁-C₂haloalkyl, and C₁-C₂haloalkoxy.

Prodrugs of Formula I are also within the scope of the disclosure.

III. Pharmaceutical Preparations

Compounds disclosed herein can be administered as the neat chemical, butcan also administered as a pharmaceutical composition, that includes aneffective amount for a host in need of treatment of the selectedcompound of Formula I, as described herein. Accordingly, the disclosureprovides pharmaceutical compositions comprising an effective amount ofcompound or pharmaceutically acceptable salt of Formula I, together withat least one pharmaceutically acceptable carrier. The pharmaceuticalcomposition may contain a compound or salt of Formula I as the onlyactive agent, or, in an alternative embodiment, Formula I and at leastone additional active agent. In certain embodiments the pharmaceuticalcomposition is in a dosage form that contains from about 0.1 mg to about2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about800 mg, or from about 200 mg to about 600 mg of a compound of Formula Iand optionally from about 0.1 mg to about 2000 mg, from about 10 mg toabout 1000 mg, from about 100 mg to about 800 mg, or from about 200 mgto about 600 mg of an additional active agent in a unit dosage form.Examples are dosage forms with at least 25, 50, 100, 200, 250, 300, 400,500, 600, 700, or 750 mg of active compound, or its salt. Thepharmaceutical composition may also include a molar ratio of a compoundof Formula I and an additional active agent. For example thepharmaceutical composition may contain a molar ratio of about 0.5:1,about 1:1, about 2:1, about 3:1 or from about 1.5:1 to about 4:1 of ananother anti-inflammatory agent.

Compounds disclosed herein may be administered orally, topically,parenterally, by inhalation or spray, sublingually, via implant,including ocular implant, transdermally, via buccal administration,rectally, as an ophthalmic solution, injection, including ocularinjection, intraveneous, intra-aortal, intracranial, or by other means,in dosage unit formulations containing conventional pharmaceuticallyacceptable carriers. The pharmaceutical composition may be formulated asany pharmaceutically useful form, e.g., as an aerosol, a cream, a gel, apill, a capsule, a tablet, a syrup, a transdermal patch, or anophthalmic solution. Some dosage forms, such as tablets and capsules,are subdivided into suitably sized unit doses containing appropriatequantities of the active components, e.g., an effective amount toachieve the desired purpose.

Carriers include excipients and diluents and must be of sufficientlyhigh purity and sufficiently low toxicity to render them suitable foradministration to the patient being treated. The carrier can be inert orit can possess pharmaceutical benefits of its own. The amount of carrieremployed in conjunction with the compound is sufficient to provide apractical quantity of material for administration per unit dose of thecompound.

Classes of carriers include, but are not limited to binders, bufferingagents, coloring agents, diluents, disintegrants, emulsifiers,flavorants, glidents, lubricants, preservatives, stabilizers,surfactants, tableting agents, and wetting agents. Some carriers may belisted in more than one class, for example vegetable oil may be used asa lubricant in some formulations and a diluent in others. Exemplarypharmaceutically acceptable carriers include sugars, starches,celluloses, powdered tragacanth, malt, gelatin; talc, and vegetableoils. Optional active agents may be included in a pharmaceuticalcomposition, which do not substantially interfere with the activity ofthe compound of the present invention.

The pharmaceutical compositions/combinations can be formulated for oraladministration. These compositions can contain any amount of activecompound for Formula I that achieves the desired result, for examplebetween 0.1 and 99 weight % (wt. %) of a compound of Formula I andusually at least about 5 wt. % of a compound of Formula I. Someembodiments contain from about 25 wt. % to about 50 wt. % or from about5 wt. % to about 75 wt. % of the compound of Formula I.

The complement factor D inhibitors of the present invention can beadministered, for example, either systemically or locally. Systemicadministration includes, for example, oral, transdermal, subdermal,intraperitioneal, subcutaneous, transnasal, sublingual, or rectal. Localadministration for ocular administration includes: topical,intravitreal, periocular, transscleral, retrobulbar, juxtascleral,sub-tenon, or via an intraocular device. The inhibitors may be deliveredvia a sustained delivery device implanted intravitreally ortranssclerally, or by other known means of local ocular delivery.

IV. Methods of Treatment

The compounds and pharmaceutical compositions disclosed herein areuseful for treating or preventing a disorder that is mediated by thecomplement pathway, and in particular, a pathway that is modulated bycomplement factor D. In certain embodiments, the disorder is aninflammatory disorder, an immune disorder, an autoimmune disorder, orcomplement factor D related disorders in a host. In one embodiment, thedisorder is an ocular disorder. Complement mediated disorders that maybe treated or prevented by the compounds and compositions of thisdisclosure include, but are not limited to, inflammatory effects ofsepsis, systemic inflammatory response syndrome (SIRS),ischemia/reperfusion injury (I/R injury), psoriasis, myasthenia gravis,system lupus erythematosus (SLE), paroxysmal nocturnal hemoglobinuria(PNH), hereditary angioedema, multiple sclerosis, trauma, burn injury,capillary leak syndrome, obesity, diabetes, Alzheimer's dementia,stroke, schizophrenia, epilepsy, age-related macular degeneration,glaucoma, diabetic retinopathy, asthma, allergy, acute respiratorydistress syndrome (ARDS), atypical hemolytic uremic syndrome (aHUS),hemolytic uremic syndrome (HUS), cystic fibrosis, myocardial infarction,lupus nephritides, Crohn's disease, rheumatoid arthritis,atherosclerosis, transplant rejection, prevention of fetal loss,biomaterial reactions (e.g. in hemodialysis, inplants), C3glomerulonephritis, abdominal aortic aneurysm, neuromyelitis optica(NMO), vasculitis, neurological disorders, Guillain Barre Syndrome,traumatic brain injury, Parkinson's disease, disorders of inappropriateor undesirable complement activation, hemodialysis complications,hyperacute allograft rejection, xenograft rejection, interleukin-2induced toxicity during I L-2 therapy, inflammatory disorders,inflammation of autoimmune diseases, adult respiratory distresssyndrome, thermal injury including burns or frostbite, myocarditis,post-ischemic reperfusion conditions, balloon angioplasty, post-pumpsyndrome in cardiopulmonary bypass or renal bypass, hemodialysis, renalischemia, mesenteric artery reperfusion after aortic reconstruction,immune complex disorders and autoimmune diseases, SLE nephritis,proliferative nephritis, liver fibrosis, hemolytic anemia, tissueregeneration and neural regeneration. In addition, other knowncomplement related disease are lung disease and disorders such asdyspnea, hemoptysis, chronic obstructive pulmonary disease (COPD),emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dustdiseases, inert dusts and minerals (e.g., silicon, coal dust, beryllium,and asbestos), pulmonary fibrosis, organic dust diseases, chemicalinjury (due to irritant gases and chemicals, e.g., chlorine, phosgene,sulfur dioxide, hydrogen sulfide, nitrogen dioxide, ammonia, andhydrochloric acid), smoke injury, thermal injury (e.g., burn, freeze),bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases,Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune vasculitis,immune complex-associated inflammation, uveitis (including Behcet'sdisease and other sub-types of uveitis), antiphospholipid syndrome,arthritis, autoimmune heart disease, inflammatory bowel disease,ischemia-reperfusion injuries, Barraquer-Simons Syndrome, hemodialysis,systemic lupus, lupus erythematosus, transplantation, diseases of thecentral nervous system and other neurodegenerative conditions,glomerulonephritis (including membrane proliferativeglomerulonephritis), blistering cutaneous diseases (including bullouspemphigoid, pemphigus, and epidermolysis bullosa), ocular cicatricalpemphigoid, MPGN II, uveitis, adult macular degeneration, diabeticretinopathy, retinitis pigmentosa, macular edema, Behcet's uveitis,multifocal choroiditis, Vogt-Koyangi-Harada syndrome, imtermediateuveitis, birdshot retino-chorioditis, sympathetic ophthalmia, oculardicatricial pemphigoid, ocular pemphigus, nonartertic ischemic opticneuropathy, postoperative inflammation, and retinal vein occlusion.

In some embodiments, complement mediated diseases include ophthalmicdiseases (including early or neovascular age-related maculardegeneration and geographic atrophy), autoimmune diseases (includingarthritis, rheumatoid arthritis), respiratory diseases, cardiovasculardiseases. In other embodiments, the compounds of the invention aresuitable for use in the treatment of diseases and disorders associatedwith fatty acid metabolism, including obesity and other metabolicdisorders.

In one embodiment, a method for the treatment of paroxysmal nocturnalhemoglobinuria (PNH) is provided that includes the administration of aneffective amount of a compound of Formula I, or a pharmaceuticallyacceptable salt thereof, optionally in a pharmaceutically acceptablecarrier. In another embodiment, a method for the treatment ofage-related macular degeneration (AMD) is provided that includes theadministration of an effective amount of a compound of Formula I, or apharmaceutically acceptable salt thereof, optionally in apharmaceutically acceptable carrier. In another embodiment, a method forthe treatment of rheumatoid arthritis is provided that includes theadministration of an effective amount of a compound of Formula I, or apharmaceutically acceptable salt thereof, optionally in apharmaceutically acceptable carrier. In another embodiment, a method forthe treatment of multiple sclerosis is provided that includes theadministration of an effective amount of a compound of Formula I, or apharmaceutically acceptable salt thereof, optionally in apharmaceutically acceptable carrier. In another embodiment, a method forthe treatment of myasthenia gravis is provided that includes theadministration of an effective amount of a compound of Formula I, or apharmaceutically acceptable salt thereof, optionally in apharmaceutically acceptable carrier. In another embodiment, a method forthe treatment of atypical hemolytic uremic syndrome (aHUS) is providedthat includes the administration of an effective amount of a compound ofFormula I, or a pharmaceutically acceptable salt thereof, optionally ina pharmaceutically acceptable carrier. In another embodiment, a methodfor the treatment of C3 glomerulonephritis is provided that includes theadministration of an effective amount of a compound of Formula I, or apharmaceutically acceptable salt thereof, optionally in apharmaceutically acceptable carrier. In another embodiment, a method forthe treatment of abdominal aortic aneurysm is provided that includes theadministration of an effective amount of a compound of Formula I, or apharmaceutically acceptable salt thereof, optionally in apharmaceutically acceptable carrier. In another embodiment, a method forthe treatment of neuromyelitis optica (NMO) is provided that includesthe administration of an effective amount of a compound of Formula I, ora pharmaceutically acceptable salt thereof, optionally in apharmaceutically acceptable carrier.

In some embodiments, the present invention provides methods of treatingor preventing an inflammatory disorder or a complement related disease,by administering to a host in need thereof an effective amount of acompound of Formula I of the invention. In some embodiments, the presentinvention provides methods of treating or preventing an inflammatorydisorder more generally, an immune disorder, autoimmune disorder, orcomplement factor D related disease, by providing an effective amount ofa compound or pharmaceutically acceptable salt of Formula I to patientwith a factor D mediated inflammatory disorder. A compound or salt ofFormula I may be provided as the only active agent or may be providedtogether with one or more additional active agents.

In one embodiment, a method for the treatment of a disorder associatedwith a dysfunction in the complement cascade is provided that includesthe administration of an effective amount of a compound of Formula I, ora pharmaceutically acceptable salt thereof, optionally in apharmaceutically acceptable carrier. In one embodiment, a method ofinhibiting activation of the alternative complement pathway in a subjectis provided that includes the administration of an effective amount of acompound of Formula I, or a pharmaceutically acceptable salt thereof,optionally in a pharmaceutically acceptable carrier. In one embodiment,a method of modulating factor D activity in a subject is provided thatincludes the administration of an effective amount of a compound ofFormula I, or a pharmaceutically acceptable salt thereof, optionally ina pharmaceutically acceptable carrier.

“Prevention” as used in this disclosure means decreasing the likelihoodof the appearance of symptoms in a patient administered the compoundprophylactically as compared to the likelihood of the appearance ofsymptoms in patients not administered the compound or decreasing theseverity of symptoms in a patient administered the compoundprophylactically as compared to the severity of symptoms experienced bypatients with the disorder or condition who were not administered thecompound. In an alternative embodiment, an effective amount of acompound of Formula I is used to prevent or prophylaxis of a complementfactor D related disorder.

An effective amount of a pharmaceutical composition/combination of theinvention may be an amount sufficient to (a) inhibit the progression ofa disorder mediated by the complement pathway, including aninflammatory, immune, including an autoimmune, disorder or complementfactor D related disease; (b) cause a regression of an inflammatory,immune, including an autoimmune, disorder or complement factor D relateddisease; or (c) cause a cure of an inflammatory, immune, including anautoimmune, disorder or complement factor D related disease.

An effective amount of a compound or pharmaceutical compositiondescribed herein will also provide a sufficient amount of the activeagent when administered to a patient to provide a clinical benefit. Suchan amount may be ascertained experimentally, for example by assayingblood concentration of the agent, or theoretically, by calculatingbioavailability.

V. Combination Therapy

In one embodiment, a compound or salt of Formula I may be provided incombination or alternation with at least one additional inhibitor of thecomplement system or a second active compound with a differentbiological mechanism of action. In one embodiment, a compound or salt ofFormula I may be provided in combination with a complement C5 inhibitoror C5 convertase inhibitor. In another embodiment, a compound or salt ofFormula I may be provided in combination with eculizumab. In oneembodiment, a compound or salt of Formula I may be provided incombination with additional inhibitors of factor D.

In one embodiment, a compound or salt of Formula I may be providedtogether with a compound that inhibits an enzyme that metabolizesprotease inhibitors. In one embodiment, a compound or salt of Formula Imay be provided together with ritonavir.

In nonlimiting embodiments, a compound or salt of Formula I may beprovided together with a protease inhibitor, a soluble complementregulator, a therapeutic antibody (monoclonal or polyclonal), complementcomponent inhibitors, receptor agonists, or siRNAs.

Nonlimiting examples of active agents in these categories are:

Protease inhibitors: plasma-derived C1-INH concentrates, for exampleCetor® (Sanquin), Berinert-P® (CSL Behring, Lev Pharma), and Cinryze®;and recombinant human C1-inhibitors, for example Rhucin®;

Soluble complement regulators: Soluble complement receptor 1 (TP10)(Avant Immunotherapeutics); sCR1-sLex/TP-20 (Avant Immunotherapeutics);MLN-2222/CAB-2 (Millenium Pharmaceuticals); Mirococept (InflazymePharmaceuticals);

Therapeutic antibodies: Eculizumab/Soliris (Alexion Pharmaceuticals);Pexelizumab (Alexion Pharmaceuticals); Ofatumumab (Genmab A/S); TNX-234(Tanox); TNX-558 (Tanox); TA106 (Taligen Therapeutics); Neutrazumab (G2Therapies); Anti-properdin (Novelmed Therapeutics); HuMax-CD₃₈ (GenmabA/S);

Complement component inhibitors: Compstatin/POT-4 (PotentiaPharmaceuticals); ARC1905 (Archemix);

Receptor agonists: PMX-53 (Peptech Ltd.); JPE-137 (Jerini); JSM-7717(Jerini);

Others: Recombinant human MBL (rhMBL; Enzon Pharmaceuticals).

In an embodiment, the present invention provides a method of treating orpreventing age-related macular degeneration (AMD) by administering to asubject in need thereof an effective amount of a composition comprisinga compound of the current invention. In one embodiment, the compositionsof the present invention are administered in combination with ananti-VEGF agent. Nonlimiting examples of anti-VEGF agents include, butare not limited to, aflibercept (Eylea®; Regeneron Pharmaceuticals);ranibizumab (Lucentis®: Genentech and Novartis); and pegaptanib(Macugen®; OSI Pharmaceuticals and Pfizer); Bevacizumab (Avastin;Genentech/Roche); anecortane acetate, squalamine lactate, andcorticosteroids, including, but not limited to, triamcinolone acetonide.

In another embodiment, a compound of Formula I can be combined with asecond agent in order to treat a disorder of the eye.

Examples of types of therapeutic agents that can be used in combinationfor ocular applications include anti-inflammatory drugs, antimicrobialagents, anti-angiogenesis agents, immunosuppressants, antibodies,steroids, ocular antihypertensive drugs and combinations thereof.Examples of therapeutic agents include amikacin, anecortane acetate,anthracenedione, anthracycline, an azole, amphotericin B, bevacizumab,camptothecin, cefuroxime, chloramphenicol, chlorhexidine, chlorhexidinedigluconate, clortrimazole, a clotrimazole cephalosporin,corticosteroids, dexamethasone, desamethazone, econazole, eftazidime,epipodophyllotoxin, fluconazole, flucytosine, fluoropyrimidines,fluoroquinolines, gatifloxacin, glycopeptides, imidazoles, itraconazole,ivermectin, ketoconazole, levofloxacin, macrolides, miconazole,miconazole nitrate, moxifloxacin, natamycin, neomycin, nystatin,ofloxacin, polyhexamethylene biguanide, prednisolone, prednisoloneacetate, pegaptanib, platinum analogues, polymicin B, propamidineisethionate, pyrimidine nucleoside, ranibizumab, squalamine lactate,sulfonamides, triamcinolone, triamcinolone acetonide, triazoles,vancomycin, anti-vascular endothelial growth factor (VEGF) agents, VEGFantibodies, VEGF antibody fragments, vinca alkaloid, timolol, betaxolol,travoprost, latanoprost, bimatoprost, brimonidine, dorzolamide,acetazolamide, pilocarpine, ciprofloxacin, azithromycin, gentamycin,tobramycin, cefazolin, voriconazole, gancyclovir, cidofovir, foscarnet,diclofenac, nepafenac, ketorolac, ibuprofen, indomethacin,fluoromethalone, rimexolone, anecortave, cyclosporine, methotrexate,tacrolimus and combinations thereof. Examples of eye disorders that maybe treated according to the compositions and methods disclosed hereininclude amoebic keratitis, fungal keratitis, bacterial keratitis, viralkeratitis, onchorcercal keratitis, bacterial keratoconjunctivitis, viralkeratoconjunctivitis, corneal dystrophic diseases, Fuchs' endothelialdystrophy, Sjogren's syndrome, Stevens-Johnson syndrome, autoimmune dryeye diseases, environmental dry eye diseases, corneal neovascularizationdiseases, post-corneal transplant rejection prophylaxis and treatment,autoimmune uveitis, infectious uveitis, anterior uveitis, posterioruveitis (including toxoplasmosis), pan-uveitis, an inflammatory diseaseof the vitreous or retina, endophthalmitis prophylaxis and treatment,macular edema, macular degeneration, age related macular degeneration,proliferative and non-proliferative diabetic retinopathy, hypertensiveretinopathy, an autoimmune disease of the retina, primary and metastaticintraocular melanoma, other intraocular metastatic tumors, open angleglaucoma, closed angle glaucoma, pigmentary glaucoma and combinationsthereof.

A compound of Formula I, or a combination of Formula I and anotheractive agent, can be administered into an eye compartment of viainjection into the vitreous chamber, subretinal space, subchoroidalspace, the episclera, the conjunctiva, the sclera, the anterior chamber,and the cornea and compartments therein (e.g., subepithelial,intrastromal, endothelial).

In an alternative embodiment, a compound of Formula I, or a combinationof Formula I and another active agent, can be administered into an eyecompartment via binding to a mucosal penetrating particle to treat acondition located in the vitreous chamber, subretinal space,subchoroidal space, the episclera, the conjunctiva, the sclera or theanterior chamber, and the cornea and compartments therein (e.g.,subepithelial, intrastromal, endothelial). Mucosal penetrating particlesare known in the art, and are described in, for example, PCT publishedapplication WO 2013166436 to Kala Pharmaceuticals, incorporated in itsentirety herein.

In other embodiments, a composition comprising compound of Formula Isuitable for topical administration to an eye is provided. Thepharmaceutical composition comprises a plurality of coated particles,comprising a core particle comprising a compound of Formula I, whereinFormula I constitutes at least about 80 wt % of the core particle, and acoating comprising one or more surface-altering agents, wherein the oneor more surface-altering agents comprise at least one of a poloxamer, apoly(vinyl alcohol), or a polysorbate. The one or more surface-alteringagents is present on the outer surface of the core particle at a densityof at least 0.01 molecules/nm. The one or more surface-altering agentsis present in the pharmaceutical composition in an amount of betweenabout 0.001% to about 5% by weight. The plurality of coated particleshave an average smallest cross-sectional dimension of less than about 1micron. The pharmaceutical composition also includes one or moreophthalmically acceptable carriers, additives, and/or diluents.

It will be appreciated by one of ordinary skill in the art thatparticles suitable for use with the presently disclosed methods canexist in a variety of shapes, including, but not limited to, spheroids,rods, disks, pyramids, cubes, cylinders, nanohelixes, nanosprings,nanorings, rod-shaped particles, arrow-shaped particles, teardrop-shapedparticles, tetrapod-shaped particles, prism-shaped particles, and aplurality of other geometric and non-geometric shapes. In someembodiments, the presently disclosed particles have a spherical shape.

In one embodiment, the present invention provides a method of treatingor preventing paroxysmal nocturnal hemoglobinuria (PNH) by administeringto a subject in need thereof an effective amount of a compositioncomprising a compound of the current invention. In one embodiment, thepresent invention provides a method of treating or preventing paroxysmalnocturnal hemoglobinuria (PNH) by administering to a subject in needthereof an effective amount of a composition comprising a compound ofthe current invention in combination or alternation with additionalinhibitors of the complement system or another active compound with adifferent biological mechanism of action. In another embodiment, thepresent invention provides a method of treating or preventing paroxysmalnocturnal hemoglobinuria (PNH) by administering to a subject in needthereof an effective amount of a composition comprising a compound ofthe current invention in combination or alternation with eculizumab.

In one embodiment, the present invention provides a method of treatingor preventing rheumatoid arthritis by administering to a subject in needthereof an effective amount of a composition comprising a compound ofthe current invention. In one embodiment, the present invention providesa method of treating or preventing rheumatoid arthritis by administeringto a subject in need thereof an effective amount of a compositioncomprising a compound of the current invention in combination oralternation with an additional inhibitor of the complement system. Inanother embodiment, the present invention provides a method of treatingor preventing rheumatoid arthritis by administering to a subject in needthereof an effective amount of a composition comprising a compound ofthe current invention in combination or alternation with methotrexate.

In certain embodiments, a compound of Formula I is administered incombination or alternation with at least one anti-rhuematoid arthritisdrug selected from: salicylates including aspirin (Anacin, Ascriptin,Bayer Aspirin, Ecotrin) and salsalate (Mono-Gesic, Salgesic);nonsteroidal anti-inflammatory drugs (NSAIDs); nonselective inhibitorsof the cyclo-oxygenase (COX-1 and COX-2) enzymes, including diclofenac(Cataflam, Voltaren), ibuprofen (Advil, Motrin), ketoprofen (Orudis),naproxen (Aleve, Naprosyn), piroxicam (Feldene), etodolac (Lodine),indomethacin, oxaprozin (Daypro), nabumetone (Relafen), and meloxicam(Mobic); selective cyclo-oxygenase-2 (COX-2) inhibitors includingCelecoxib (Celebrex); disease-modifying antirheumatic drugs (DMARDs),including azathioprine (Imuran), cyclosporine (Sandimmune, Neoral), goldsalts (Ridaura, Solganal, Aurolate, Myochrysine), hydroxychloroquine(Plaquenil), leflunomide (Arava), methotrexate (Rheumatrex),penicillamine (Cuprimine), and sulfasalazine (Azulfidine); biologicdrugs including abatacept (Orencia), etanercept (Enbrel), infliximab(Remicade), adalimumab (Humira), and anakinra (Kineret); corticosteroidsincluding betamethasone (Celestone Soluspan), cortisone (Cortone),dexamethasone (Decadron), methylprednisolone (SoluMedrol, DepoMedrol),prednisolone (Delta-Cortef), prednisone (Deltasone, Orasone), andtriamcinolone (Aristocort); gold salts, including Auranofin (Ridaura);Aurothioglucose (Solganal); Aurolate; Myochrysine; or any combinationthereof.

In one embodiment, the present invention provides a method of treatingor preventing multiple sclerosis by administering to a subject in needthereof an effective amount of a composition comprising a compound ofthe current invention. In one embodiment, the present invention providesa method of treating or preventing multiple sclerosis by administeringto a subject in need thereof an effective amount of a compositioncomprising a compound of the current invention in combination oralternation with additional inhibitors of the complement system. Inanother embodiment, the present invention provides a method of treatingor preventing multiple sclerosis by administering to a subject in needthereof an effective amount of a composition comprising a compound ofthe current invention in combination or alternation with acorticosteroid. Examples of corticosteroids include, but are not limitedto, prednisone, dexamethasone, solumedrol, and methylprednisolone.

In one embodiment, a compound of Formula I is combined with at least oneanti-multiple sclerosis drug selected from: Aubagio (teriflunomide),Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone(glatiramer acetate), Extavia (interferon beta-1b), Gilenya(fingolimod), Lemtrada (alemtuzumab), Novantrone (mitoxantrone),Plegridy (peginterferon beta-1a), Rebif (interferon beta-1a), Tecfidera(dimethyl fumarate), Tysabri (natalizumab), Solu-Medrol(methylprednisolone), High-dose oral Deltasone (prednisone), H.P. ActharGel (ACTH), and combinations thereof.

In one aspect, a compound or salt of Formula I may be provided incombination or alternation with an immunosuppressive agent or ananti-inflammatory agent.

In one embodiment of the present invention, a compound described hereincan be administered in combination or alternation with at least oneimmunosuppressive agent. The immunosuppressive agent as nonlimitingexamples, may be a calcineurin inhibitor, e.g. a cyclosporin or anascomycin, e.g. Cyclosporin A (NEORAL®), FK506 (tacrolimus),pimecrolimus, a mTOR inhibitor, e.g. rapamycin or a derivative thereof,e.g. Sirolimus (RAPAMUNE®), Everolimus (Certican®), temsirolimus,zotarolimus, biolimus-7, biolimus-9, a rapalog, e.g. ridaforolimus,azathioprine, campath 1H, a S1P receptor modulator, e.g. fingolimod oran analogue thereof, an anti IL-8 antibody, mycophenolic acid or a saltthereof, e.g. sodium salt, or a prodrug thereof, e.g. MycophenolateMofetil (CELLCEPT®), OKT3 (ORTHOCLONE OKT3®), Prednisone, ATGAM®,THYMOGLOBULIN®, Brequinar Sodium, OKT4, T10B9.A-3A, 33B3.1,15-deoxyspergualin, tresperimus, Leflunomide ARAVA®, CTLA4lg,anti-CD_(25,) anti-IL2R, Basiliximab (SIMULECT®), Daclizumab (ZENAPAX®),mizorbine, methotrexate, dexamethasone, ISAtx-247, SDZ ASM 981(pimecrolimus, Elidel®), CTLA4lg (Abatacept), belatacept, LFA3lg,etanercept (sold as Enbrel® by Immunex), adalimumab (Humira®),infliximab (Remicade®), an anti-LFA-1 antibody, natalizumab (Antegren®),Enlimomab, gavilimomab, antithymocyte immunoglobulin, siplizumab,Alefacept efalizumab, pentasa, mesalazine, asacol, codeine phosphate,benorylate, fenbufen, naprosyn, diclofenac, etodolac and indomethacin,aspirin and ibuprofen.

Examples of anti-inflammatory agents include methotrexate,dexamethasone, dexamethasone alcohol, dexamethasone sodium phosphate,fluromethalone acetate, fluromethalone alcohol, lotoprendol etabonate,medrysone, prednisolone acetate, prednisolone sodium phosphate,difluprednate, rimexolone, hydrocortisone, hydrocortisone acetate,lodoxamide tromethamine, aspirin, ibuprofen, suprofen, piroxicam,meloxicam, flubiprofen, naproxan, ketoprofen, tenoxicam, diclofenacsodium, ketotifen fumarate, diclofenac sodium, nepafenac, bromfenac,flurbiprofen sodium, suprofen, celecoxib, naproxen, rofecoxib,glucocorticoids, diclofenac, and any combination thereof. In oneembodiment, a compound of Formula I is combined with one or morenon-steroidal anti-inflammatory drugs (NSAIDs) selected from naproxensodium (Anaprox), celecoxib (Celebrex), sulindac (Clinoril), oxaprozin(Daypro), salsalate (Disalcid), diflunisal (Dolobid), piroxicam(Feldene), indomethacin (Indocin), etodolac (Lodine), meloxicam (Mobic),naproxen (Naprosyn), nabumetone (Relafen), ketorolac tromethamine(Toradol), naproxen/esomeprazole (Vimovo), and diclofenac (Voltaren),and combinations thereof.

VI. Process of Preparation of Compounds of Formula I Abbreviations

-   (Boc)₂O di-tert-butyl dicarbonate-   ACN Acetonitrile-   AcOEt, EtOAc ethyl acetate-   CH₃OH, MeOH Methanol-   CsF Cesium fluoride-   CuI Cuprous iodide-   DCM, CH₂Cl₂ Dichloromethane-   DIEA, DIPEA N,N-diisopropylethylamine-   DMA N,N-dimethylacetamide-   DMF N,N-dimethylformamide-   DMSO Dimethyl sulfoxide-   DPPA Diphenyl phosphoryl azide-   Et₃N, TEA Triethylamine-   EtOAc Ethyl acetate-   EtOH Ethanol-   HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo    [4,5-b]pyridinium 3-oxide hexafluorophosphate-   HCl Hydrochloric acid-   ^(i)Pr₂NEt N,N-diisopropylethylamine-   K₂CO₃ Potassium carbonate-   LiOH Lithium hydroxide-   MTBE Methyl ^(t)butylether-   Na₂SO₄ Sodium sulfate-   NaCl Sodium chloride-   NaH Sodium hydride-   NaHCO₃ Sodium bicarbonate-   NEt₃, TEA Triethylamine-   (OAc)₂ Palladium acetate-   Pd(dppf)Cl₂ [1,1′-Bis(diphenylphosphino)    ferrocene]dichloropalladium(II)-   Pd(PPh₃)₂Cl₂ Bis(triphenylphosphine)palladium(II) dichloride-   Pd(PPh₃)₄ Tetrakis(triphenylphosphine)palladium(0)-   Pd₂ (dba)₃ Tris(dibenzylideneacetone)dipalladium(0)-   PPh₃ Triphenylphosphine-   RT Room temperature-   TBTU O-Benzotriazolyl tetramethylisouronium tetrafluoroborate-   tBuOK potassium tert-butoxide-   Tf₂O trifluoromethanesulfonic anhydride-   TFA Trifluoroacetic acid-   THF Tetrahydrofuran-   TMSBr Bromotrimethylsilane-   t_(R) Retention time-   Zn (CN)₂ Zinc cyanide    General Methods

All nonaqueous reactions were performed under an atmosphere of dry argonor nitrogen gas using anhydrous solvents. The progress of reactions andthe purity of target compounds were determined using one of the twoliquid chromatography (LC) methods listed below. The structure ofstarting materials, intermediates, and final products was confirmed bystandard analytical techniques, including NMR spectroscopy and massspectrometry.

LC Method A

Instrument: Waters Acquity Ultra Performance LC

Column: ACQUITY UPLC BEH C18 2.1×50 mm, 1.7 μm

Column Temperature: 40° C.

Mobile Phase: Solvent A: H₂O+0.05% FA; Solvent B: CH₃CN+0.05% FA

Flow Rate: 0.8 mL/min

Gradient: 0.24 min @15% B, 3.26 min gradient (15-85% B), then 0.5 min@85% B.

Detection: UV (PDA), ELS, and MS (SQ in EI mode)

LC Method B

Instrument: Shimadzu LC-2010A HT

Column: Athena, C18-WP, 50×4.6 mm, 5 μm

Column Temperature: 40° C.

Mobile Phase: Solvent A: H₂O/CH₃OH/FA=90/10/0.1; Solvent B:H₂O/CH₃OH/FA=10/90/0.1

Flow Rate: 3 mL/min

Gradient: 0.4 min @30% B, 3.4 min gradient (30-100% B), then 0.8 min@100% B

Detection: UV (220/254 nm)

Example 1. General Route of Synthesis

A compound of the present invention can be prepared, for example, from acentral core. In one embodiment, for example, the central core Structure1 is an N-protected aminoacid where X¹ is nitrogen and PG=protectinggroup. In one embodiment, the central core is coupled to an amine togenerate an amide of Structure 2 (wherein L-B includes a C(O)N moiety).Structure 2 can then be deprotected to generate Structure 3. Structure 3is coupled to Structure 4 (A-COOH) to generate a second amide bond,forming a compound within Formula I. The chemistry is illustrated inRoute 1.

In an alternative embodiment, central core Structure 5 is reacted with aheterocyclic or heteroaryl compound to generate a compound of Structure6. In one embodiment, Structure 6 is deprotected to generate acarboxylic acid, Structure 7. In one embodiment, Structure 7 is coupledto an amine to generate a compound of Formula I. This chemistry isillustrated in Route 2.

In an alternative embodiment, Structure 8 is deprotected to generate anamine which is Structure 9. Structure 9 is then coupled to generate anamide which is Structure 6. Structure 6 is then deprotected to generatea carboxylic acid which is Structure 7. Structure 7 is then coupled toform the amide which falls within Formula I. The chemistry isillustrated in Route 3.

In an alternate embodiment, a heteroaryl or aryl moiety, 4-1, is coupledto a central core to generate 4-2. The protected acid, 4-2 is deblockedto form the carboxylic acid, 4-3. The carboxylic acid is then coupled toform an amide (L-B) which is 4-4. The heteroaryl or aryl moiety, A′, canthen be further derivitized to add substituents at the X¹¹, X¹², X¹³ andX¹⁴ positions to generate compounds of Formula I. This chemistry isillustrated in Route 4.

In an alternate embodiment, Structure 5-1 is coupled to an acid,Structure 5-2, to generate Structure 5-3. The carboxylic acid, Structure5-3, is deblocked to generate a carboxylic acid which is Structure 5-4.Carboxylic acid Structure 5-4 is coupled to an amine to form the productamide (L-B) which is a compound within Formula I. This chemistry isillustrated in Route 5.

In an alternate embodiment, Structure 6-1 is coupled to an amine togenerate an amide (L-B) which is Structure 6-2. Structure 6-2 is coupledto an amine to generate compounds within Formula I. This chemistry isillustrated in Route 6.

In another embodiment, a heteroaryl compound, for example, Structure 7-1is iodinated to incorporate an iodide group at the R⁶ position. Other R⁶groups can be introduced by those skilled in the art. For example,Structure 7-1 can be acylated to introduce an acyl group at the R⁶position. Structure 7-2 is coupled to an activated ester, Structure 7-3,to generate Structure 7-4. In some embodiments, the leaving group, LG,is a halide. Structure 7-4 is treated with inorganic cyanide and twoorganometallic catalysts to generate a cyano group at the R⁶ position.In some embodiments, the inorganic cyanide is zinc cyanide. In someembodiments, the organometallic catalyst are Pd(dppf)₂ and Pd₂(dba)₃.Structure 7-4 is treated with an organic acid to generate Structure 7-5.In some embodiments, the organic acid is trifluoroacetic acid. Structure7-5 is coupled to Structure 3, from Route 1, to generate compounds ofFormula I. This chemistry is illustrated in Route 7.

In another embodiment, a heteroaryl compound, for example, Structure8-1, is coupled to an activated ester, Structure 8-2, to generateStructure 8-3. In some embodiments, R⁶ is C(O)OEt. In some embodiments,the leaving group, LG, is a halide. Structure 8-3 is treated with anorganic acid to generate Structure 8-4. In some embodiments, the organicacid is trifluoroacetic acid. Structure 8-4 is coupled to Structure 3from Route 1 to generate compounds of Formula I. In some embodiments,wherein R⁶ is C(O)OEt, the ester can be hydrolyzed and the acid used togenerate an amide, —C(O)NH₂ at the R⁶ position. This chemistry isillustrated in Route 8.

In another embodiment, a heteroaryl compound, Structure 9-1, is coupledto an activated ester, Structure 9-2, to generate Structure 9-3. In someembodiments, the leaving group, LG₁, is a halide. In some embodiments,LG is a halide. In some embodiments, Structure 9-3 is treated with aninorganic cyanide and two organometallic catalyst to generate structure9-4. In some embodiments, the inorganic cyanide is zinc cyanide. In someembodiments, the two organometallic catalysts are Pd₂(dba)₃ andPd(dppf)Cl₂. Structure 9-4 is treated with an organic acid to generateStructure 9-5. In some embodiments, the organic acid is trifluoroaceticacid. Structure 9-5 is coupled to Structure 3 from Route 1 to generatecompounds of Formula I. This chemistry is illustrated in Route 9.

In another embodiment, a heteroaryl compound, Structure 10-1, is coupledto an activated ester, Structure 10-2, to generate Structure 10-3. Insome embodiments, the leaving group, LG₁, is a halide. In someembodiments, LG is a halide. In some embodiments, Structure 10-3 istreated with an inorganic cyanide and two organometallic catalyst togenerate structure 10-4. In some embodiments, the inorganic cyanide iszinc cyanide. In some embodiments, the two organometallic catalysts arePd₂(dba)₃ and Pd(dppf)Cl₂. Structure 10-4 is treated with an organicacid to generate Structure 10-5. In some embodiments, the organic acidis trifluoroacetic acid. Structure 10-5 is coupled to Structure 3 fromRoute 1 to generate compounds of Formula I. This chemistry isillustrated in Route 10.

A central core that is directed linked to an aryl or heteroaryl group inplace of the L-B region can be prepared according to known processes.For example, a central core is alkylated to generate a central core-Acompound comprising a carboxylic acid is reduced to an alcohol and usedto generate an alkyl halide. The alkyl halide is treated with aheteroaryl compound to generate a compound of Formula I. This chemistrycan be carried out by those skilled in the art of organic chemistry. Seefor example: Advanced Organic Chemistry: Reactions, Mechanisms andStructure by J. March.

In one embodiment, a pyrrolidine compound is alkylated to generate apyrrolidine-C(O)-A compound. The product is chlorinated alpha to thepyrrolidine and treated with base to generate an imine. The imineproduct is treated with a heteroaryl compound to generate a compound ofFormula I. This chemistry can be carried out by those skilled in the artof organic chemistry. See for example: Advanced Organic Chemistry:Reactions, Mechanisms and Structure by J. March.

In one embodiment, an amino indole is treated with phosgene or aphosgene equivalent to generate a compound of Formula I. This chemistrycan be carried out by those skilled in the art of organic chemistry. Seefor example: Advanced Organic Chemistry: Reactions, Mechanisms andStructure by J. March.

Example 2. Examples of Central Synthons

Z^(A) is halogen.

In one embodiment, deuterated L-proline synthons are disclosed.Deuterated synthons include, but are not limited to, for example, thefollowing compounds:

Structure A can be treated with deuterium oxide to generate Structure B.See, Barraclough, P. et al. Tetrahedron Lett. 2005, 46, 4653-4655;Barraclough, P. et al. Org. Biomol. Chem. 2006, 4, 1483-1491 and WO2014/037480 (p. 103). Structure B can be reduced to generate StructureC. See, Barraclough, P. et al. Tetrahedron Lett. 2005, 46, 4653-4655;Barraclough, P. et al. Org. Biomol. Chem. 2006, 4, 1483-1491. StructureC can be treated with Mitsunobu reaction conditions to generateStructure D. Structure B can be treated with DAST to generate StructureE. See, WO 2014/037480. Structure A can be treated with sodiumborodeuteride to generate Structure F. See, Dormoy, J.-R.; Castro, B.Synthesis 1986, 81-82. Compound F can be used to generate Structure K.See, Dormoy, J.-R.; Castro, B. Synthesis 1986, 81-82. Structure B can betreated with a deuterated reducing agent, for example sodiumborodeuteride to generate Structure G. Structure G can be treated withDAST to generate Structure H. Structure F can be used to generateStructure K. See, Dormoy, J.-R.; Castro, B. Synthesis 1986, 81-82.Structure G can be used to generate Structure I. Structure J can beprepared according to Hruby, V. J. et al. J. Am. Chem. Soc. 1979, 101,202-212. Structures A-J can be used to prepare compounds of Formula I.

Example 3. Preparation of Central-L-B Synthons

In Route 1a, 5-azaspiro[2.4]heptane-4,5-dicarboxylic acid,5-(1,1-dimethylethyl) ester, (4S)-, CAS 209269-08-9, can be prepared asdescribed in Tandon, M. et al. Bioorg. Med. Chem. Lett. 1998, 8,1139-1144. In Step 2, the protected azaspiro[2.4]heptane is coupled toan amine in the presence of an organic solvent, a base and a couplingreagent to generate an amide bond; the L-B moiety. In one embodiment,the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment,the organic solvent is DMF. In one embodiment, the base isdiisopropylethylamine. In one embodiment, the coupling reagent is HATU.In Step 3, the protecting group is removed. In one embodiment, thestarting material is reacted with an acid in the presence of an organicsolvent. In one embodiment, the acid is 4N hydrochloric acid. In oneembodiment, the organic solvent is dioxane.

In Route 1b, (4S) 4-oxazolidinecarboxylic acid, hydrochloride is treatedwith an amine protecting reagent. In one embodiment, the amineprotecting reagent is di-tert-butyl dicarbonate. In another embodiment,3,4-oxazolidinedicarboxylic acid, 3-(1,1-dimethylethyl) ester, (4S)—, iscommercially available from JPM2 Pharmaceuticals. In one embodiment thereaction is carried out in an organic solvent in the presence of a base.In one embodiment, the organic solvent is acetonitrile. In oneembodiment, the base is 4-dimentylaminopyridine (DMAP). In Step 2, theprotected 4-oxazolidinecarboxylic acid is coupled to an amine in thepresence of an organic solvent, a base and a coupling reagent togenerate an amide bond; the L-B moiety. In one embodiment, the amine is(3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organicsolvent is DMF. In one embodiment, the base is diisopropylethylamine. Inone embodiment, the coupling reagent is HATU. In Step 3, the protectinggroup is removed. In one embodiment, the starting material is reactedwith an acid in the presence of an organic solvent. In one embodiment,the acid is 4N hydrochloric acid. In one embodiment, the organic solventis dioxane.

In Route 1c,(S)-5-(tert-Butoxycarbonyl)-5-azaspiro[2.4]heptane-6-caboxylic acid, CAS1129634-44-1, is commercially available from Ark Pharm. In Step 2, thecarboxylic acid is coupled to an amine in the presence of an organicsolvent, a base and a coupling reagent to generate an amide bond; theL-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl)methanamine. In one embodiment, the organic solvent is DMF. In oneembodiment, the base is diisopropylethylamine. In one embodiment, thecoupling reagent is HATU. In Step 3, the protecting group is removed. Inone embodiment, the starting material is reacted with an acid in thepresence of an organic solvent. In one embodiment, the acid is 4Nhydrochloric acid. In one embodiment, the organic solvent is dioxane.

In Route 2a, commercially available Boc-L-proline is coupled to an aminein the presence of an organic solvent, a base and a coupling reagent togenerate an amide bond; the L-B moiety. In one embodiment, the amine is(3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organicsolvent is DMF. In one embodiment, the base is diisopropylethylamine. Inone embodiment, the coupling reagent is HATU. In Step 2, the Bocprotecting group is removed. In one embodiment, the starting material isreacted with an acid in the presence of an organic solvent. In oneembodiment, the acid is 4N hydrochloric acid. In one embodiment, theorganic solvent is dioxane.

In Route 2b, commercially available (1R, 3S,5R)-2-[(tert-butoxy)carbonyl]-2-azabicyclo[3.1.0]hexane-3-carboxylicacid, from Enamine, is coupled to an amine in the presence of an organicsolvent, a base and a coupling reagent to generate an amide bond; theL-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl)methanamine. In one embodiment, the organic solvent is DMF. In oneembodiment, the base is diisopropylethylamine. In one embodiment, thecoupling reagent is HATU. In Step 2, the Boc protecting group isremoved. In one embodiment, the starting material is reacted with anacid in the presence of an organic solvent. In one embodiment, the acidis 4N hydrochloric acid. In one embodiment, the organic solvent isdioxane.

In Route 2c, commercially available(2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid,from Manchester Organics, is coupled to an amine in the presence of anorganic solvent, a base and a coupling reagent to generate an amidebond; the L-B moiety. In one embodiment, the amine is(3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organicsolvent is DMF. In one embodiment, the base is diisopropylethylamine. Inone embodiment, the coupling reagent is HATU. In Step 2, the Bocprotecting group is removed. In one embodiment, the starting material isreacted with an acid in the presence of an organic solvent. In oneembodiment, the acid is 4N hydrochloric acid. In one embodiment, theorganic solvent is dioxane.

In Route 2d, commercially available(S)-1-(tert-butoxycarbonyl)indoline-2-carboxylic acid, from Chem-Impex,is coupled to an amine in the presence of an organic solvent, a base anda coupling reagent to generate an amide bond; the L-B moiety. In oneembodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In oneembodiment, the organic solvent is DMF. In one embodiment, the base isdiisopropylethylamine. In one embodiment, the coupling reagent is HATU.In Step 2, the Boc protecting group is removed. In one embodiment, thestarting material is reacted with an acid in the presence of an organicsolvent. In one embodiment, the acid is 4N hydrochloric acid. In oneembodiment, the organic solvent is dioxane. This chemistry isillustrated in Scheme 2.

Additional starting materials that can readily be converted toCentral-L-B-Synthons include, but are not limited to:(S)-1-(tert-butoxycarbonyl)-2,3-dihydro-1H-pyrrole-2-carboxylic acid,CAS 90104-21-5, available from Ark Pharm;cyclopent-1-ene-1,2-dicarboxylic acid, CAS 3128-15-2, purchased from ArkPharm; imidazole, 1H-imidazole-1,2-dicarboxylic acid,1-(1,1-dimethylethyl) 2-ethyl ester, CAS 553650-00-3, commerciallyavailable from FCH Group; Boc-L-octahydroindole-2-carboxylic acid can bepurchased from Chem Impex. The compound,

can be prepared according to the procedures disclosed in WO 2004/111041;(S)-Boc-5-oxopyrrolidine-2-carboxylic acid is available from the AldrichChemical Co.;(1S,2S,5R)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.3.0]hexane-2-carboxylicacid is available from Ark Pharm; (S)-3-Boc-thiazolidine-2-carboxylicacid is available from Alfa Aesar;(2S,4R)-1-(tert-butoxycarbonyl)-4-chloropyrrolidine-2-carboxylic acid isavailable from Arch Bioscience;(1S,3aR,6aS)-2-(tert-butoxycarbonyl)octahydrocyclopenta[c]pyrrole-1-carboxylicacid is available from Ark Pharm; 1,2-pyrrolidinedicarboxylic acid,3-[[(phenylmethoxy)carbonyl]amino]-, 1-(1,1-dimethylethyl) ester,(2S,3R) can be prepared as disclosed in WO 2004/007501. The Cbz groupcan be removed and the amino group can be alkylated to generate centralcore compounds of the present invention.

The compound

can be prepared as disclosed by Braun, J. V.; Heymons, Albrecht Berichteder Deutschen Chemischen Gesellschaft [Abteilung] B: Abhandlungen (1930)63B, 502-7.

The compounds (2S,3S,4S)-4-fluoro-3-methoxy-pyrrolidine-1,2-dicarboxylicacid 1-tert-butyl ester and(2R,3R,4R)-3-fluoro-4-methoxy-pyrrolidine-1,2-dicarboxylic acid1-tert-butyl ester can be prepared as a mixture according to WO2012/093101 to Novartis and the regioisomers can be ultimately separatedonce coupled to generate the central core-L-B synthons. The compound(S)-Boc-5-oxopyrrolidine-2-carboxylic acid is available from the AldrichChemical Co.

Example 4. Preparation of A-C(O)-Moiety

Examples of the preparation of the A-C(O)-Moiety can be found in Example1 and below.

In an alternate embodiment, a heteroaryl compound of Structure 1-1 isacylated to generate Structure 1-2. In an alternate embodiment,Structure 1-1 is treated with an inorganic cyanide and organometalliccatalysts to generate a compound where R⁶=cyano. The cyano compound canbe treated with an oxime to generate an amide, —C(O)NH₂, at the R⁶position. Structure 1-2 is coupled to an activated ester of Structure1-3 to generate Structure 1-4. In some embodiments, the leaving group,LG, is a halide. The ester is hydrolyzed to generate acid Structure 1-5.This chemistry is illustrated in Route 4a.

In an alternate embodiment, a heteroaryl compound of Structure 2-1 isacylated to generate Structure 2-2. In an alternate embodiment,Structure 2-1 is treated with an inorganic cyanide and organometalliccatalysts to generate a compound where R⁶=cyano. The cyano compound canbe treated with an oxime to generate an amide, —C(O)NH₂, at the R⁶position. Structure 2-2 is coupled to an activated ester of Structure2-3 to generate Structure 2-4. In some embodiments, the leaving group,LG, is a halide. The ester group in Structure 2-4 is hydrolyzed togenerate acid Structure 2-5. This chemistry is illustrated in Route 4b.

In an alternate embodiment, a heteroaryl compound of Structure 3-1 isacylated to generate Structure 3-2. In an alternate embodiment,Structure 3-1 is treated with an inorganic cyanide and organometalliccatalysts to generate a compound where R⁶=cyano. The cyano compound canbe treated with an oxime to generate an amide, —C(O)NH₂, at the R⁶position. Structure 3-2 is coupled to an activated ester of Structure3-3 to generate Structure 3-4. In some embodiments, the leaving group,LG, is a halide. The ester is hydrolyzed to generate an acid which isStructure 3-5. This chemistry is illustrated in Route 4c.

Example 5. Coupling of Central-L-B-Synthons to A-C(O)-Moieties

Examples of the coupling of central-L-B-synthons to A-C(O)-moieties canbe found in Example 1 and below.

In one embodiment, Structure 1-5, from Example 4 Route 4a, is coupled toStructure 3 from Route 1 to generate compounds of Formula I. Thischemistry is illustrated in Route 5a.

In one embodiment, Structure 2-5 from Example 4 Route 4b is coupled to acentral core-L-B to generate compounds of Formula I. This chemistry isillustrated in Route 5b.

In one embodiment, Structure 3-5, from Example 4 Route 4c, is coupled toStructure 3 from Route 1 to generate compounds of Formula I. Thischemistry is illustrated in Route 5c.

Example 6. Syntheses of Non-Limiting Examples of Compounds of Formula IScheme 1. Synthesis of(2S,4R)—N-(2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-4-fluoropyrrolidine-2-carboxamidehydrochloride (Int-1)

Step 1: 2′-Chloro-2-fluoro-[1,1′-biphenyl]-3-amine hydrochloride (SM3)

A mixture of SM1 (30 g), SM2 (60 g), K₂CO₃ (91 g), and Pd(dppf)₂Cl₂(19.25 g) in solvent (dioxane 400 mL, H₂O 100 mL) was purged with argonin a pressure vessel for 5 min and stirred for 15 h at 100° C. Thesolvent was removed under reduced pressure and the remaining residue waspurified by column chromatography. The purified material was thendissolved in MeOH and treated with HCl/MeOH. The solvent was removedunder reduced pressure and the remaining solid was washed withIPA-heptane (1/1) to afford SM3.

Step 2: (2S,4R)-tert-Butyl2-((2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate(SM5)

To an ice-cold solution of SM4 (530 mg) in DCM (20 mL) was added1-chloro-N,N,2-trimethyl-1-propenylamine (0.333 mL, 1.1 equiv) dropwisewith stirring. The stirring was continued for 3 h at this temperatureand then solid SM3 (640 mg, 1.1 equiv) was added, followed by DIEA (1.12mL, 3 equiv). The cooling bath was removed and the reaction mixture wasstirred overnight at rt. The reaction mixture was then added to water(20 mL) and extracted with DCM (2×25 mL). The organic layer was washedsuccessively with an aqueous solution of NaHCO₃ (20 mL), water (20 mL),and brine (20 mL), then dried over Na₂SO₄ and concentrated under reducedpressure. The remaining residue was purified by column chromatography(eluted with hexanes/EtOAc) to give SM5.

Step 3:(2S,4R)—N-(2′-Chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-4-fluoropyrrolidine-2-carboxamidehydrochloride (Int-1)

(2S,4R)-tert-Butyl2-((2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidine-1-carboxylateSM5 (700 mg) was taken in 4 N HCl in dioxane (25 mL) and the resultingreaction mixture was stirred at rt for 3 h. The solvent was then removedunder reduced pressure and the remaining residue Int-1 was used directlywithout further purification.

Scheme 2. Synthesis of(2S,4R)—N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide TFASalt (Int-2)

Step 1: (2S,4R)-tert-Butyl2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate(SM8)

To an ice-cold solution of SM6 (30 g) in DCM (600 mL) was added1-chloro-N,N,2-trimethyl-1-propenylamine (18.7 mL, 1.1 equiv) dropwisewith stirring. The stirring was continued for 3 h at this temperature.Solid SM7 (24.48 g, 1.1 equiv) was then added, followed by DIEA (67.2mL, 3 equiv). The cooling bath was removed and the reaction mixture wasstirred overnight at rt. The solvent was co-evaporated with MeOH (30mL). The residue was then dissolved in chloroform (300 mL) and washedsuccessively with cold 1 N aq HCl (3×200 mL), water (300 mL), andsaturated aq NaHCO₃ (300 mL). The organic layer was dried (Na₂SO₄) andconcentrated under reduced pressure. The remaining residue was stirredin a 1:1 solution of DCM and heptane (150 mL). The white solid wasisolated by filtration and dried under high vacuum to afford SM8 (37.3g).

Step 2:(2S,4R)—N-(6-Bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide TFASalt (Int-2)

SM8 was dissolved in DCM and equal volume of TFA was added. The mixturewas stirred for 30 min at rt. The volatiles were removed under reducedpressure and the the residue Int-2 was used without furtherpurification.

Scheme 3: Synthesis of1-(2-((2S,4R)-2-((2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-1H-thieno[3,2-c]pyrazole-3-carboxamide(99)

Step 1: 1H-Thieno[3,2-c]pyrazole (99b)

The title compound 99b (310 mg) was prepared from3-bromothiophene-2-carbaldehyde 99a according to the literature (Airey,J. et al. Synthesis 2014, 96-100). ¹H NMR (400 MHz, CDCl₃, 300 K): δ7.11 (s, 1H), 7.60 (s, 1H), 7.76+8.03 (1H), 13.33+13.0 (1H).

Step 2: 3-Iodo-1H-thieno[3,2-c]pyrazole (99c)

1H-Thieno[3,2-c]pyrazole 99b (310 mg, 2.5 mmol) in DMF (10 mL) wastreated with iodine (954 mg, 3.76 mmol), followed by powdered KOH (421mg, 7.5 mmol). The mixture was stirred overnight at rt. The mixture wasdiluted with water (50 mL), followed by addition of 10% Na₂S₂O₃ solution(5 mL). The mixture was extracted with ethyl acetate (3×50 mL). Thecombined organic extracts were washed with brine and dried overmagnesium sulfate. The solution was filtered and concentrated, and theresidue 99c was used in the next step without purification.

Step 3: tert-Butyl 2-(3-iodo-1H-thieno[3,2-c]pyrazol-1-yl)acetate (99d)

The residue 99c from Step 2 was dissolved in CH₃CN (50 mL). To thissolution, tert-butyl 2-bromoacetate (634 mg, 0.48 mL, 3.25 mmol) andsolid potassium carbonate (1.03 g, 7.5 mmol) were added. The mixture wasrefluxed overnight under an atmosphere of argon. The reaction mixturewas cooled to rt and filtered through a pad of Celite®. The solid cakewas washed with CH₃CN (20 mL), and the combined solution wasconcentrated under reduced pressure. The remaining residue was purifiedby column chromatography to afford pure compound 99d (610 mg) and impureisomer tert-butyl 2-(3-iodo-2H-thieno[3,2-c]pyrazol-2-yl)acetate (130mg). ¹H NMR (400 MHz, CDCl₃): δ 1.45 (s, 9H), 4.93 (s, 2H), 6.93 (d,J=5.2 Hz, 1H), 7.42 (d, J=5.2 Hz, 1H). LC/MS (EI) m/z: [M+H]⁺ 365.

Step 4: tert-Butyl 2-(3-cyano-1H-thieno[3,2-c]pyrazol-1-yl)acetate (99e)

To a degassed solution of t-butyl2-(3-iodo-1H-thieno[3,2-c]pyrazol-1-yl)acetate 99d (610 mg, 1.67 mmol)in the co-solvents DMF (14 mL) and water (2 mL) were added Zn(CN)₂ (235mg, 2.0 mmol), Pd(dppf)₂ (125 mg, 0.17 mmol), and Pd₂(dba)₃ (156 mg,0.17 mmol) under an atmosphere of argon. The mixture was heated at 110°C. for 6 h. The reaction mixture was cooled to rt and the volatiles wereremoved under reduced pressure. The remaining residue was diluted withethyl acetate (50 mL) and filtered through a pad of Celite®. The solidwas washed with ethyl acetate (30 mL). The combined organic solution wasconcentrated under reduced pressure and the remaining residue waspurified by column chromatography to afford the title compound 99e (290mg). ¹H NMR (400 MHz, CDCl₃, 300 K): δ 1.47 (s, 9H), 5.0 (s, 2H), 6.93(d, J=5.2 Hz, 1H), 7.52 (d, J=5.2 Hz, 1H). LC/MS (EI) m/z: [M+H]⁺ 264.

Step 5: 2-(3-Carbamoyl-1H-thieno[3,2-c]pyrazol-1-yl)acetic acid (99f)

A solution of tert-butyl 2-(3-cyano-1H-thieno[3,2-c]pyrazol-1-yl)acetate(59 mg, 0.22 mmol) in TFA (2 mL) was subjected to microwave irradiationat 140° C. for 30 min. The mixture was concentrated under reducedpressure, and the residue was co-evaporated with toluene (10 mL) twice.The dried residue 99f was used directly in the next step. LC/MS (EI)m/z: 226.

Step 6:1-(2-((2S,4R)-2-((2′-Chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-1H-thieno[3,2-c]pyrazole-3-carboxamide(99)

To a solution of the residue 99f (0.22 mmol) from Step 5 was added(2S,4R)—N-(2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-4-fluoropyrrolidine-2-carboxamidehydrochloride Int-1 (90 mg, 0.24 mmol) in DMF (2 mL) followed by HATU(109 mg, 0.29 mmol) and dropwise addition of DIEA (0.3 mL) at rt. Thereaction mixture was stirred for 1 h at rt and the volatiles wereremoved under reduced pressure. The residue was diluted with 20 mL of10% sodium carbonate and extracted with ethyl acetate (3×20 mL). Thecombined organic solution was washed with water and brine, and thendried over MgSO₄. The solution was filtered and the solvent was removedunder reduced pressure. The remaining residue was purified by columnchromatography to afford 99 (50.7 mg). ¹H NMR (400 MHz, DMSO-d₆, 300 K):(major rotamer) δ 2.00-2.19 (m, 1H), 2.47-2.53 (m, 1H), 3.75-3.88 (m,1H), 4.02-4.11 (m, 1H), 4.70 (t, J=8.8 Hz, 1H), 5.26 (d, J=17.2 Hz, 1H),5.38-5.49 (m, 2H), 6.97-7.01 (m, 1H), 7.05 (d, J=5.2 Hz, 1H), 7.15 (t,J=7.6 Hz, 1H), 7.30-7.41 (m, 4H), 7.51-7.54 (m, 2H), 7.60-7.62 (m, 1H),7.89-7.93 (m, 1H), 9.92 (s, 1H); ¹⁹F NMR (376 MHz, DMSO-d₆, 300K):(major rotamer) δ −126.8, −175.8. LC (method A): t_(R)=1.94 min. LC/MS(EI) m/z: [M+H]⁺ 544.

Scheme 4: Synthesis of1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-1H-thieno[3,2-c]pyrazole-3-carboxamide(106)

To a solution of 2-(3-carbamoyl-1H-thieno[3,2-c]pyrazol-1-yl)acetic acid99f (0.193 mmol) was added(2S,4R)—N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamidehydrochloride (0.212 mmol) in DMF (1.5 mL) followed by TBTU (93 mg, 0.29mmol) and dropwise addition of DIEA (0.21 mL, 1.2 mmol). The reactionmixture was stirred for 0.5 h at rt, then quenched by aq NaHCO₃ (5 mL).The precipitate was collected by filtration and purified by columnchromatography (eluent: 5% MeOH in DCM) to give 106 (68 mg). ¹H NMR (400MHz, CDCl₃-CD₃OD, 300 K): (major rotamer) δ 2.37 (m, 1H), 2.39-2.41 (m,1H), 2.59-2.70 (m, 1H), 3.65 (dd, J=36.0, 12.4 Hz, 1H), 3.90-3.98 (dd,J=20.0, 12.0 Hz, 1H), 4.80 (t, J=8.0 Hz, 1H), 5.18 (d, J=8.0 Hz, 1H),5.4 (m, 1H), 6.96 (d, J=8.0 Hz, 1H), 7.22 (d, J=8.0 Hz, 1H), 7.50 (d,J=4.0 Hz, 1H), 7.55 (t, J=8.0 Hz, 1H), 8.14 (d, J=8.0 Hz, 1H). ³¹F NMR(376 MHz, CDCl₃-CD₃OD, 300 K): (major rotamer) δ −177.0. LC (method A):t_(R)=1.33 min. LC/MS (EI) m/z: [M+H]⁺ 497.

Scheme 5: Synthesis of1-(2-((1R,3S,5R)-3-((3-chloro-2-fluorobenzyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-thieno[3,2-c]pyrazole-3-carboxamide(109)

To a solution of 2-(3-carbamoyl-1H-thieno[3,2-c]pyrazol-1-yl)acetic acid99f (0.287 mmol) was added(1R,3S,5R)—N-(3-chloro-2-fluorobenzyl)-2-azabicyclo[3.1.0]hexane-3-carboxamidehydrochloride (48 mg, 0.158 mmol) in DMF (1.5 mL) followed by TBTU (69mg, 0.216 mmol) and dropwise addition of DIEA (0.13 mL, 0.75 mmol). Thereaction mixture was stirred for 0.5 h at rt, then quenched by aq NaHCO₃(5 mL). The mixture was extracted with EtOAc (30 mL) and the organiclayer was washed with water and brine. The solvent was removed underreduced pressure and the remaining residue was purified by columnchromatography (eluent: 5% MeOH in DCM) to give 109 (57 mg). ¹H NMR (400MHz, CDCl₃, 300 K): (major rotamer) δ 0.59-0.61 (m, 1H), 1.08-1.12 (m,1H), 1.95-2.06 (m, 3H), 2.70-2.72 (m, 1H), 3.34-3.62 (m, 1H), 4.41 (s,2H), 4.57-4.60 (m, 1H), 5.21-5.32 (m, 2H), 6.00 (s, 1H), 6.70 (s, 1H),6.84-6.85 (m, 1H), 6.92-6.94 (m, 1H), 7.11-7.13 (m, 1H), 7.21-7.26 (m,1H), 7.36-7.38 (m, 1H), 7.43 (m, 1H). ¹³C NMR (100 MHz, CDCl₃, 300 K):(major rotamer) δ 19.40, 20.74, 29.97, 37.14, 37.52, 53.43, 65.54,108.95, 120.76, 120.94, 123.07, 124.58, 124.63, 126.83, 126.98, 127.93,129.56, 134.78, 137.27, 150.91, 154.84, 157.30, 163.16, 167.60, 170.45.³¹F NMR (376 MHz, CDCl₃, 300 K): (major rotamer) δ −120.9. LC (methodA): t_(R)=1.49 min. LC/MS (EI) m/z: [M+H]⁺ 476.

Scheme 6: Synthesis of1-(2-((2S,4R)-2-((2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-methyl-1H-thieno[3,2-c]pyrazole-3-carboxamide(113)

Step 1: 3-Bromo-5-methylthiophene-2-carbaldehyde (113b)

To a solution of 4-bromo-2-methylthiophene 113a (11 g, 62 mmol) inanhydrous THF (100 mL) cooled to −78° C. was added dropwise a 2 MLDA-THF solution (34 mL, 68 mmol) under an atmosphere of argon. Themixture was stirred for 2 h at −78° C. and then anhydrous DMF (9.6 mL,124 mmol) was added. The reaction mixture was kept at −78° C. for 1 hand quenched with 10% aq citric acid (10 mL). The volatiles were removedunder reduced pressure and the remaining residue was diluted with ethylacetate (150 mL). The organic layer was successively washed with 5% aqcitric acid (80 mL), water (100 mL), and brine (50 mL), and then driedover MgSO₄. The solution was filtered and concentrated under reducedpressure to afford 113b (12.3 g) as a pale yellow oil, which was used inthe next step without further purification.

Step 2: 5-Methyl-1H-thieno[3,2-c]pyrazole (113c)

The title compound 113c (3.0 g) was prepared from3-bromo-5-methylthiophene-2-carbaldehyde 113b (12.2 g) in a mannersimilar to that reported in the literature (Airey, J. et al. Synthesis2014, 96-100). ¹H NMR (400 MHz, CDCl₃, 300 K): δ 2.49 (s, 3H), 6.86 (s,1H), 7.65+7.89 (1H), 12.83+13.10 (1H). LC/MS (EI) m/z: [M+H]⁺ 139.

Step 3: 3-Iodo-5-methyl-1H-thieno[3,2-c]pyrazole (113d)

The title compound 113d was prepared from5-methyl-1H-thieno[3,2-c]pyrazole (1.0 g) in a manner similar to thatdescribed in Step 2 of Scheme 3.

Step 4: tert-Butyl2-(3-iodo-5-methyl-1H-thieno[3,2-c]pyrazol-1-yl)acetate (113e)

The title compound 113e was prepared from3-iodo-5-methyl-1H-thieno[3,2-c]pyrazole in a similar manner asdescribed in Step 3 of Scheme 3. ¹H NMR (400 MHz, CDCl₃): 1.46 (s, 9H),2.53 (s, 3H), 4.87 (s, 2H), 6.64 (s, 1H) ppm. MH⁺ 379.09. Minor productis tert-butyl 2-(3-iodo-5-methyl-2H-thieno[3,2-c]pyrazol-2-yl)acetate.¹H NMR (400 MHz, CDCl₃, 300 K): δ 1.47 (s, 9H), 2.51 (s, 3H), 4.98 (s,2H), 6.80 (s, 1H). LC/MS (EI) m/z: [M+H]⁺ 379.

Step 5: tert-Butyl2-(3-cyano-5-methyl-1H-thieno[3,2-c]pyrazol-1-yl)acetate (113f)

The title compound 113f was prepared from tert-butyl2-(3-iodo-5-methyl-1H-thieno[3,2-c]pyrazol-1-yl)acetate (823 mg, 2.15mmol) in a manner similar to that described in Step 4 of Scheme 3. ¹HNMR (400 MHz, CDCl₃, 300 K): δ 1.47 (s, 9H), 2.56 (s, 3H), 4.93 (s, 2H),6.65 (s, 1H). LC/MS (EI) m/z: [M+H]⁺ 278.

Step 6: 2-(3-Carbamoyl-5-methyl-1H-thieno[3,2-c]pyrazol-1-yl)acetic acid(113g)

The title compound 113g was prepared from tert-butyl2-(3-cyano-5-methyl-1H-thieno[3,2-c]pyrazol-1-yl)acetate (143 mg) in amanner similar to that described in Step 5 of Scheme 3. LC/MS (EI) m/z:[M+H]⁺ 240.

Step 7:1-(2-((2S,4R)-2-((2′-Chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-methyl-1H-thieno[3,2-c]pyrazole-3-carboxamide(113)

The title compound 113 (86.9 mg) was prepared from2-(3-carbamoyl-5-methyl-1H-thieno[3,2-c]pyrazol-1-yl)acetic acid (105mg, 0.3 mmol) in a manner similar to that described in Step 6 of Scheme3. ¹H NMR (400 MHz, DMSO-d₆, 300 K): (major rotamer) δ 2.06-2.19 (m,1H), 2.39 (s, 3H), 2.40-2.55 (m, 1H), 3.74-3.87 (m, 1H), 4.02-4.10 (m,1H), 4.69 (t, J=8.8 Hz, 1H), 5.18 (d, J=17.2 Hz, 1H), 5.31-5.51 (m, 2H),6.79 (s, 1H), 7.0 (t, J=7.2 Hz, 1H), 7.15 (t, J=8.0 Hz, 1H), 7.24-7.46(m, 4H), 7.50-7.53 (m, 2H), 7.87-7.92 (m, 1H), 9.92 (s, 1H); ¹⁹F NMR(376 MHz, DMSO-d₆, 300K): (major rotamer) δ −126.71, −175.87. LC (methodA): t_(R)=2.10 min. LC/MS (EI) m/z: [M+H]⁺ 558.

Scheme 7: Synthesis of1-(2-((2S,4R)-2-((2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide(104)

Step 1: Ethyl1-(2-(tert-butoxy)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate(104b)

To a solution of ethyl 4,5,6,7-tetrahydro-1H-indazole-3-carboxylate 104a(1.03 g, 5.35 mmol) in CH₃CN (50 mL) was added tert-butyl 2-bromoacetate(1.17 g, 0.89 mL, 6.0 mmol) and potassium carbonate (1.5 g, 10.6 mmol).The mixture was refluxed overnight under an atmosphere of argon. LC-MSanalysis indicated two isomers were formed in a ratio of 4:1. Thereaction mixture was cooled to rt and filtered through a pad of Celite®.The solid cake was washed with CH₃CN (20 mL), and the combined solutionwas concentrated under reduced pressure. The remaining residue waspurified by column chromatography to afford the major isomer ethyl1-(2-(tert-butoxy)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate104b (1.37 g) and the minor isomer ethyl2-(2-(tert-butoxy)-2-oxoethyl)-4,5,6,7-tetrahydro-2H-indazole-3-carboxylate104c (0.28 g). ¹H NMR (400 MHz, CDCl₃, 300 K): (major isomer) δ 1.38 (t,J=7.2 Hz, 3H), 1.45 (s, 9H), 1.75 (m, 2H), 1.82 (m, 2H), 2.52 (t, J=5.2Hz, 2H), 2.75 (t, J=5.2 Hz, 2H), 4.37 (q, J=7.2 Hz, 2H), 4.77 (s, 2H).LC/MS (EI) m/z: 309. ¹H NMR (400 MHz, CDCl₃, 300 K): (minor isomer) δ1.35 (t, J=7.2 Hz, 3H), 1.47 (s, 9H), 1.74-1.80 (m, 4H), 2.67 (t, J=5.2Hz, 2H), 2.75 (t, J=5.2 Hz, 2H), 4.30 (q, J=7.2 Hz, 2H), 5.11 (s, 2H).LC/MS (EI) m/z: [M+H]⁺ 309.

Step 2: 2-(3-(Ethoxycarbonyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)aceticacid (104d)

Ethyl1-(2-(tert-butoxy)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate104b (1.35 g, 4.38 mmol) was treated with TFA (5 mL) and DCM (5 mL) andstirred overnight at rt. The volatiles were removed under reducedpressure and the remaining residue was co-evaporated with toluene (10mL) twice. The dried residue 104d was used directly in the next step.

Step 3: Ethyl1-(2-((2S,4R)-2-((2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate(104e)

To a solution of the residue 104d from Step 2 (375 mg, 1.5 mmol) wasadded(2S,4R)—N-(2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-4-fluoropyrrolidine-2-carboxamidehydrochloride (560 mg, 1.5 mmol) in DMF (2 mL) followed by HATU (741 mg,1.95 mmol) and dropwise addition of DIEA (4.5 mmol, 0.78 mL). Themixture was stirred for 1 h at rt and the volatiles were removed underreduced pressure. The remaining residue was diluted with 10% aq sodiumcarbonate (20 mL) and water (50 mL), then extracted with ethyl acetate(3×50 mL). The combined organic extract was washed with water and brine,then dried over MgSO₄. The solution was filtered and the solvent wasremoved under reduced pressure. The remaining residue was purified bycolumn chromatography to afford the title compound 104e (608 mg). LC/MS(EI) m/z: [M+H]⁺ 571.

Step 4:1-(2-((2S,4R)-2-((2′-Chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylicacid (104f)

Compound 104e from Step 3 (608 mg, 1.06 mmol) was dissolved in a mixtureof MeOH-THF-H₂O (3 mL-3 mL-3 mL) and treated with LiOH (100 mg, 4.25mmol). The reaction mixture was stirred overnight at rt. The volatileswere removed under reduced pressure and the remaining residue wasacidified with 10% aq citric acid (10 mL). The solid 104f was collectedby filtration, washed with water, and dried in vacuo for use in the nextstep. LC/MS (EI) m/z: [M+H]⁺ 543.

Step 5:1-(2-((2S,4R)-2-((2′-Chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide(104)

Acid 104f (252 mg, 0.46 mmol) from Step 4 was mixed with NH₄Cl (125 mg,2.32 mmol) in DMF (3 mL). To this solution was added HATU (262 mg, 0.69mmol) followed by dropwise addition of DIEA (1.38 mmol, 0.24 mL). Themixture was stirred for 3 h at rt and the volatiles were removed underreduced pressure. The remaining residue was diluted with 10% aq sodiumcarbonate (15 mL) and water (15 mL), and then extracted with ethylacetate (3×25 mL). The combined organic solution was washed with waterand brine, and then dried over MgSO₄. The mixture was filtered and thefiltrate was concentrated under reduced pressure. The remaining residuewas purified by column chromatography to afford the title compound 104(160 mg). ¹H NMR (400 MHz, DMSO-d₆, 300 K): (major rotamer) δ 1.53-1.61(m, 4H), 1.99-2.16 (m, 1H), 2.38-2.41 (m, 3H), 2.54-2.56 (m, 2H),3.40-3.53 (m, 1H), 3.93-4.07 (m, 1H), 4.68 (t, J=8.8 Hz, 1H), 4.90-5.14(m, 2H), 5.36-5.49 (1H), 6.93-7.19 (m, 4H), 7.32-7.43 (m, 3H), 7.52-7.54(m, 1H), 7.92 (t, J=6.8 Hz, 1H), 9.90 (s, 1H); ¹⁹F NMR (376 MHz,DMSO-d₆, 300K): (major rotamer) δ −126.8, −176.06. LC (method A):t_(R)=2.02 min. LC/MS (EI) m/z: [M+H]⁺ 542.

Scheme 8: Synthesis of(2S,4R)-1-(2-(3-acetyl-8-(3-chlorophenyl)-1H-imidazo[1,2-a]pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide(105)

Step 1: Methyl2-(3-acetyl-8-(3-chlorophenyl)-1H-pyrazolo[4,3-g]indolizin-1-yl)acetate(105c)

A mixture of 1-(1-azidovinyl)-3-chlorobenzene 105a (0.05 g) (prepared asreported by Donthiri et al. J. Org. Chem 2014, 79, 11277-11284), methyl2-(3-acetyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate 105b (0.195 g), CuI(1 mg) and 4 Å molecular sieves was placed in a vial and dryacetonitrile (3 mL) was added. The sealed vial was heated at 65° C. for24 h. The reaction mixture was allowed to cool to rt and the solvent wasremoved under reduced pressure. The remaining residue was purified bycolumn chromatography (eluent: DCM) to give 105c (20 mg) as a lightorange solid.

Step 2:2-(3-Acetyl-8-(3-chlorophenyl)-1H-pyrazolo[4,3-g]indolizin-1-yl)aceticacid (105d)

The solid 105c (20 mg, 0.052 mmol) from Step 1 was taken in THF (3 mL),water (0.3 mL), and MeOH (1 mL), and then 1 N aq NaOH (1 mL) was added.The resulting mixture was stirred at rt overnight and concentrated underreduced pressure. The remaining residue was diluted with EtOAc andwater. The organic layer was separated and the aq layer was extractedrepeatedly with EtOAc. The combined organic layer was dried andconcentrated to give 105d as a light yellow solid, which was used assuch in the next step.

Step 3:(2S,4R)-1-(2-(3-Acetyl-8-(3-chlorophenyl)-1H-imidazo[1,2-a]pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide(105)

To a solution of2-(3-acetyl-8-(3-chlorophenyl)-1H-pyrazolo[4,3-g]indolizin-1-yl)aceticacid 105d (0.052 mmol) and(2S,4R)—N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide TFAsalt (0.05 mmol) in DMF (1 mL) cooled to 0-5° C. was added DIEA (47 μL).HATU (24 mg) was then added to this cooled solution and the cooling bathwas removed. The reaction mixture was stirred at rt for 30 min andpoured into water (10 mL) with stirring. The solid was isolated byfiltration and purified by column chromatography (eluent: 0-1.5% MeOH inDCM) to afford 105 (10 mg) as light yellow solid. ¹H NMR (400 MHz,CDCl₃, 300 K): (major rotamer) δ 2.48-2.52 (m, 1H), 2.73 (s, 3H),2.78-2.94 (m, 1H), 4.04-4.27 (m, 2H), 4.95 (t, J=7.6 Hz, 1H), 5.51 (d,J=52.4 Hz, 1H), 5.77 (d, J=16 Hz, 1H), 5.88 (d, J=16 Hz, 1H), 6.99 (d,J=8.4 Hz, 1H), 7.19-7.23 (m, 2H), 7.54-7.56 (m, 1H), 7.69-7.71 (m, 2H),7.75 (d, J=8 Hz, 1H), 7.85 (s, 1H), 7.87 (d, J=7.2 Hz, 1H), 8.97 (br s,1H); ³¹F NMR (376 MHz, CDCl₃, 300 K): (major rotamer) δ −176.04; LC(method A): t_(R)=2.60 min. LC/MS (EI) [M+H]⁺ 640.

Scheme 9: Synthesis of1-(2-((2S,4R)-2-((2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-7-cyano-1H-indazole-3-carboxamide(111)

Step 1: 7-Bromo-1H-indazole-3-carboxamide (111b)

To a solution of bromoindazole 111a (3 g) in DMF (30 mL) were addedammonium chloride (1.8 g) and DIEA (10.38 mL). The reaction mixture wascooled in an ice bath and then HATU (5.7 g) was added. The reactionmixture was warmed to rt and stirred overnight. The reaction mixture waspoured into water (300 mL) containing LiOH (630 mg). The product wasisolated by filtration and washed with water. The tan colored solid wasdried under high vacuum to give 111b (2.15 g).

Step 2: tert-Butyl 2-(7-bromo-3-carbamoyl-1H-indazol-1-yl)acetate (111c)

A mixture of 7-bromo-1H-indazole-3-carboxamide 111b (2.15 g), tert-butylbromoacetate (1.45 mL), and potassium carbonate (1.36 g) in anhydrousacetonitrile (40 mL) was refluxed for 2 h. The reaction mixture was thencooled to rt and the solvent was removed under reduced pressure. Theremaining residue was sonicated with water (40 mL) and filtered. Thesolid obtained was washed thoroughly with water and further washed with2:1 mixture of tert-butyl methyl ether and heptane (30 mL) and driedunder high vacuum to give 111c (2.5 g).

Step 3: tert-Butyl 2-(3-carbamoyl-7-cyano-1H-indazol-1-yl)acetate (111d)

A mixture of tert-butyl 2-(7-bromo-3-carbamoyl-1H-indazol-1-yl)acetate111c (0.5 g), zinc cyanide (0.198 g), Pd(dppf)Cl₂ (0.115 g), andPd₂(dba)₃ (0.129 g) in DMF (5 mL) and water (1 mL) was bubbled withargon for 5 min. The vial was then sealed and heated at 80° C. for 3 h.After cooling the reaction mixture to rt, it was diluted with EtOAc. Themixture was then washed with water and a saturated aq NaHCO₃ solution.The separated organic layer was dried (Na₂SO₄) and concentrated. Theremaining residue was purified by column chromatography (0-2% MeOH inDCM) to give a slightly yellow solid (0.3 g). The solid was then washedwith ether (3 mL) to give 111d (0.23 g) as a colorless solid.

Step 4: 2-(3-Carbamoyl-7-cyano-1H-indazol-1-yl)acetic acid (111e)

The title compound 111e was prepared from tert-butyl2-(3-carbamoyl-7-cyano-1H-indazol-1-yl)acetate (50 mg) in a mannersimilar to that described in Step 2 of Scheme 7, and used in the nextstep without further purification.

Step 5:1-(2-((2S,4R)-2-((2′-Chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-7-cyano-1H-indazole-3-carboxamid(111)

2-(3-Carbamoyl-7-cyano-1H-indazol-1-yl)acetic acid 111e from Step 4above was coupled with(2S,4R)—N-(2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-4-fluoropyrrolidine-2-carboxamidehydrochloride using the procedure described in Step 6 of Scheme 3. Thecrude product was purified by column chromatography (0-2% MeOH in DCM)to afford the title compound 111 (50 mg). ¹H NMR (400 MHz, CD₃OD, 300K): (major rotamer) δ 2.65-2.75 (m, 1H), 4.1-4.14 (m, 1H), 4.16-4.24 (m,1H), 4.89 (t, J=8.4 Hz, 1H), 5.52 (d, J=52.8 Hz, 1H), 5.73 (d, J=17.6Hz, 1H), 5.89 (d, J=17.6 Hz, 1H), 7.07 (t, J=7.2 Hz, 1H), 7.19 (t, J=8Hz, 1H), 7.28-7.44 (m, 5H), 7.49-7.59 (m, 1H), 7.87 (d, J=7.2 Hz, 1H),7.91 (s, 1H), 7.97 (t, J=7.2 Hz, 1H), 8.59 (d, J=8 Hz, 1H).). ³¹F NMR(376 MHz, CD₃OD, 300 K): (major rotamer) δ −178.5, −128.8. LC (methodA): t_(R)=2.09 min. LC/MS (EI) m/z: [M+H]⁺ 563.

Scheme 10:1-(2-((2S,4R)-2-((5′-Acetyl-2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-1H-indazole-3-carboxamide(117)

Step 1: 1-(3′-Amino-6-chloro-2′-fluoro-[1,1′-biphenyl]-3-yl)ethanone(117c)

To a mixture of 3-bromo-2-fluoroaniline 117a (1.0 g),(5-acetyl-2-chlorophenyl)boronic acid 117b (3.132 g), Pd(dppf)Cl₂ (0.860g), and K₂CO₃ (3.64 g) under an atmosphere of argon was added dioxane(40 mL) and water (10 mL). The mixture was bubbled with argon for 5 minand heated with stirring at 100° C. overnight. The reaction mixture wasthen filtered through a pad of Celite® and the filtrate was concentratedunder reduced pressure. The remaining residue was purified by columnchromatography (0-0.5% MeOH in DCM) to afford 117c (0.9 g) asorange-yellow oil.

Step 2: (2S,4R)-tert-Butyl2-((5′-acetyl-2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate(117d)

To an ice-cold solution of(2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid(0.25 g, 1.07 mmol) in DCM (15 mL) was added1-chloro-N,N,2-trimethylprop-1-en-1-amine (1.2 mmol, 0.16 mL, 1.1 equiv)dropwise with stirring. The stirring was continued for 3 h at thistemperature. Solid1-(3′-amino-6-chloro-2′-fluoro-[1,1′-biphenyl]-3-yl)ethanone 117c (256mg, 0.97 mmol) was then added, followed by DIEA (0.56 mL, 3.6 mmol, 3equiv). The cooling bath was removed and the reaction mixture wasstirred overnight at rt. The solvent was co-evaporated with MeOH (3 mL).The remaining residue was then dissolved in chloroform (30 mL) andwashed successively with cold 1 N aq HCl (3×20 mL), water (30 mL), and asaturated aq NaHCO₃ solution (30 mL). The organic layer was dried(Na₂SO₄) and concentrated under reduced pressure. Finally, the residuewas stirred with a 1:1 solution of DCM and heptane (15 mL). The productwas isolated by filtration and dried under high vacuum to give 117d (0.2g) as a white solid.

Step 3:(2S,4R)—N-(5′-Acetyl-2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-4-fluoropyrrolidine-2-carboxamideTFA Salt (117e)

(2S,4R)-tert-Butyl2-((5′-acetyl-2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate117d (110 mg) was stirred in DCM (2 mL) and TFA (2 mL) for 30 min. Thevolatiles were removed under reduced pressure and the resulting residue117e was used as such for the next step.

Step 4:1-(2-((2S,4R)-2-((5′-Acetyl-2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-1H-indazole-3-carboxamide(117)

The title compound 117 was prepared in a manner similar to thatdescribed in Step of Scheme 8. Thus,(2S,4R)—N-(5′-acetyl-2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-4-fluoropyrrolidine-2-carboxamideTFA salt 117e (obtained from Step 3) was coupled with2-(3-carbamoyl-1H-indazol-1-yl)acetic acid (0.05 g) using HATU (0.104 g)and DIEA (0.2 mL) in DMF (1.5 mL). The crude product was purified bycolumn chromatography (0-2% MeOH in DCM) to give 117 (60 mg). ¹H NMR(400 MHz, CD₃OD, 300 K): (major rotamer) δ 2.65-2.75 (m, 1H), 3.91-4.04(m, 1H), 4.20-4.29 (m, 1H), 4.84 (t, J=8 Hz, 1H), 5.48 (d, J=52 Hz, 1H),5.42 (d, J=17.2 Hz, 1H), 5.57 (d, J=17.2 Hz, 1H), 7.12 (t, J=6.8 Hz,1H), 7.21-7.32 (m, 2H), 7.43 (t, J=7.2 Hz, 1H), 7.59 (d, J=8.4 Hz, 1H),7.65 (d, J=8.4 Hz, 1H), 7.89 (s, 1H), 7.93 (s, 1H), 7.96-8.02 (m, 2H),8.22 (d, J=8 Hz, 1H). ³¹F NMR (376 MHz, CD₃OD, 300 K): (major rotamer) δ−128.5, −178.6 ppm. LC (method A): t_(R)=1.92 min. LC/MS (EI) m/z:[M+H]⁺ 580.

Scheme 11: Synthesis of1-(2-((2S,4R)-2-((2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-4-(2-methoxypyrimidin-5-yl)-1H-pyrazole-3-carboxamide(110)

Step 1: tert-Butyl 2-(4-bromo-3-carbamoyl-1H-pyrazol-1-yl)acetate (110b)

A mixture of 4-bromo-1H-pyrazole-3-carboxamide 110a (1.0 g, 5.26 mmol),tert-butyl bromoacetate (1.13 g, 0.84 mL 5.78 mmol), and potassiumcarbonate (798 mg, 5.78 mmol) in anhydrous acetonitrile (20 mL) wasrefluxed for 5 h. The reaction mixture was then cooled to rt and thesolvent was removed under reduced pressure. The residue was taken in a1:1 mixture of DCM and water (100 mL:100 mL). The two layers wereseparated and the organic layer was washed with water (2×100 mL).Finally, the organic layer was dried (Na₂SO₄) and concentrated. Theresulting residue was purified by column chromatography to givetert-butyl 2-(4-bromo-3-carbamoyl-1H-pyrazol-1-yl)acetate 110b.

Step 2: tert-Butyl2-(3-carbamoyl-4-(2-methoxypyrimidin-5-yl)-1H-pyrazol-1-yl)acetate(110c)

A mixture of tert-butyl 2-(4-bromo-3-carbamoyl-1H-pyrazol-1-yl)acetate110b (150 mg, 0.49 mmol), (2-methoxypyrimidin-5-yl)boronic acid (154 mg,1 mmol), cesium carbonate (380 mg, 1.17 mmol), and DMF (2 mL) was purgedwith argon in a pressure vessel for 5 min.Tetrakis(triphenylphosphine)palladium (0) (30 mg, 0.025 mmol) was thenadded under argon and the pressure vessel was sealed and irradiated withmicrowaves at 90° C. for 30 min. The reaction mixture was cooled to rtand the solvent was removed under reduced pressure. The remainingresidue was purified by column chromatography to give 110c.

Step 3:2-(3-Carbamoyl-4-(2-methoxypyrimidin-5-yl)-1H-pyrazol-1-yl)acetic acid(110d)

tert-Butyl2-(3-carbamoyl-4-(2-methoxypyrimidin-5-yl)-1H-pyrazol-1-yl)acetate 110c(120 mg, 0.36 mmol) in DCM (5 mL) was treated with TFA (5 mL). Aftercompletion of the reaction (as judged by LC-MS analysis), the solventwas removed under reduced pressure. The remaining material 110d was useddirectly in the next step.

Step 4:1-(2-((2S,4R)-2-((2′-Chloro-2-fluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-4-(2-methoxypyrimidin-5-yl)-1H-pyrazole-3-carboxamide(110)

2-(3-Carbamoyl-4-(2-methoxypyrimidin-5-yl)-1H-pyrazol-1-yl)acetic acid110d (0.36 mmol) from Step 3 was dissolved in DMF (4 mL) and DIEA (1.8mmol) was added, which was followed by the addition of(2S,4R)—N-(2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-4-fluoropyrrolidine-2-carboxamidehydrochloride (120 mg, 0.32 mmol) at 5° C. HATU (287 mg, 0.76 mmol) wasthen added slowly at this temperature and the reaction mixture wasstirred for 3 h at rt. The reaction mixture was then added to water (50mL+10 g solid NaCl) and extracted with DCM (2×25 mL). The organic layerwas washed successively with an aq solution of NaHCO₃ (20 mL), water (20mL), and brine (20 mL), then dried over Na₂SO₄ and concentrated underreduced pressure. The remaining residue was purified by columnchromatography (eluted with DCM/CH₃OH) to give the title compound 110.¹H NMR (400 MHz, DMSO-d₆, 300 K): (major rotamer) δ 2.20-2.26 (m, 1H),2.51-2.62 (m, 1H), 3.79-3.91 (m, 1H), 3.94 (s, 3H), 4.09-4.17 (m, 1H),4.80 (t, J=8.0 Hz, 1H), 5.17-5.41 (m, 2H), 5.50 (d, J=7 Hz, 1H), 7.08(t, J=7.2 Hz, 1H), 7.24 (t, J=8.0 Hz, 1H), 7.30 (s, 1H), 7.39-7.47 (m,4H), 7.58-7.61 (m, 1H), 7.96-8.13 (m, 2H), 8.74 (s, 2H), 10.05 (s, 1H);¹⁹F NMR (376 MHz, DMSO-d₆, 300 K): (major rotamer) δ −126.84, −175.97ppm. LC (method A): t_(R)=1.85 min. LC/MS (EI) m/z: [M+H]⁺ 596.

Scheme 12: Synthesis of(1R,3S,5R)-2-(2-(4-bromo-3-carbamoyl-1H-pyrazol-1-yl)acetyl)-N-(2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide(77)

Step 1: 2-(4-Bromo-3-carbamoyl-1H-pyrazol-1-yl)acetic acid (77a)

tert-Butyl 2-(4-bromo-3-carbamoyl-1H-pyrazol-1-yl)acetate 110b (120 mg,0.40 mmol) in DCM (5 mL) was treated with TFA (5 mL) in a similar mannerto that described in Step 2 of Scheme 7. The volatiles were removedunder reduced pressure and the remaining material was used directly inthe next synthetic step.

Step 2:(1R,3S,5R)-2-(2-(4-Bromo-3-carbamoyl-1H-pyrazol-1-yl)acetyl)-N-(2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide(77)

The title compound 77 (50 mg) was prepared from2-(4-bromo-3-carbamoyl-1H-pyrazol-1-yl)acetic acid 77a and(1R,3S,5R)—N-(2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamidehydrochloride (131 mg) in a manner similar to that described in Scheme5. ¹H NMR (400 MHz, DMSO-d₆, 300 K): (major rotamer) δ 0.65 (d, J=1.6Hz, 1H), 0.97-1.02 (m, 1H), 1.86-1.88 (m, 1H), 2.24-2.29 (m, 2H), 3.66(t, J=5.2 Hz, 1H), 4.52-4.56 (m, 1H), 5.19-5.47 (m, 2H), 7.09 (t, J=7.2Hz, 1H), 7.24 (t, J=8.0 Hz, 1H), 7.28 (s, 1H), 7.39-7.47 (m, 4H),7.59-7.61 (m, 1H), 7.94 (t, J=7.2 Hz, 1H), 7.99 (s, 1H), 9.79 (s, 1H);¹⁹F NMR (376 MHz, DMSO-d₆, 300 K): (major rotamer) δ −126.64. LC (methodA): t_(R)=1.97 min. LC/MS (EI) m/z: [M+H]⁺ 560.

Scheme 13: Synthesis of1-(2-((2S,4R)-2-((2′-chloro-2,4′,5′-trifluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-1H-indazole-3-carboxamide(80)

Step 1: 2-Fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline(80b)

A solution of 3-bromo-2-fluoroaniline (0.5 g, 2.63 mmol),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.67 g, 6.6mmol), and KOAc (0.77 g) in dioxane (10 mL) was degassed and refilledwith argon twice. To this solution was added Pd(dppf)₂Cl₂ (289 mg) underan atmosphere of argon. The solution was heated at 90° C. for 15 h. Thereaction mixture was cooled to rt and the volatiles were removed underreduced pressure. The remaining residue was purified by columnchromatography to afford 80b (803 mg).

Step 2: 2′-Chloro-2,4′,5′-trifluoro-[1,1′-biphenyl]-3-aminehydrochloride (80c)

A solution of2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 80b(26.0 g, 110 mmol), 1-bromo-2,4,5-trifluorobenzene (12.5 g, 60 mmol),and K₂CO₃ (38 g, 275 mmol) in co-solvent of dioxane (250 mL) and water(63 mL) was degassed and refilled with argon twice. To this solution wasadded Pd(dppf)₂Cl₂ (8.04 g) under an atmosphere of argon. The solutionwas refluxed for 15 h. The reaction mixture was cooled to rt and thevolatiles were removed under reduced pressure. The remaining residue waspurified by column chromatography. The desired product fractions werecollected and concentrated, and then the HCl salt 80c was made bytreatment with HCl/MeOH. 13.1 g of 80c was obtained.

Step 3: (2S,4R)-tert-Butyl2-(((2′-chloro-2,4′,5′-trifluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate(80d)

To an ice-cold solution of(2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid(9.5 g, 40.7 mmol) in DCM (200 mL) was added1-chloro-N,N,2-trimethyl-1-propenylamine (5.92 mL, 1.1 equiv) dropwisewith stirring. The stirring was continued for 3 h at this temperature,and then solid 2′-chloro-2,4′,5′-trifluoro-[1,1′-biphenyl]-3-aminehydrochloride 80c (13.1 g, 44.5 mmol) was added, followed by DIEA (21.3mL). The cooling bath was removed and the reaction mixture was stirredovernight at rt. The reaction mixture was then added to water (120 mL)and extracted with DCM (2×120 mL). The organic layer was washedsuccessively with an aq solution of NaHCO₃ (20 mL), water (20 mL), andbrine (20 mL), and then dried over Na₂SO₄ and concentrated under reducedpressure. The remaining residue was purified by column chromatography(eluted with hexanes/EtOAc) to give 14.1 g of the desire title compound80d.

Step 4:(2S,4R)—N-(2′-Chloro-2,4′,5′-trifluoro-[1,1′-biphenyl]-3-yl)-4-fluoropyrrolidine-2-carboxamidehydrochloride (80e)

(2S,4R)-tert-Butyl2-((2′-chloro-2,4′,5′-trifluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate80d (1.0 g) was taken in 4 N HCl in dioxane (10 mL) and the resultingreaction mixture was stirred at rt for 2 h. The solvent was then removedunder reduced pressure and the remaining residue 80e was used directlywithout further purification.

Step 5: tert-Butyl 2-(3-carbamoyl-1H-indazol-1-yl)acetate (80g)

1H-Indazole-3-carboxamide 80f (56 g, 347 mmol) was dissolved in CH₃CN(500 mL). To this solution were added tert-butyl 2-bromoacetate (82 g,61.5 mL) and potassium carbonate (77.4 g, 560 mmol). The mixture washeated at 90° C. for 3 h under an atmosphere of argon. The reactionmixture was cooled to rt and filtered through a pad of Celite®. Thesolid cake was washed with CH₃CN (120 mL), and the combined filtrate wasconcentrated under reduced pressure. The remaining residue was purifiedby column chromatography to afford the title compound 80g (70 g).

Step 6: 2-(3-Carbamoyl-1H-indazol-1-yl)acetic acid (80h)

tert-Butyl 2-(3-carbamoyl-1H-indazol-1-yl)acetate 80g (1.0 g) was takenin 4 N HCl in dioxane (10 mL) and the resulting reaction mixture wasstirred at rt for 2 h. The solvent was then removed under reducedpressure and the remaining residue 80h was used directly without furtherpurification.

Step 7:1-(2-((2S,4R)-2-((2′-Chloro-2,4′,5′-trifluoro-[1,1′-biphenyl]-3-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-1H-indazole-3-carboxamide(80)

To a solution of 2-(3-carbamoyl-1H-indazol-1-yl)acetic acid 80h (5.3 g,24.2 mmol),(2S,4R)—N-(2′-chloro-2,4′,5′-trifluoro-[1,1′-biphenyl]-3-yl)-4-fluoropyrrolidine-2-carboxamidehydrochloride 80e (9.0 g, 22.0 mmol) in DMF (50 mL) was added HATU (10g) followed by dropwise addition of DIEA (18.0 mL) at rt. The mixturewas stirred for 1 h at rt and the volatiles were removed under reducedpressure. The remaining residue was diluted with 10% aq sodium carbonate(50 mL) and extracted with ethyl acetate. The organic extract was washedwith water and brine, then dried over MgSO₄. The solution was filteredand the filtrate was evaporated under reduced pressure. The remainingresidue was purified by column chromatography to afford the titlecompound 80 (10.0 g). ¹H NMR (400 MHz, DMSO-d₆, 300 K): (major rotamer)δ 2.13-2.26 (m, 1H), 2.45-2.57 (m, 1H), 3.88-4.00 (m, 1H), 4.18-4.27 (m,1H), 4.76 (t, J=8.4 Hz, 1H), 5.43-5.68 (m, 3H), 7.07-7.09 (m, 1H),7.20-7.27 (m, 2H), 7.35-7.42 (m, 2H), 7.59-7.64 (m, 2H), 7.85-7.89 (m,1H), 7.91-7.99 (m, 1H), 8.17 (d, J=8.4 Hz, 1H), 10.00 (s, 1H). ¹⁹F NMR(376 MHz, DMSO-d₆, 300K): (major rotamer) δ −126.7, −135.8, −139.4,−175.9. LC (method A): t_(R)=2.28 min. LC/MS (EI) m/z: [M+H]⁺ 574.

Example 7. Non-Limiting Examples of Compounds of Formula I

Table 1 shows illustrative compounds of Formula I with characterizingdata. The assay of Example 8 was used to determine the IC₅₀'s of thecompounds. Other standard factor D inhibition assays are also available.Three ***s are used to denote compounds with an IC₅₀ less than 1micromolar; two **s indicate compound with an IC₅₀ between 1 micromolarand 10 micromolar, and one * denotes compounds with an IC₅₀ greater than10 micromolar.

TABLE 1 RT min MS Cmp (Method (M + No. Structure Name IC₅₀ A or B) 1) 1

(2S,3aS,7aS)-1-(2-(3- acetyl-1H-indol-1- yl)acetyl-N-(3-chloro-2-fluorobenzyl)octahydro- 1H-indole-2- carboxamide *** 2.33 (A) 510 2

(S)-N1-(1-carbamoyl- 1H-indol-3-yl)-N2-(3- chloro-2-fluorobenzyl)indoline- 1,2-dicarboxamide ** 2.04 (A) 506 3

(2S,4R)-N2-(1-acetyl- 1H-indol-3-yl)-N1-(3- chloro-2-fluorobenzyl)-4-fluoropyrrolidine-1,2- dicarboxamide * 2.07 (A) 475 4

(2S,4S)-N2-(1-acetyl- 1H-indol-3-yl)-N1-(3- chloro-2-fluorobenzyl)-4-fluoropyrrolidine-1,2- dicarboxamide * 2.05 (A) 475 5

(2S,4S)-N2-(1-acetyl- 1H-indol-3-yl)-N1- benzyl-4-fluoropyrrolidine-1,2- dicarboxamide * 1.78 (A) 423 6

(2S,4R)-N1-(1- carbamoyl-1H-indol-3- yl)-N2-(3-chloro-2-fluorophenylsulfonyl)- 4-fluoropyrrolidine-1,2- dicarboxamide * 1.33 (A)526 7

(2S,4R)-N1-(1-acetyl- 1H-indol-3-yl)-N2-(3- chloro-2-fluorophenylsulfonyl)- 4-fluoropyrrolidine-1,2- dicarboxamide * 1.67 (A)525 8

(R)-N2-(1-acetyl-1H- indol-3-yl)-N1-(3- chloro-2-fluorobenzyl)-4,4-difluoropyrrolidine- 1,2-dicarboxamide * 2.25 (A) 493 9

(R)-N2-(1-acetyl-1H- indol-3-yl)-N1-(3- chloro-2-fluorobenzyl)pyrrolidine- 1,2-dicarboxamide * 2.14 (A) 457 10

3-((2S,4R)-2-(5-(3- chlorophenyl)-1H- imidazol-2-yl)-4-fluoropyrrolidine-1- carboxamido)-1H- indole-1-carboxamide ** 1.49 (A)467 11

2-(3-acetyl-1H-indol-1- yl)-1-((2S,4R)-2-(5-(3- chlorophenyl)-1H-imidazol-2-yl)-4- fluoropyrrolidin-1- yl)ethanone * 1.46 (A) 465 12

3-((2S,4R)-2-(5-(6- bromopyridin-2-yl)-1H- imidazol-2-yl)-4-fluoropyrrolidine-1- carboxamido)-1H- indole-1-carboxamide ** 1.34 (A)512 13

2-(3-acetyl-1H-indol-1- yl)-1-((2S,4R)-2-(5-(6- bromopyridin-2-yl)-1H-imidazol-2-yl)-4- fluoropyrrolidin-1- yl)ethanone ** 1.43 (A) 510 14

3-((2S,4R)-2-(5-chloro- 1H-benzo[d]imidazol-2- yl)-4-fluoropyrrolidine-1-carboxamido)-1H- indole-1-carboxamide ** 1.42 (A) 441 15

2-(3-acetyl-1H-indol-1- yl)-1-((2S,4R)-2-(5- chloro-1H-benzo[d]imidazol-2-yl)- 4-fluoropyrrolidin-1- yl)ethanone * 1.54 (A) 43916

(R)-N2-(1-acetyl-1H- indol-3-yl)-N1-(2- fluoro-3-(trifluoromethoxy)phenyl) pyrrolidine-1,2- dicarboxamide * 2.30 (A) 49317

(R)-N-(1-acetyl-1H- indol-3-yl)-1-(2-(3- chloro-2- fluorophenyl)acetyl)-4,4-difluoropyrrolidine- 2-carboxamide * 2.28 (A) 478 18

(2S,3R)-1-(2-(3-acetyl- 1H-indol-1-yl)acetyl)- N-(3-chloro-2-fluorobenzyl)-3- (cyclopropylmethoxy) pyrrolidine-2- carboxamide ***2.12 (A) 526 19

(2S,4R)-N1-(1-acetyl- 1H-indol-3-yl)-N2-(3- chloro-2-fluorobenzyl)-4-(7-methoxy-2- phenylquinolin-4- yloxy)pyrrolidine-1,2- dicarboxamide *2.10 (A) 706 20

1,3-bis(1-acetyl-1H- indol-3-yl)urea * 1.98 (A) 375 21

(2S,3S,4S)-1-(2-(3- acetyl-6-hydroxy-1H- indol-1-yl)acetyl)-N-(3-chloro-2-fluorobenzyl)- 3-(cyclopropylmethoxy)- 4-fluoropyrrolidine-2-carboxamide *** 1.91 (A) 560 22

(1R,3S,5R)-N-(3- chloro-2-fluorobenzyl)- 2-(2-(3-(cyclopropanecarbonyl)- 1H-indol-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.07 (A) 494 23

(1R,2R)-N1-(1- carbamoyl-1H-indol-3- yl)-N2-(3-chloro-2- fluorobenzyl)cyclopentane-1,2- dicarboxamide ** 1.87 (A) 457 24

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-1-(2-(3- (cyclopropanecarbonyl)-1H-indol-1-yl)acetyl)- 4-fluoropyrrolidine-2- carboxamide *** 2.02 (A)500 25

(2S)-1-(2-(3-acetyl-6- hydroxy-1H-indol-1- yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-3- (cyclopropylmethoxy)- 4-fluoropyrrolidine-2-carboxamide *** 1.82 (A) 560 26

(1R,2R)-N1-(1- carbamoylindolin-3-yl)- N2-(3-chloro-2- fluorobenzyl)cyclopentane-1,2- dicarboxamide * 1.35 (A) 459 27

2-(3-acetyl-1H-indol-1- yl)-1-((2S,4R)-4-fluoro- 2-((4-(4-fluorophenyl)-1H-1,2,3-triazol-1- yl)methyl)pyrrolidin-1- yl)ethanone * 1.72 (A) 46428

3-((2S,4R)-4-fluoro-2- ((4-(4-fluorophenyl)- 1H-1,2,3-triazol-1-yl)methyl)pyrrolidine-1- carboxamido)-1H- indole-1-carboxamide * 1.60(A) 466 29

(2S,4R)-1-(2-(3-acetyl- 1H-indol-1-yl)acetyl)- N-(3-chloro-2-fluorobenzyl)-4-(7- methoxy-2- phenylquinolin-4- yloxy)pyrrolidine-2-carboxamide * 2.00 (A) 705 30

(2S,4R)-2-((4-(3- chloro-4-fluorophenyl)- 1H-1,2,3-triazol-1-yl)methyl)-4- fluoropyrrolidine-1- carboxamide * 1.15 (A) 342 31

N1-(1-carbamoyl-1H- indole-3-yl)-N2-(3- chloro-2-fluorobenzyl)cyclopent- 1-ene-1,2- dicarboxamide * 1.97 (A) 455 32

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-1-(2-(3- (1-(cyanoimino)ethyl)-1H-indol-1-yl)acetyl)-4- fluoropyrrolidine-2- carboxamide ** 1.48 (A)498 33

2-(3-acetyl-1H-indol-1- yl)-1-((2S,4R)-4-fluoro- 2-(isoindoline-2-carbonyl)pyrrolidin-1- yl)ethanone * 0.95 (A) 434 34

(2S,4R)-1-(2-(3-acetyl- 1H-indol-1-yl)acetyl)- N-(3-chloro-2-fluorobenzyl)-4-fluoro- N-methylpyrrolidine-2- carboxamide * 1.35 (A)488 35

(2S,3aS,7aS)-1-(2-(3- acetyl-6-hydroxy-1H- indol-1-yl)acetyl)-N-(3-chloro-2- fluorobenzyl)octahydro- 1H-indole-2- carboxamide *** 1.30 (A)526 36

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-1-(2-(3- cyano-1H-indol-1-yl)acetyl)-4- fluoropyrrolidine-2- carboxamide *** 1.38 (A) 457 37

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-4-fluoro- 1-(2-(4-oxo-3,4-dihydro-1H-carbazol- 9(2H)- yl)acetyl)pyrrolidine-2- carboxamide ***1.18 (A) 500 38

tert-butyl (S)-1- ((2S,4R)-2-(3-chloro-2- fluorobenzylcarbamoyl)-4-fluoropyrrolidin-1- yl)-3-(1H-indol-3-yl)-1- oxopropan-2-ylcarbamate * 1.66 (A) 561 39

(2S,4R)-1-((S)-2- amino-3-(1H-indol-3- yl)propanoyl)-N-(3-chloro-2-fluorobenzyl)- 4-fluoropyrrolidine-2- carboxamide * 0.40 (A)461 40

2-(3-acetyl-6-hydroxy- 1H-indol-1-yl)-1- ((2S,4R)-2-(5-(6-bromopyridin-2-yl)-1H- imidazol-2-yl)-4- fluoropyrrolidin-1- yl)ethanone** 0.93 (A) 526 41

(S)-7-(2-(3-acetyl-6- hydroxy-1H-indol-1- yl)acetyl)-N-(2-fluoro-3-(trifluoromethoxy) phenyl)-1,4-dioxa-7- azaspiro[4.4]nonane-8-carboxamide ** 1.21 (A) 566 42

(2S,4R)-1-(2-(3-acetyl- 1H-indol-1-yl)acetyl)- N-(2,3-dihydro-1H-inden-1-yl)-4- fluoropyrrolidine-2- carboxamide ** 1.06 (A) 448 43

(2S,4R)-1-(2-(3-acetyl- 1H-indol-1-yl)acetyl)- N-(2,3-dihydro-1H-inden-2-yl)-4- fluoropyrrolidine-2- carboxamide *** 1.05 (A) 448 44

(2S,4R)-1-(2-(3-acetyl- 1H-indol-1-yl)acetyl)- N-(4-chloro-2,3-dihydro-1H-inden-1-yl)- 4-fluoropyrrolidine-2- carboxamide ** 1.15 (A)482 45

(2S,4R)-1-(2-(3-acetyl- 1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)-4-fluoro-N-(3- (trifluoromethylthio) phenyl)pyrrolidine-2- carboxamide*** 1.16 (A) 511 46

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-4-fluoro- 1-(2-(3-nitro-1H-indol-1-yl)acetyl)pyrrolidine- 2-carboxamide *** 1.37 (A) 477 47

(2S,4R)-1-(2-(3- acetamido-1H-indol-1- yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-4- fluoropyrrolidine-2- carboxamide *** 1.01 (A) 489 48

(2S,4R)-1-(2-(3-acetyl- 6-hydroxy-1H-indol-1- yl)acetyl)-4-fluoro-N-(3-(trifluoromethylthio) phenyl)pyrrolidine-2- carboxamide *** 1.09 (A)524 49

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-1-(2-(1,1- dioxido-2H-benzo[e][1,2,4]thiadiazin- 3-yl)acetyl)-4- fluoropyrrolidine-2-carboxamide ** 0.86 (A) 497 50

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-4-fluoro- 1-(2-(pyridin-3-yl)thiazole-4- carbonyl)pyrrolidine-2- carboxamide * 0.77 (A) 463 51

(2S,4R)-1-(6- acetamidonicotinoyl)- N-(3-chloro-2- fluorobenzyl)-4-fluoropyrrolidine-2- carboxamide * 0.55 (A) 437 52

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-4-fluoro- 1-(2-(3-iodo-1H-pyrazolo[3,4-c]pyridin- 1-yl)acetyl)pyrrolidine- 2-carboxamide *** 1.00(A) 560 53

diethyl 1-(2-((2s,4R)-2- (3-chloro-2- fluorobenzylcarbamoyl)-4-fluoropyrrolidin-1- yl)-2-oxoethyl)-1H- pyrazolo[3,4-c]pyridin-3-ylphosphonate ** 0.82 (A) 570 54

(2S,4R)-N2-(3-chloro- 2-fluorobenzyl)-N1-(1- (cyclopropanecarbonyl)-1H-indol-3-yl)-4- fluoropyrrolidine-1,2- dicarboxamide *** 1.28 (A) 50155

(2S,4R)-1-(2-(3-acetyl- 1H-indol-1- yl)propanoyl)-N-(3-chloro-2-fluorobenzyl)- 4-fluoropyrrolidine-2- carboxamide * 1.17 (A)488 56

(2S,4R)-1-(2-(3-acetyl- 1H-indol-1-yl)-2- methylpropanoyl)-N-(3-chloro-2-fluorobenzyl)- 4-fluoropyrrolidine-2- carboxamide * 1.96 (A)502 57

1-(2-((2S,4R)-2-(3- chloro-2- fluorobenzylcarbamoyl)-4-fluoropyrrolidin-1- yl)-2-oxoethyl)-1H- pyrazolo[3,4-c]pyridin-3-ylphosphonic acid * 0.72 (A) 514 58

(2S,4R)-1-(2-(4- acetylnaphthalen-1- yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-4- fluoropyrrolidine-2- carboxamide ** 2.04 (A) 485 59

diethyl 3-((2S,4R)-1-(2- (3-acetyl-1H-indol-1- yl)acetyl)-4-fluoropyrrolidine-2- carboxamido)-5- chlorophenylphosphonate ** 1.89 (A)578 60

ethyl hydrogen 1-(2- ((2S,4R)-2-(3-chloro-2- fluorobenzylcarbamoyl)-4-fluoropyrrolidin-1- yl)-2-oxoethyl)-1H- pyrazolo[3,4-c]pyridin-3-ylphosphonate ** 0.86 (A) 542 61

diethyl 3-(((2S,4R)-1- (2-(3-acetyl-1H-indol-1- yl)acetyl)-4-fluoropyrrolidine-2- carboxamido)methyl)-5- chloro-4-fluorophenylphosphonate *** 1.82 (A) 610 62

(2S,3aR,6aR)-1-(2-(3- acetyl-6-hydroxy-1H- indol-1-yl)acetyl)-N-(3-chloro-2- fluorobenzyl)octahydro cyclopenta[b]pyrrole-2- carboxamide ***1.88 (A) 512 63

3-(((2S,4R)-1-(2-(3- acetyl-1H-indol-1- yl)acetyl)-4-fluoropyrrolidine-2- carboxamido)methyl)-5- chloro-4-fluorophenylphosphonic acid *** 0.98 (A) 554 64

(2S,4R)-1-(2-(3-acetyl- 6-hydroxy-1H-indol-1- yl)acetyl)-N-((1R,2S)-1-(cyclopropylsulfonyl- carbamoyl)- 2-vinylcyclopropyl)-4-fluoropyrrolidine-2- carboxamide ** 1.16 (A) 561 65

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-1-(2-(1,1- dioxido-4H-benzo[e][1,2,4]thiadiazin- 4-yl)acetyl)-4- fluoropyrrolidine-2-carboxamide * 1.25 (A) 497 66

(2S,3aR,7aR)-1-(2-(3- acetyl-6-hydroxy-1H- indol-1-yl)acetyl)-N-(3-chloro-2- fluorobenzyl)octahydro- 1H-indole-2- carboxamide ** 1.93 (A)526 67

tert-butyl 9-(2-((2S,4R)- 2-(3-chloro-2- fluorobenzylcarbamoyl)-4-fluoropyrrolidin-1- yl)-2-oxoethyl)-3,4- dihydro-1H-pyrido[3,4-b]indole-2(9H)- carboxylate * 2.71 (A) 587 68

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-1-(2-(3,4- dihydro-1H-pyrido[3,4-b]indol-9(2H)- yl)acetyl)-4- fluoropyrrolidine-2- carboxamide * 1.38 (A)487 69

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-4-fluoro- 1-(2-(2-(methylsulfonyl)-3,4- dihydro-1H-pyrido[3,4- b]indol-9(2H)-yl)acetyl)pyrrolidine-2- carboxamide ** 2.06 (A) 565 70

ethyl 3-(9-(2-((2S,4R)- 2-(3-chloro-2- fluorobenzylcarbamoyl)-4-fluoropyrrolidin-1- yl)-2-oxoethyl)-3,4- dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-3- oxopropanoate * 2.16 (A) 601 71

(2S,4R)-1-(2-(1-acetyl- 1H-indol-3-yl)-2- oxoacetyl)-N-(3-chloro-2-fluorobenzyl)-4- fluoropyrrolidine-2- carboxamide * 2.31 (A) 488 72

4-(9-(2-((2S,4R)-2-(3- chloro-2- fluorobenzylcarbamoyl)-4-fluoropyrrolidin-1- yl)-2-oxoethyl)-3,4- dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-4- oxobutanoic acid * 1.88 (A) 587 73

(2S,4R)-1-(2-(3-(1H- pyrazol-4-yl)-1H- pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(3- chloro-2-fluorobenzyl)- 4-fluoropyrrolidine-2-carboxamide *** 1.00 (A) 500 74

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-4-fluoro- 1-(2-(3-(1-fluorovinyl)-1H-pyrazolo[3,4- c]pyridin-1- yl)acetyl)pyrrolidine-2- carboxamide ***1.61 (A) 478 75

(2S,4R)-1-(2-(3-(1H- imidazol-5-yl)-1H- pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(3- chloro-2-fluorobenzyl)- 4-fluoropyrrolidine-2-carboxamide *** 0.84 (A) 500 76

(2S,4R)-N-(3-chloro-2- fluorobenzyl)-4-fluoro- 1-(2-(3-sulfamoyl-1H-indol-1- yl)acetyl)pyrrolidine-2- carboxamide *** 1.62 (A) 511 77

(1R,3S,5R)-2-(2-(4- bromo-3-carbamoyl- 1H-pyrazol-1-yl)acetyl)-N-(2′-chloro- 2-fluorobiphenyl-3-yl)-2-azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.97 (A) 560 78

(2S,4R)-1-(2-(3-(1- amino-2,2,2- trifluoroethyl)-1H-indol-1-yl)acetyl)-N-(3- chloro-2-fluorobenzyl)- 4-fluoropyrrolidine-2-carboxamide ** 1.45 (A) 531 79

(2S,4R)-1-(2-(3-acetyl- 7-cyano-1H-indol-1- yl)acetyl)-N-(2′-chloro-2-fluorobiphenyl-3-yl)- 4-fluoropyrrolidine-2- carboxamide *** 2.41 (A)561 80

1-(2-((2S,4R)-2-(2′- chloro-2,4′,5′- trifluorobiphenyl-3-ylcarbamoyl)-4- fluoropyrrolidin-1-yl)- 2-oxoethyl)-1H-indazole-3-carboxamide *** 2.28 (A) 574 81

(2S,4R)-1-(2-(3-acetyl- 5-(1-(1,3- dioxoisoindolin-2-yl)cyclopropyl)-1H- indol-1-yl)acetyl)-N-(6- bromopyridin-2-yl)-4-fluoropyrrolidine-2- carboxamide *** 2.17 (A) 674 82

(2S,4R)-1-(2-(3-acetyl- 1H-indol-1-yl)acetyl)- N-(2′-chloro-2,4′,5′-trifluorobiphenyl-3-yl)- 4-fluoropyrrolidine-2- carboxamide *** 2.87 (A)572 83

1-(2-((2S,4R)-2-(2′- chloro-2,4′,5′- trifluorobiphenyl-3-ylcarbamoyl)-4- fluoropyrrolidin-1-yl)- 2-oxoethyl)-1H- pyrazolo[3,4-c]pyridine-3- carboxamide *** 2.26 (A) 575 84

2-(3-acetyl-1H-indol-1- yl)-1-(4-(2,3,4- trimethoxybenzyl)piperazin-1-yl) ethanone 85

(R)-3-(1-benzyl-1H- indole-3-carbonyl)-N- isobutylthiazolidine-4-carboxamide 86

2-(3-acetyl-1H-indol-1- yl)-1-(4- benzylpiperazin-1- yl)ethanone 87

methyl 1-(2- ((benzo[d][1,3]dioxol- 5-ylmethyl)(cyclopentyl)amino)-2-oxoethyl)-1H- indole-3-carboxylate 88

(S)-2-(1-(2-(3-acetyl- 1H-indol-1- yl)acetyl)piperidin-3-yl)-1H-imidazol-3-ium 89

(S)-methyl 1-(2-(2-(4- methoxyphenyl)azepan- 1-yl)-2-oxoethyl)-1H-indole-3-carboxylate 90

(2S,4R)-1-(2-(6-acetyl- 6H-thieno[2,3-b]pyrrol- 4-yl)acetyl)-N-(2′-chloro-2- fluorobiphenyl-3-yl)-4- fluoropyrrolidine-2- carboxamide ***2.68 (A) 542 91

(2S,4R)-1-(2-(4- acetamido-3-acetyl-1H- indol-1-yl)acetyl)-N-(2′-chloro-2- fluorobiphenyl-3-yl)-4- fluoropyrrolidine-2- carboxamide *2.16 (A) 593 92

1-(2-((2S,4R)-2-(2′- chloro-2,3′,4′- trifluorobiphenyl-3-ylcarbamoyl)-4- fluoropyrrolidin-1-yl)- 2-oxoethyl)-1H-indazole-3-carboxamide *** 2.68 (A) 574 93

(2S,4R)-1-(2-(3-acetyl- 1H-indol-1-yl)acetyl)- N-(2′-chloro-2,3′,4′-trifluorobiphenyl-3-yl)- 4-fluoropyrrolidine-2- carboxamide *** 2.88 (A)572 94

1-(2-((2S,4R)-2-(2′- chloro-2,3′,5′- trifluorobiphenyl-3-ylcarbamoyl)-4- fluoropyrrolidin-1-yl)- 2-oxoethyl)-1H-indazole-3-carboxamide *** 2.82 (A) 574 95

(2S,4R)-1-(2-(3-acetyl- 1H-indol-1-yl)acetyl)- N-(2′-chloro-2,3′,5′-trifluorobiphenyl-3-yl)- 4-fluoropyrrolidine-2- carboxamide *** 3.06 (A)572 96

(2S,4R)-1-(2-(3-acetyl- 4-methoxy-1H-indol-1- yl)acetyl)-N-(2′-chloro-2-fluorobiphenyl-3-yl)- 4-fluoropyrrolidine-2- carboxamide ** 2.28 (A)566 97

(2S,4R)-1-(2-(3-acetyl- 4-cyano-1H-indol-1- yl)acetyl)-N-(2′-chloro-2-fluorobiphenyl-3-yl)- 4-fluoropyrrolidine-2- carboxamide *** 2.13 (A)561 98

6-(2-((2S,4R)-2-(2′- chloro-2- fluorobiphenyl-3- ylcarbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-6H- thieno[2,3-b]pyrrole-4-carboxamide *** 2.52 (A) 543 99

1-(2-((2S,4R)-2-(2′- chloro-2- fluorobiphenyl-3- ylcarbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-1H- thieno[3,2-c]pyrazole-3-carboxamide *** 1.94 (A) 544 100

1-(2-((2S,4R)-2-(6-(2- chloro-4,6- difluorophenyl)pyridin-2-ylcarbamoyl)-4- fluoropyrrolidin-1-yl)- 2-oxoethyl)-1H- pyrazolo[3,4-c]pyridine-3- carboxamide *** 1.55 (A) 558 101

1-(2-((2S,4R)-2-(2′- chloro-4′,6′- difluorobiphenyl-3- ylcarbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-1H- pyrazolo[3,4- c]pyridine-3-carboxamide *** 1.73 (A) 557 103

4-(2-((2S,4R)-2-(2′- chloro-2- fluorobiphenyl-3- ylcarbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-4H- thieno[3,2-b]pyrrole-6-carboxamide *** 1.94 (A) 544 104

1-(2-((2S,4R)-2-(2′- chloro-2- fluorobiphenyl-3- ylcarbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-4,5,6,7- tetrahydro-1H-indazole-3-carboxamide *** 2.02 (A) 542 105

1-(2-((2S,4R)-2-(6- bromopyridin-2- ylcarbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-7-(3- chlorophenyl)-1,5a-dihydroimidazo[4,5- g]indazole-3- carboxamide *** 2.60 (A) 640 106

1-(2-((2S,4R)-2-(6- bromopyridin-2- ylcarbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-1H- thieno[3,2-c]pyrazole-3-carboxamide *** 1.33 (A) 497 107

1-(2-(1R,3S,5R)-3-(3- chloro-2- fluorobenzylcarbamoyl)-2-azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-1H- thieno[3,2-c]pyrazole-3-carboxamide *** 1.49 (A) 476 110

1-(2-((2S,4R)-2-(2′- chloro-2- fluorobiphenyl-3- ylcarbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-4-(2- methoxylpyrimidin-5-yl)-1H-pyrazole-3- carboxamide * 1.85 (A) 596 111

1-(2-((2S,4R)-2-(2′- chloro-2- fluorobiphenyl-3- ylcarbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-7-cyano- 1H-indazole-3- carboxamide*** 2.09 (A) 563 112

(2S,4R)-1-(2-(3-acetyl- 7-(6-chloropyridin-3- yl)-1H-indol-1-yl)acetyl)-N-(2′-chloro- 2-fluorobiphenyl-3-yl)- 4-fluoropyrrolidine-2-carboxamide *** 2.66 (A) 647 113

1-(2-((2S,4R)-2-(2′- chloro-2- fluorobiphenyl-3- ylcarbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-5-methyl- 1H-thieno[3,2-c]pyrazole-3- carboxamide *** 2.10 (A) 558 114

(2S,4R)-1-(2-(3-acetyl- 7-(1H-pyrazol-4-yl)- 1H-indol-1-yl)acetyl)-N-(2′-chloro-2- fluorobiphenyl-3-yl)-4- fluoropyrrolidine-2- carboxamide*** 2.12 (A) 602 115

(2S,4R)-1-(2-(3-acetyl- 7-cyclopropyl-1H- indol-1-yl)acetyl)-N-(2′-chloro-2- fluorobiphenyl-3-yl)-4- fluoropyrrolidine-2- carboxamide ***2.59 (A) 576 117

1-(2-((2S,4R)-2-(5′- acetyl-2′-chloro-2- fluorobiphenyl-3-ylcarbamoyl)-4- fluoropyrrolidin-1-yl)- 2-oxoethyl)-1H-indazole-3-carboxamide *** 1.92 (A) 580 118

1-(2-((2S,4R)-2-(6- bromopyridin-2- ylcarbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-5-methyl- 1H-thieno[3,2-c]pyrazole-3- carboxamide *** 1.56 (A) 509 119

N-(1-(3-acetyl-1-(2- ((2S,4R)-2-(6- bromopyridin-2- ylcarbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-1H-indol- 5-yl)cyclopropyl)pyrimidine- 2-carboxamide *** 1.57 (A) 648 120

1-(2-((2S,4R)-2-(2′- chloro-2-fluoro-5′- (trifluoromethoxy) biphenyl-3-ylcarbamoyl)-4- fluoropyrrolidin-1- yl)-2-oxoethyl)-1H-indazole-3-carboxamide *** 2.42 (A) 622 121

1-(2-((2S,4R)-2-(5-(2- chlorophenyl)-1H- benzo[d]imidazol-2-yl)-4-fluoropyrrolidin-1- yl)-2-oxoethyl)-1H- indole-3-carboxamide * 1.68(A) 516 122

1-(2-((2S,4R)-2-(3-(4- chloro-1H- benzo[d]imidazol-5-yl)-2-fluorophenylcarbamoyl)- 4-fluoropyrrolidin-1- yl)-2-oxoethyl)-1H-indazole-3-carboxamide *** 1.27 (A) 578 123

tert-butyl 1-(3-acetyl-1- (2-((2S,4R)-2-(6- bromopyridin-2-yl)carbamoyl)-4- fluoropyrrolidin-1-yl)- 2-oxoethyl)-1H-indol-5-yl)cyclopropylcarbamate *** 2.20 (A) 644 124

(2S,4R)-1-(2-(3-acetyl- 7-((5-fluoropyrimidin- 2-yl)ethynyl)-1H-indol-1-yl)acetyl)-N-(2′- chloro-2- fluorobiphenyl-3-yl)-4-fluoropyrrolidine-2- carboxamide *** 2.59 (A) 656 126

N-(1-(3-acetyl-1-(2- ((2S,4R)-2-(6- bromopyridin-2- yl)carbamoyl)-4-fluoropyrrolidin-1-yl)- 2-oxoethyl)-1H-indol- 5-yl)cyclopropyl)pyrimidine-5- carboxamide 1.55 (A) 649 127

(1R,3S,5R)-2-(2-(3- carbamoyl-1H- pyrazolo[3,4-c]pyridin-1-yl)acetyl)-2- azabicyclo[3.1.0]hexane- 3-carboxammide, N-(3- chloro-2-fluorophenylmethyl-d₂) *** 1.07 (A) 473 128

(2S,4R)-1-(2-(3- carbamoyl-1H- pyrazolo[3,4-c]pyridin- 1-yl)acetyl)-4-fluoropyrrolidine-2- carboxamide, N-(3- chloro-2- fluorophenylmethyl-d₂)*** 0.86 (A) 479

Example 8. Human Factor D Assay

Human factor D (purified from human serum, Complement Technology, Inc.)at 80 nM final concentration is incubated with test compound at variousconcentrations for 5 minutes at room temperature in 50 mM Tris, 1M NaCl,pH 7.5. A synthetic substrate Z-L-Lys-SBzl and DTNB (Ellman's reagent)are added to final concentrations of 100 μM each. The increase in coloris recorded at OD₄₀₅ nm in a microplate in kinetic mode over 30 minuteswith 30 second time points in a spectrofluorimeter. IC₅₀ values arecalculated by non-linear regression from the percentage of inhibition ofcomplement factor D activity as a function of test compoundconcentration.

Example 9. Hemolysis Assay

The hemolysis assay was previously described by G. Ruiz-Gomez, et al.,J. Med. Chem. (2009) 52: 6042-6052. In the assay red blood cells (RBC),rabbit erythrocyctes (purchased from Complement Technologies), arewashed using GVB Buffer (0.1% gelatin, 5 mM Veronal, 145 mM NaCl, 0.025%NaN₃, pH 7.3) plus 10 mM final Mg-EGTA. Cells are used at aconcentration of 1×10⁸ cells/mL. Prior to the hemolysis assay, theoptimum concentration of Normal Human Serum (NHS) needed to achieve 100%lysis of rabbit erythrocytes is determined by titration. NHS (ComplementTechnologies) is incubated with inhibitor for 15 min at 37° C., rabbiterythrocytes in buffer were added and incubated for an additional 30 minat 37° C. Positive control (100% lysis) consists of serum and RBC andnegative control (0% lysis) of Mg-EGTA buffer and RBC only. Samples arecentrifuged at 2000 g for 5 min, and supernatants collected. Opticaldensity of the supernatant is monitored at 405 nm using a UV/visiblespectrophotometer. Percentage lysis in each sample is calculatedrelative to positive control (100% lysis).

This specification has been described with reference to embodiments ofthe invention. However, one of ordinary skill in the art appreciatesthat various modifications and changes can be made without departingfrom the scope of the invention as set forth in the claims below.Accordingly, the specification is to be regarded in an illustrativerather than a restrictive sense, and all such modifications are intendedto be included within the scope of invention.

What is claimed is:
 1. A pharmaceutical composition comprising acompound of Formula I or a pharmaceutically acceptable salt thereof in apharmaceutically acceptable carrier:

or a pharmaceutically acceptable salt thereof, wherein Q¹ isC(R¹R^(1′)); Q² is C(R²R^(2′)); Q³ is C(R³R^(3′)); X¹ is N and X² is CH;R¹, R^(1′), R², R^(2′), R³, and R^(3′) are independently selected fromhydrogen, halogen, hydroxyl, nitro, cyano, amino, C₁-C₆alkyl,C₂-C₆alkenyl, C₁-C₆alkoxy, C₂-C₆alkynyl, C₂-C₆alkanoyl, C₁-C₆thioalkyl,hydroxyC₁-C₆alkyl, aminoC₁-C₆alkyl, —C₀-C₄alkylNR⁹R¹⁰, —C(O)OR⁹,—OC(O)R⁹, —NR⁹C(O)R¹⁰, —C(O)NR⁹R¹⁰, —OC(O)NR⁹R¹⁰, —O(heteroaryl),—NR⁹C(O)OR¹⁰, C₁-C₂haloalkyl, C₀-C₄alkyl(C₃-C₇cycloalkyl),—O—C₀-C₄alkyl(C₃-C₇cycloalkyl) and C₁-C₂haloalkoxy; or R¹ and R^(1′) orR³ and R^(3′) may be taken together to form a 3- to 6-memberedcarbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ringcontaining 1 or 2 heteroatoms independently chosen from N, O, or S; orR² and R^(2′) may be taken together to form a 3- to 6-memberedcarbocyclic spiro ring, or R² and R^(2′) may be taken together to form a3- to 6-membered heterocyclic spiro ring, each of which spiro ring isunsubstituted or substituted with one or more halogen or methylsubstituents; or R¹ and R² may be taken together to form a 3-memberedcarbocyclic ring; or R¹ and R² may be taken together to form a 4- to6-membered carbocyclic ring or a 4- to 6-membered heterocyclic ringcontaining 1 or 2 heteroatoms independently chosen from N, O, and S; orR² and R³, if bound to adjacent carbon atoms, may be taken together toform a 3- to 6-membered carbocyclic ring or a 3- to 6-memberedheterocyclic ring; each of which non-spiro ring may be unsubstituted orsubstituted with 1 or more substituents independently chosen fromhalogen, hydroxyl, cyano, —COOH, C₁-C₄alkyl, C₂-C₄alkenyl, C₁-C₄alkoxy,C₂-C₄alkanoyl, hydroxyC₁-C₄alkyl, (mono- anddi-C₁-C₄alkylamino)C₀-C₄alkyl, —C₀-C₄alkyl(C₃-C₇cycloalkyl),—O—C₀-C₄alkyl(C₃-C₇cycloalkyl), C₁-C₂haloalkyl, and C₁-C₂haloalkoxy; R⁹and R¹⁰ are independently chosen at each occurrence from hydrogen,C₁-C₆alkyl, and (C₃-C₇cycloalkyl)C₀-C₄alkyl; A is

R⁶ is independently chosen from CHO, —C(O)NH₂, —C(O)NH(CH₃),C₂-C₆alkanoyl, hydrogen, hydroxyl, halogen, cyano, nitro, —COOH,—SO₂NH₂, —C(NH₂)C₁-C₃ alkyl, —C(NH₂)C₁-C₃haloalkyl, —CF(C═CH₂),—C(═NCN)C₁-C₆alkyl, C₁-C₆alkyl, C₂-C₆alkenyl, C₁-C₆alkoxy,—C₀-C₄alkyl(C₃-C₇cycloalkyl), —C(O)C₀-C₄alkyl(C₃-C₇cycloalkyl),—P(O)(OR⁹)₂, —OC(O)R⁹, —C(O)OR⁹, —C(O)N(CH₂CH₂R⁹)(R¹⁰), —NR⁹C(O)R¹⁰,phenyl, or 5- to 6-membered heteroaryl each R⁶ other than hydrogen,hydroxyl, cyano, and —COOH is unsubstituted or substituted with one ormore substituents independently chosen from halogen, hydroxyl, amino,imino, cyano, cyanoimino, C₁-C₂alkyl, C₁-C₄alkoxy, —C₀-C₂alkyl(mono- anddi-C₁-C₄alkylamino), C₁-C₂haloalkyl, C₁-C₂haloalkoxy, C(O)alkyl,C(O)cycloalkyl, C(O)aryl, C(O)heterocycle, and C(O)heteroaryl; R⁸ andR^(8′) are independently chosen from hydrogen, halogen, hydroxyl,C₁-C₆alkyl, C₁-C₆alkoxy, and (C₁-C₄alkylamino)C₀-C₂alkyl, or R⁸ andR^(8′) are taken together to form an oxo group; X¹² is N or CR¹²; X¹³ isN or CR¹³; R¹² and R¹³ are independently chosen from (q) and (r), (q)hydrogen, halogen, hydroxyl, nitro, cyano, amino, —COOH, C₁-C₂haloalkyl,and C₁-C₂haloalkoxy, (r) C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkanoyl,C₁-C₆alkoxy, C₂-C₆alkenyloxy, —C(O)OR⁹, C₁-C₆thioalkyl,—C₀-C₄alkylNR⁹R¹⁰, —C(O)NR⁹R¹⁰, —SO₂R⁹, —SO₂NR⁹R¹⁰, —OC(O)R⁹, and—C(NR⁹)NR⁹R¹⁰, each of which (r) is unsubstituted or substituted withone or more substituents independently selected from halogen, hydroxyl,nitro, cyano, amino, —COOH, —CONH₂, C₁-C₂haloalkyl, and C₁-C₂haloalkoxy,and each of which (r) is also optionally substituted with onesubstituent chosen from phenyl and 4- to 7-membered heterocyclecontaining 1, 2, or 3 heteroatoms independently chosen from N, O, and S;which phenyl or 4- to 7-membered heterocycle is unsubstituted orsubstituted with one or more substituents independently chosen fromhalogen, hydroxyl, nitro, cyano, C₁-C₆alkyl, C₂-C₆alkenyl,C₂-C₆alkanoyl, C₁-C₆alkoxy, (mono- and di-C₁-C₆alkylamino)C₀-C₄alkyl,C₁-C₆alkylester, —C₀-C₄alkyl(C₃-C₇cycloalkyl), C₁-C₂haloalkyl, andC₁-C₂haloalkoxy; L is

where R¹⁷ is hydrogen or C₁-C₆alkyl and R¹⁸ and R^(18′) areindependently chosen from hydrogen, halogen, and methyl; and m is 0, 1,2, or 3; B is a monocyclic or bicyclic carbocyclic or carbocyclic-oxygroup or a monocyclic, bicyclic, or tricyclic heterocyclic group having1, 2, 3, or 4 heteroatoms independently selected from N, O, and S andfrom 4 to 7 ring atoms per ring, or B is a C₂-C₆alkenyl or C₂-C₆alkynylgroup; or B is —(C₀-C₄alkyl)(aryl), —(C₀-C₄alkyl)(heteroaryl), or—(C₀-C₄alkyl)(biphenyl) each of which B is unsubstituted or substitutedwith one or more substituents independently chosen from (w) and (x) and0 or 1 substituents chosen from (y) and (z) (w) halogen, hydroxyl,—COOH, cyano, C₁-C₆alkyl, C₂-C₆alkanoyl, C₁-C₆alkoxy, —C₀-C₄alkylNR⁹R¹⁰,—SO₂R⁹, C₁-C₂haloalkyl, and C₁-C₂haloalkoxy; (x) nitro, C₂-C₆alkenyl,C₂-C₆alkynyl, C₁-C₆thioalkyl, -JC₃-C₇cycloalkyl, —B(OH)₂, -JC(O)NR⁹R²³,-JOSO₂OR²¹, SR⁹, —C(O)(CH₂)₁₋₄S(O)R²¹, —O(CH₂)₁₋₄S(O)NR²¹R²²,-JOP(O)(OR²¹)(OR²²), -JP(O)(OR²¹)(OR²²), -JOP(O)(OR²¹)R²²,-JP(O)(OR²¹)R²², -JOP(O)R²¹R²², -JP(O)R²¹R²², -JSP(O)(OR²¹)(OR²²),-JSP(O)(OR²¹)(R²²), -JSP(O)(R²¹)(R²²), -JNR⁹P(O)(NHR²¹)(NHR²²),-JNR⁹P(O)(OR²¹)(NHR²²), -JNR⁹P(O)(OR²¹)(OR²²), -JC(S)R²¹, -JNR²¹SO₂R²²,-JSO₂NR⁹COR²², -JSO₂NR⁹CONR²¹R²², -JNR²¹SO₂R²², -JC(O)NR²¹SO₂R²²,-JC(NH₂)NR²², -JC(NH₂)NS(O)₂R²², -JOC(O)NR²¹R²², -JNR²¹C(O)OR²²,-JNR²¹OC(O)R²², —(CH₂)₁₋₄C(O)NR²¹R²², -JNR⁹C(O)R²¹, -JC(O)R²¹,-JNR⁹C(O)NR¹⁰R²², —CCR²¹, —(CH₂)₁₋₄OC(O)R²¹, and -JC(O)OR²³; each ofwhich (x) may be unsubstituted or substituted with one or moresubstituents independently chosen from halogen, hydroxyl, nitro, cyano,amino, oxo, —B(OH)₂, —Si(CH₃)₃, —COOH, —CONH₂, —P(O)(OH)₂, C₁-C₆alkyl,C₁-C₆alkoxy, —C₀-C₂alkyl(mono- and di-C₁-C₄alkylamino), C₁-C₆alkylester,C₁-C₄alkylamino, C₁-C₄hydroxylalkyl, C₁-C₂haloalkyl, andC₁-C₂haloalkoxy; (y) naphthyl, naphthyloxy, indanyl, (4- to 7-memberedheterocycloalkyl)C₀-C₄alkyl containing 1 or 2 heteroatoms chosen from N,O, and S, and bicyclic heterocycle containing 1, 2, or 3 heteroatomsindependently chosen from N, O, and S, and containing 4- to 7-ring atomsin each ring; each of which (y) is unsubstituted or substituted with oneor more substituents independently chosen from halogen, hydroxyl, nitro,cyano, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkanoyl, C₁-C₆alkoxy, (mono- anddi-C₁-C₆alkylamino)C₀-C₄alkyl, C₁-C₆alkylester,—C₀-C₄alkyl(C₃-C₇cycloalkyl), —SO₂R⁹, C₁-C₂haloalkyl, andC₁-C₂haloalkoxy; and (z) tetrazolyl, (phenyl)C₀-C₂alkyl,(phenyl)C₁-C₂alkoxy, phenoxy, and 5- or 6-membered heteroaryl containing1, 2, or 3 heteroatoms independently chosen from N, O, B, and S, each ofwhich (z) is unsubstituted or substituted with one or more substituentsindependently chosen from halogen, hydroxyl, nitro, cyano, C₁-C₆alkyl,C₂-C₆alkenyl, C₂-C₆alkanoyl, C₁-C₆alkoxy, (mono- anddi-C₁-C₆alkylamino)C₀-C₄alkyl, C₁-C₆alkylester,—C₀-C₄alkyl(C₃-C₇cycloalkyl), —SO₂R⁹, —OSi(CH₃)₂C(CH₃)₃, C₁-C₂haloalkyl,and C₁-C₂haloalkoxy; J is independently chosen at each occurrence from acovalent bond, C₁-C₄alkylene, —OC₁-C₄alkylene, C₂-C₄alkenylene, andC₂-C₄alkynylene; R²¹ and R²² are independently chosen at each occurrencefrom hydrogen, hydroxyl, cyano, amino, C₁-C₆alkyl, C₁-C₆haloalkyl,C₁-C₆alkoxy, (C₃-C₇cycloalkyl)C₀-C₄alkyl, (phenyl)C₀-C₄alkyl,—C₁-C₄alkylOC(O)OC₁-C₆alkyl, —C₁-C₄alkylOC(O)C₁-C₆alkyl,—C₁-C₄alkylC(O)OC₁-C₆alkyl, (4- to 7-memberedheterocycloalkyl)C₀-C₄alkyl having 1, 2, or 3 heteroatoms independentlychosen from N, O, and S, and (5- or 6-membered unsaturated or aromaticheterocycle)C₀-C₄alkyl having 1, 2, or 3 heteroatoms independentlychosen from N, O, and S; and R²³ is independently chosen at eachoccurrence from (C₃-C₇cycloalkyl)C₀-C₄alkyl, (phenyl)C₀-C₄alkyl, (4- to7-membered heterocycloalkyl)C₀-C₄alkyl having 1, 2, or 3 heteroatomsindependently chosen from N, O, and S, and (5- or 6-membered unsaturatedor aromatic heterocycle)C₀-C₄alkyl having 1, 2, or 3 heteroatomsindependently chosen from N, O, and S.
 2. The pharmaceutical compositionof claim 1, wherein the

ring is selected from:


3. The pharmaceutical composition of claim 1, wherein B is selectedfrom:


4. The pharmaceutical composition of claim 1, wherein B is selectedfrom:


5. The pharmaceutical composition of claim 1, wherein B is selectedfrom:


6. The pharmaceutical composition of 1, wherein A is:


7. The pharmaceutical composition of claim 6, wherein X¹² is CR¹² andX¹³ is CR¹³.
 8. The pharmaceutical composition of claim 7, wherein R¹²is C₁-C₆alkyl.
 9. The pharmaceutical composition of claim 8, wherein R¹³is hydrogen.
 10. The pharmaceutical composition of claim 8, whereinC₁-C₆alkyl is methyl.
 11. The pharmaceutical composition of claim 10,wherein R¹³ is hydrogen.
 12. The pharmaceutical composition of claim 7,wherein R¹² and R¹³ are both hydrogen.
 13. The pharmaceuticalcomposition of claim 6, wherein the

ring is selected from:


14. The pharmaceutical composition of claim 6, wherein B is selectedfrom:


15. The pharmaceutical composition of claim 1, wherein the compound isselected from:

or a pharmaceutically acceptable salt thereof.
 16. The pharmaceuticalcomposition of claim 1, wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.
 17. The pharmaceuticalcomposition of claim 1, wherein the composition is suitable for deliveryto a human.
 18. The pharmaceutical composition of claim 1, wherein thecomposition is suitable for systemic delivery.
 19. The pharmaceuticalcomposition of claim 1, wherein the composition is suitable for topicaldelivery.
 20. The pharmaceutical composition of claim 1, wherein thecomposition is suitable for ocular delivery.
 21. The pharmaceuticalcomposition of claim 1, wherein the composition is suitable forintravitreal delivery.